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ABSTRACT 
Bone repair is modulated by different stimuli. There is evidence that the Transforming 
Growth Factor-beta (TGF-β) super-family of cytokines have significant effects on bone 
structure by regulating the replication and differentiation of chondrocytes, osteoblasts 
and osteoclasts. There is also significant evidence that interactions with extracellular 
matrix molecules also influence cell behaviour.  
 
This study aimed at determining the role of the TGF-βs, Collagen type I, Fibronectin 
and Laminin in bone cell behaviour. To do this MG63 bone cells were used to examine 
cell adhesion and alignment to different micro-contact printed ECM protein patterns of 
different widths. The study also aimed at examining how TGF-β1, 2 and 3 and their 
solvent and carrier (HCl and BSA, respectively) effected cell surface interactions, cell 
morphology, cell proliferation and integrin expression. Finally, this study also aimed at 
examining how the TGF-βs and their solvent and carrier influenced wound closure in an 
in vitro wound closure model and how TGF-βs influence ECM secretion and integrin 
expression. 
 
5, 10, 25, 50 and 100m wide repeat gratings of Collagen type I, Fibronectin and 
Laminin patterns were stamp patterned onto glass slides and plated with MG63 cells at 
50,000 cells per coverslip. Cells on the fibronectin pattern attached and elongated soon 
after seeding, but did not adhere readily to collagen and laminin and appeared more 
rounded until 18hrs after seeding. Cells aligned significantly well on the 50m and 
100µm wide fibronectin patterned coverslips with mean angles of alignment ~7.87˚  
3.06SD and 6.45˚  5.08SD, respectively, compared to those with smaller width 
(p<0.001). In comparison, cells aligned less readily to the other two ECM proteins, 
showing optimal alignments of 9.66˚  4.18SD and 14.36˚  1.57SD to the 50µm wide 
collagen and laminin patterns, respectively. Differences in cell length mirrored those of 
alignment, with cells acquiring the greatest length when showing the greatest degree of 
alignment. The results indicate that MG63 cells responded significantly better to 50 and 
100m wide fibronectin patterns compared to those with smaller width (p<0.001) 
indicating that the cells may attach mostly via fibronectin specific integrins. 
 
Cell surface attachment was examined via a trypsinisation assay in which the time taken 
to trypsinise cells from the surface provided a means of assessing the strength of 
attachment. The results indicated that treatment with the solvent (HCl), TGF-1, 2 and 3 
all decreased cell attachment, but this effect was significantly greater in the case of HCl 
and TGF-3 (p<0.001). However, there were significant differences in trypsinisation 
 vi 
rates between HCl and TGF-3 (p<0.001). The wound healing response to the TGF-s 
and their solvent/carrier was also investigated in 300µm ± 10-30µm SD wide model 
wounds induced in fully confluent monolayers of MG63 bone cells. The results 
indicated that TGF-β3 and HCl significantly enhance wound closure when compared 
against negative controls, TGF-1 and TGF-2 treatment (p<0.001). It was also found 
that TGF-1 and TGF-2 treatment significantly improved wound closure rate in 
comparison to the controls (p<0.001).  
 
Experiments were performed to determine if the HCl effects on wound closure were 
dose dependent. Cells were incubated with 20µM, 40µM, 80µM and 160µM 
concentrations of HCl prior to wounding and wound closure rates were recorded. 
Wound closure was dependent on HCl dose with the 80µM and 160µM concentrations 
inducing increases in wound closure rates that were both significantly greater than those 
induced by 20µM, 40µM and control treatments (p<0.001). However, there were 
significant differences in wound closure between the 80µM and 160µM treatment 
groups after 30hrs of treatment (p<0.001). 
 
The effect of different TGF-β isomers and their combinations on proliferation rate and 
cell length of human bone cells were also assessed. The results suggest that cell 
morphology changes were observed significantly more in cells treated with TGF-β(2+3)  
and TGF-β(1+3) (p<0.001). Any cell treated with TGF-β1, TGF-β(1+2) and TGF-
β(1+2+3) showed significantly less elongation compared to the control and other TGF-β 
isomers. In terms of proliferation rate, TGF-3 and TGF-β(2+3) increased cell numbers 
more than TGF-β1, TGF-β2 and other combinations. TGF-1 and its combinations did 
not show significant proliferation and attachment compared to the control due to 
perhaps its inhibitory effect in contact with human bone cells.  
 
Immunostaining indicated that treatment with TGF-β3 significantly promoted the 
secretion of collagen type I and anti-human fibronectin in addition to integrin (α3 and 
β1) expression. Statistically TGF-β3 and their combinations showed significant 
differences in number of cells stained for collagen type I, anti-human fibronectin, α3 
and β1integrin. Any cell treated with TGF-β1 or any combination with TGF-β1 showed 
significantly lower cell number stained with the same proteins and integrins (p<0.001). 
Imaging with WSPR allowed observation of the focal contacts without the need for 
immunostaining. WSPR images revealed guided cells with high contrast band like 
structures at the border of cells distal to the edge of guidance cue to which they aligned 
and with less concentrically formed band like features across the cell body. It is 
believed that the high contrast features are associated with the formation of focal 
contacts on the edge of the cells distal to the edge of fibronectin patterns, which 
suggests that cell guidance is aided by a decrease in cell attachment along a guidance 
feature. The WSPR experiments also indicated that TGF-βs influenced the distribution 
of focal contacts. In the case of TGF-β1 treated cells the bright high contrast regions 
were intense but only arranged around the periphery of the cell. In TGF-β2 and TGF-β3 
cells the bright contrast regions were weaker but again mostly localised around the 
periphery. These findings supported the earlier trypsinisation results.  
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CHAPTER ONE 
1. INTRODUCTION AND LITERATURE 
REVIEW 
1.1  OVERVIEW OF BONE 
Bone is a living tissue that makes up the body's skeleton. Bones are classified by their 
anatomical shape as long (e.g. femur, humerus), short (e.g. wrist, ankle), flat (e.g. 
membrane bone), and irregular (e.g. vertebra). Bone is a specialised form of connective 
tissue and like other connective tissues including cartilage and blood is derived from 
mesoderm. Excluding teeth and sesamoid bones, there are a total of 206 bones in the 
adult human body which are normally separated by various types of cartilage to provide 
support to the skeletal system and facilitate joint movement (Hollinger, 2004, 
Bilezikian, 2008, Marolt, 2012). The entire framework of bones and their cartilages 
together constitute the skeletal system, (see Figure 1.1). 
 
1.1.1   Structure of bone 
The outer surface of all bones, except at the joints of long bones, is covered with a 
membrane consisting of dense irregular connective tissue known as periosteum (Netter, 
1987) and a similar tissue, the endosteum, lines the inner surface of all bones. There are 
three gross types of bone in the human body; compact (cortical), spongy (trabecular or 
cancellous) and subchondral bone which can be distinguished by their appearance. At 
the microscopic level, the differences between subchondral, compact and cancellous 
bone are not easily distinguished (Bilezikian, 2008, Glorieux, 2011). 
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Figure 1.1 Human body skeleton. 
Adapted from: http://hkeducationcenter.com 
 
 
Figure 1.2 Structure of human bone. 
Adapted from: http://training.seer.cancer.gov 
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All types of bone have an identical microscopic structure at comparable stages of 
maturity of bone tissue. The difference between them lies in the relationship of each to 
the blood supply. Cancellous bone is bony tissue surrounded by blood vessels; compact 
bone is blood vessels surrounded by bony tissue; and subchondral bone is more 
vascularised than compact bone and less vascularised than cancellous bone. Compact 
bone makes up 80% of the skeleton and has a solid, compact structure and 80-90% of its 
volume is calcified. Spongy bone makes up 20% of the skeleton. This type of bone has 
more surface area compared to compact bone but it is less dense. It is typically located 
at the end of long bones and is highly vascularised. It also contains red bone marrow 
where the production of blood cells (hematopoiesis) occurs (Hollinger, 2004, Glorieux, 
2011). 
 
The microscopic structure of bone varies according to its maturity and the speed with 
which it must be laid down. There are three forms of immature or new bone: woven, 
laminar, and fine cancellous. Woven bone is deposited in the initial formation of bone 
in the fetus or where rapid repair of bone is needed. Woven bone is remodelled into 
mature bone, which has a more ordered structure. In human the remodelling process 
may be too slow to keep up with growth, so another type of immature bone is formed 
where greater strength is needed: laminar bone. Laminar bone is composed of sheets, or 
laminae, of bony tissue seperated from each other by intervening networks of blood 
vessles. Laminar bone has a smaller volume of vascular canals than other types of bone 
and is probably stronger in some ways. The third type of rapidly growing bone, fine 
cancellous bone, is found in places where transient reinforcement of the extant bone is 
needed. For example, fine cancellous bone may appear on the brow ridge of an animal 
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when the stresses involved in chewing increase, as when a new tooth is erupting 
(Bilezikian, 2008).  
 
The differences between immature and mature bone lie mainly in the relationships 
between the vascular canals and the bony tissue. Mature or adult bone is called lamellar 
bone. Such bone is arranged in thin sheets or lamellae, which are roughly 3-7 microns 
thick. In each lamella, the bundles of collagen fibres are arranged parallel to one 
another, although the predominant orientation may vary from lamella to lamella for 
strength. This arrangement gives lamellar bone a layered appearance in cross section. A 
group of lamellae may be organised in one of two ways, depending upon its location 
within the whole bone. The basic unit of lamellar bone is the osteon (Hollinger, 2004), 
in which sets of 15-20 lamellae are arranged in concentric tubes around an opening for a 
blood vessel (See Figure 1.2). The placement of vascular canals within these rings of 
bone differentiates mature from immature bone. Surrounding each osteon is a cement 
line, a dense ring that demarcates its boundaries and surrounds the outer lamella 
throughout the entire length of the osteon. Because osteons are formed by remodelling 
either immature bone or older mature bone, adjacent osteons may cut across each other, 
may touch each other at their cement line, or may be separated by regions of less 
organised bone tissue. These intervening regions of bone, called interstitial bone, are 
irregular in shape (Marks, 2002, Bilezikian, 2008).  
 
The vascular canal at the centre of each osteon is part of a network of canals, the 
Haversian system, which brings nourishment to the bone tissue. Within this system are 
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two types of canals, Haversian and Volkmann’s. Haversian canals are oriented more or 
less longitudinally within the bone. They are connected to each other, to the marrow 
cavity, and to the surface of the skeletal element by a complex system of oblique and 
transversely oriented canals, or Volkmann’s canals. Volkmann’s canals are not 
surrounded by concentric lamellae and in fact frequently cut through lamellae. Not all 
mature bone is organised into osteons. Near both the inner and outer surface of long 
bones, this organisation of bone tissue is replaced by several large-scale lamellae that 
encircle the entrie perimeter of the shaft; these are called outer and inner circumferential 
lamellae (Bilezikian, 2008, Glorieux, 2011). 
 
1.1.2 Cellular structure of bone 
Bone contains four different types of cells including osteoprogenitor, osteocyte, 
osteoblast and osteoclast. In general osteoprogenitor cells can be considered as bone 
stem cells and they are located in the inner portion of periosteum and in endosteum. 
These cells have the capacity to divide and differentiate into osteoblast bone cells. 
Osteoprogenitor cells are immature progenitor cells and are induced to differentiate into 
osteoblast under the influence of growth factors mainly Bone Morphogenetic Proteins 
(BMP) (Agata, 2007). Bone tissue is formed by osteoblasts, maintained by osteocytes 
and broken down by osteoclasts (Lee, 1999). The osteoblasts mainly functions in bone 
formation and these cells secret collagen and ECM substances that constitute 
unmineralised bone osteoid and subsequently are responsible for calcification and 
remodelling. Osteoblasts originate in the bone marrow and are derived from 
mesenchymal stem cells (Mundy, 2008). Osteoblasts are also able to communicate with 
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one another and with osteocytes by a gap junction. Alkaline phosphatase is an enzyme 
that is plentiful in osteoblasts and this enzyme is important in the formation of mineral 
deposits in the matrix (Marks, 2002). Some osteoblasts become embedded in the matrix 
of bony tissue to become osteocytes. Osteocytes are mature bone cells, and these cells 
maintain bones’ daily metabolism, such as exchanging nutrients and waste with the 
blood and are completely surrounded by the bone matrix. Lacuna is the place in which 
octeocytes are located and they are able to communicate with adjacent octeocytes 
through canaliculi, which are used for the exchange of nutrients and waste (Hollinger, 
2004). They are actively involved in the routine turnover of bony matrix, through 
various mechanosensory mechanisms. The osteoclasts like the osteoblasts originate in 
the bone marrow. The osteoclasts are derived from the mononuclear/phagocytic cell 
lineage. Osteoclasts are phagocytic cells responsible for removing bone tissue (Mundy, 
2008) via bone resorption. Osteoclasts are huge cells with a diameter of 20-100μm and 
they migrate across the surfaces of the bone and release enzymes such as collagenase 
and proteolytic enzymes to remove the organic component of the bone and stabilise 
minerals by lowering the pH of isolated areas (Lee, 1992). Osteoclasts are found on 
bone surfaces and are important in the normal growth, maintenance and repair of bone 
(Marks, 2002).  
 
1.1.3 Molecular structure of bone 
Human bone is composed of bone cells and a matrix of collagen fibres impregnated 
with bone salts (mainly calcium carbonate and calcium phosphate) (Sasano, 2012). The 
Extracellular Matrix (ECM) makes up 60% of bone and consists of organic and 
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inorganic parts. The inorganic component (bone minerals) consists of calcium 
phosphate and hydroxyapetite [Ca10 (PO4)6(OH)2]. Water makes up 5-8% of bone’s 
composition. The organic component of matrix consists of type I collagen fibers (90%), 
proteoglycan, osteopontin, osteocalcin, osteonectin, bone sialo protein, alkaline 
phosphatise, regulatory factors such as cytokines and growth factors (Hollinger, 2004, 
Ferreira, 2012). Proteoglycan helps the calcification of bone.  
 
The organic matrix consists of a highly vascular connective tissue consists of ECM 
proteins  and enclosed by a fibrocellular layer, the periosteum (Archambault, 2000). 
One of the main functions of most cells is to produce its own extracellular matrix 
(ECM). ECM components consist of the mixture of collagens, fibronectin and 
individual proteoglycans. This is an interactive natural scaffold that provides 
mechanical stability and cell anchorage, and is also able to control cell functions. In 
order to manufacture the ECM, cells synthesise mainly high-molecular-weight fibrous 
proteins. This protein is secreted out of the cell and builds up in the surrounding 
environment to form an insoluble network. In some tissues like skin and muscle the 
ECM is soft and elastic, whereas mechanically strong structures are formed in tendon, 
cartilage and bone. ECM plays an important role in the human body and some of its 
functions are to provide structural support and tensile strength. It also provides 
substrates for cell adhesion and cell migration. The ECM also regulates cellular 
differentiation and metabolic functions.  
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1.1.3.1 Collagen 
Collagen is the most important structural protein of the extracellular matrix (Ferreira, 
2012). The collagens are large families of proteins, comprising of at least 19 related 
glycoproteins, numbered in a series from collagen I to collagen XIX. All are based on a 
structure called the triple helix, a tight right-handed helix of three individual collagen 
chains, each individual chain having the structure of a left-handed helix (Davies, 2001). 
Collagen is synthesized by an extensive number of cell types such as fibroblasts, 
osteoblasts, chondroblasts, odontoblasts, reticular cells, epithelial cells, endothelial 
cells, smooth muscle cells, Schwann cells, etc. Cells do not secrete collagens directly, 
but rather secrete large precursors called procollagens that have ‘extra’ domains at each 
end of the peptides of a mature collagen. These domains are cleaved off outside the cell 
by specific proteinases, and once free of them most collagen chains can associate with 
each other to form fibrils, which line up with one another to form larger fibres. Collagen 
types I, II and III account for about 90% of all collagen in the body, and form strong 
fibrils. In life, most individual fibrils are composed of a mixture of these collagens and 
may also include small amounts of the other fibrillar collagens (e.g. V and XI), with 
collagen types IX, XII and XIV coating fibrils to alter their sticky or slippery properties. 
While these fibrillar collagens are common in connective tissue, the basement 
membranes of epithelia usually contain a quite different collagen, collagen IV, which 
forms three-dimensional gels rather than fibrils. In contrast to these common collagens, 
some types are expressed only in a small number of sites in the body. Collagen type I is 
the main component of bone (Davies, 2001). 
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1.1.3.2 Fibronectins 
Fibronectins are a family of proteins produced by alternative splicing of a single gene. 
Some forms of fibronectin remain soluble and may be found in blood plasma, while 
others associate into disulfide-bonded fibrils in the ECM. Each fibronectin molecule, 
itself a dimer of two fibronectin peptides, contains binding sites for a variety of other 
molecules, such as heparan sulphate proteoglycan, integrins and collagens. Fibronectins 
therefore serve to bind different components of the ECM together, and to serve as sites 
on the ECM to which cells can bind. 
 
1.1.3.3 Laminin 
Laminins are large ECM proteins, typically the shape of a cross, that are composed of 
three different types of chain, called a, b and g. The three short arms of the cross 
represent the N-terminal ends of each chain, while the middle and C-terminal portions 
of the chains run together down the long arm of the cross. There are several types of a, b 
and g chains, and these can associate promiscuously to generate many types of laminin 
(e.g. laminin-1has a1, b1 g1chains, laminin-2 has a2, b1, g1chains, etc.). Laminins 
contain various sites for binding to receptors on the cell surface, and to other 
components of the cell matrix such as collagens and proteoglycans. Laminin is not 
normally present in bone (Colucci, 1996), but however, laminin was used in this study 
as a control and also to verify this ECM protein has any effect on bone cell behaviour. 
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1.1.3.4 Non-collagenous bone proteins 
Osteocalcin, osteonectin, osteopontin and bone sialoprotein are four major non-
collagenous bone proteins. Both osteopontin and bone sialoprotein are necessary for the 
initiation of bone mineralisation (Roach, 1994). Osteocalcin is secreted by osteoblats 
and plays a role in the body's metabolic regulation and is found in bone and dentin. It is 
also used as a biochemical marker for the bone formation process. Osteonectin is a 
glycoprotein in the bone which is secreted by osteoblasts during bone formation, 
initiating mineralisation and promoting mineral crystal formation. It is an acidic, 
secreted ECM glycoprotein that plays a major role in bone mineralisation, cell-matrix 
interactions, and collagen binding (Guweidhi, 2005). Osteopontin is a glycoprotein that 
was first identified in 1986 in osteoblasts. It is also known as an important factor in 
bone remodelling.  
 
1.1.4   Osteogenesis 
The development of bone tissue (ossification) is known as osteogenesis (Parsh, 2012). 
There are two types of osteogenesis, intramembranous ossification in which formation 
of bone occurs directly within the early development of connective tissue and 
endochondral ossification in which cartilage develops into bone. Both require a solid 
base and a well-developed vascular supply for the elaboration and mineralization of the 
exteracellular matrix. Intramembranous ossification occurs during embryonic 
development by the direct transformation of mesenchymal cells into osteoblasts 
(Bilezikian, 2008). This type of ossification for entire bones is restricted to those of the 
cranial vault, some facial bones, and parts of the mandible and clavicle. The flat bones 
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of the skull grow toward each other from primary ossification centres in each and meet 
at sutures. This mechanism provides a steady source of osteoblasts and allows bones to 
expand at their edges. When growth is complete, sutures remain as fibrous connections 
or disappear, depending on the suture site. Bones that participate in joints and bear 
weight form by endochondral ossification, a method by which the unique properties of 
cartilage and bone are exploited to provide a mechanism for formation and growth of 
the skeleton during growth of the individual (Glorieux, 2011). In such bones the 
condensed embryonic mesenchyme transforms into cartilage, which reflects in both 
position and form the eventual bone to be formed at that site. In the central part of such 
a bone, endochondral ossification provides for a linear, interstitial proliferation of 
columns of chondrocytes. Their progressive hypertrophy, mineralisation of the 
intercolumnar cartilage matrix in the long axis of the bone, and the presisence of 
mineralised cartilage after disapperanace of its cells acts as an elongating scaffold for 
the deposition of subchondral bone. In the circumference of such a bone, starting 
initially at the centre and progressing toward the ends, the investing cartilage cells and 
stroma transform into osteoblast that form a periosteal collar after the underlying 
chondrocytes have mineralised the matrix. The peripheral osteoblast (periosteum) arrive 
with a blood supply whose vessles penetrate the central hypertrophied, mineralised 
cartilage core and carry to the interior the skeletal cell progenitor for the formation and 
turnover of bone. Thus, peripherally extension of the periosteum and centrally 
mineralisation of cartilage, hypertrophy, and disappearance of chondrocytes and bone 
formation on the mineralised cartilaginous scaffold proceed toward the end of each 
growing long bone (Bilezikian, 2008). 
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1.1.5   Functions 
Bones perform four major functions in the body, having to do with its support, defence, 
movment, and supplies (Glorieux, 2011). First, the skeleton and its individual elements 
provide a framework or scaffolding that supports the soft tissues of the body and 
permits them to function without collapsing. Second, the skeleton functions to protect 
the body. In one sense it acts as a sort of hard protective device to shield important soft 
tissue from damage arising from external sources. The ribs, for example, form a partial 
cage protecting the heart and lungs from injuries, and the skull acts as a bony box 
surrounding the brain and special sense organs. The joints and spongy bone tissue in the 
skeleton function as shock absorbers, modulating the impacts produced by locomotion 
and other movements so as to protect the soft tissue of the body. Third, the bones of the 
body act as lever, to be pulled upon by muscles, producing movement and locomotion. 
Finally, bone marrow, located within the medullary cavitiy of long bones and interstices 
cancellous bone, produces red blood cells (RBC), white blood cells (WBC), and 
platelets in a process called hematopoiesis (Kale, 2004a). In addition, the bony tissues 
of the entire body are a huge warehouse of minerals to be trapped by the body in 
response to different physiological needs. For example pregnant women with an 
insufficient intake of calcium will resorb part of their own bone tissue to supply the 
needs of the growing fetus. The principal mineral constituent of bone is calcium, 99% 
of the body's supply being stored in this way, and phosphorus is also found in large 
quantities (Kovacevic, 2011). Calcium is concentrated particularly in the dense cortical 
bone, although the most liable volume is located in cancellous bone (Talmage, 2007). 
The metabolic functions of bone also consist of storage of growth factors (BMP, TGF-β 
and Inslulin-like growth factor) and fat. Bone naturalizes the blood against excessive pH 
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changes by absorbing/releasing alkaline salts. Bone cells also release osteocalcin 
hormone which regulates blood sugar and fat deposition. 
 
1.2   BONE DAMAGE AND REPAIR 
Bone is the main source of calcium (Ca) in the human body. Calcium can be released 
from bone to the blood or vice versa. In this process old bone is removed and resorption 
occurs in which old bone is removed by bone removing osteoclast cells and new bone is 
laid down by bone forming osteoblast cells. Bone formation and resorption normally 
occurs in the body through a lifelong process known as bone remodelling  (Lee, 1999, 
Wolff, 2012). Overall remodelling provides a balance between bone formation and 
resorption. Any imbalance in the regulation of bone remodelling will result in various 
metabolic bone diseases such as Osteomalacia which is the softening of the bones 
caused by defective bone mineralisation (inadequate amounts of available phosphorus 
and calcium), or because of overactive resorption of calcium from the bone as a result of 
hyperparathyroidism (Kovacevic, 2011). The control of mineral homeostasis involves 
both physio-chemical and biological factors. Outstanding among the biological factors 
affecting calcium level are two hormones, firstly the parathyroid hormone (PTH); and 
secondly, thyrocalcitonin (TCT) or calcitonin (Wolff, 2012). Vitamin D is also vital for 
calcium homeostasis and for optimal skeletal health. The main function of vitamin D is 
to increase the efficiency of calcium absorption from the small intestine. Vitamin D 
deficiency in children can manifest as rickets, which presents as bowing of the legs 
(Palmieri, 1989, Schwartz, 1993). 
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Remodelling takes place very fast in the first year of life and becomes slower in adults. 
Remodelling is the result of many factors such as mechanical stimuli, metabolic causes, 
effects of drugs and endocrine changes. Bone healing, or bone repair, is a process in 
which the body facilitates the repair of bone fractures (Ogasawara, 2008, Kovacevic, 
2011). Bone repair is mainly determined by the periosteum. The periosteum is the 
primary source of precursor cells, which develop into the chondroblast and osteoblast 
that are essential to the healing of bone. Secondary sources of precursor cells are bone 
marrow, endosteum, small blood vessels and fibroblasts. Fracture healing can be 
described in three phases: the reactive phase (fracture inflammatory phase and 
granulation tissue formation), reparative phase (callus formation and lamellar bone 
deposition) and remodelling phase (remodelling to original bone contour) (Tosounidisa, 
2009, Nakamura, 1998). In the reactive phase bleeding stops due to blood vessel 
constriction (Brighton, 1997). A few hours later a blood clot is formed by hematoma 
(extravascular blood cells) and cells within the blood clot die (Brighton, 1991). 
Inflammatory cells such as macrophages, monocytes, lymphocytes infiltrate the bone.  
Fibroblasts survive in this area and replicate with granulation tissue formation which is 
a loose aggregate of cells, distributed with blood vessels (Ham, 1972). This results in the 
formation of granulation tissue, ingrowth of vascular tissue, and migration of 
mesenchymal cells. The primary nutrient and oxygen supply of this early process is 
provided by the exposed cancellous bone and muscle (Kalfas, 2001).  
 
In the reparative phase (days after fracture) periosteum cells replicate and transform. 
The peristeal cells distal to the fracture gap, develop into osteoblasts and form woven 
bone (Brighton, 1997). Chondroblast also develop proximal to the fracture gap to form 
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hyaline cartilage. Fibroblasts begin to lay down a stroma that helps support vascular 
ingrowths. As vascular ingrowth progresses, a collagen matrix is laid down whilst 
osteoid (unmineralized organic portion of the bone matrix) is secreted and subsequently 
mineralized, which leads to the formation of a soft callus around the repair site (Kalfas, 
2001, Brighton, 1986). Hyaline cartilage and woven bone provide a bridge within the 
fracture gap to restore some of its strength. Hyaline cartilage and woven bone are then 
replaced with lamellar bone referred to as endochondral ossification. Eventually, all 
Hyaline cartilage and woven bone are replaced by trabecular bone (Brighton, 1986).  
 
Remodelling is the last phase in bone repair and bone fracture healing is completed 
during the remodelling stage. In this stage the healing bone is restored to its original 
shape, structure, and mechanical strength (Tosounidisa, 2009). This process occurs 
slowly over months to years and is facilitated by mechanical stress placed on the bone. 
Initially, this involves converting the irregular woven bone callus into lamellar bone, 
although the standard cortical structure is eventually restored. This process is driven by 
a coupled process of orderly bone resorption followed by the formation of lamellar bone 
(Teitelbaum, 2000). Osteoclasts are the main cell type involved with the resorption of 
mineralised bone. Once bone resorption completed, osteoblasts are able to lay down 
new bone on the eroded surface (Schindeler, 2008). 
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1.3  CURRENT THERAPIES AND LIMITATIONS FOR 
BONE HEALING 
The processes described above are a part of the natural healing process of human bones. 
However, many conditions exist where the natural healing process is insufficient and 
adjunctive measures are needed to assure full regeneration. Examples include infections, 
fracture mobility, and critical-size defects. This section will discuss treatments that are 
currently used in these situations to augment natural bone repair (Blitterswijk, 2008, 
Shapiro, 2008). Tissue substitutes provide a means of treatment in order to repair or 
replace damaged or diseased tissues/organs. Tissue substitutes include man-made 
materials and devices, autografting, allografting and xenographting (Banwart, 1995, 
Finkemeier, 2002a). Other treatments also involve stem cell therapy, gene therapy and 
drug therapy.  
 
Man-made biomimetic devices and materials are artificial tissue substitutes that replace 
the function performed by biological systems. They include stainless steel, cobalt 
chrome, titanium alloys, polyethylene and ceramics as prosthetic hips, knees, etc. 
(Cássio do Nascimento, 2007). Titanium alloys are also used for cement less joint 
replacements, screw and paltes for fracture fixation (Grupp, 2010), biodegradable 
polymers (for ankle and phalangeal fractures) (Eglin, 2008), shape memory allys (for 
orthopaedic implants specifically for small bone in face) (Kawakita, 2012) and many 
more. These devices may be limited by factors such as toxicity, initiation of 
inflammation, wear, fracture, and fatigue failures. Also, they may not remodel with time 
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(Parikh, 2002), for example, a titanium plate in a child would not deform or remodel as 
bone grows, which may cause further problems (Matthias Schieker, 2006).  
  
Autografting or autologous bone grafting involves harvesting and transplantation. In 
this procedure a tissue is harvested from one location in the patient and transplanted into 
the defect side of the same patient. In autografting rejection immunogenicity is not a 
major issue as tissue/cells are provided from the patient’s own body. Spinal fusions are 
common autografting procedures (Mummaneni, 2011). Spinal fusion involves grafting a 
bone from a patient’s hip to repair a vertebral defect. Additional surgical problems for 
harvesting include infection, blood loss and pain at the harvesting site (Parikh, 2002). 
An autologous cancellous bone graft is the most effective
 
grafting material as it 
provides the three elements required
 
for bone regeneration: osteoconduction, 
osteoinduction, and
 
osteogenic cells (Finkemeier, 2002a). Autologous cortical bone 
grafts provide these
 
three components to a limited extent and also provides
 
the structural 
integrity important in reconstruction of larger
 
defects (Keating, 2001). There are several 
shortcomings associated with this form of treatment, including complications in shaping 
the graft to fill the defect, a need for several procedures, high recovery time, donor site 
morbidity (Goulet, 1997), risk of disease transmission, loss of biological and 
mechanical properties and high cost (Parikh, 2002).  
 
Allografting consists of harvesting tissue or an organ from a live or dead donor (same 
species) and then transplanting it to the patient. Replacing bone damaged by accicdent 
from a healthy person to a patient with bone fracture is an example of allografts 
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(Finkemeier, 2002b). The main problems with allografting are shortages of donors and 
cell/tissue rejection (immunogenicity). Use of immunosuppressant drugs such as 
sirolimus (SRL) and Cyclosporine A (CsA) (Goodman, 2001) make allografting more 
common, at the expense of reducing the effectiveness of the immune system (Bruno, 
2007).  
 
Xenografting consists of harvesting cell/tissue from individuals of another species. 
Animal cells are the main source for this and there is still a considerable ethical debate 
relating to the use of this group with additional problems such as tissue rejection and 
disease transmission. An example of a xenograft is when bone is taken from a cuttlefish 
and transplanted into rabbit’s femur. At the end of the 30-day postoperative 
experimental period, bone defects filled with various graft materials were evaluated 
using macroscopic and radiographic methods (Okumus, 2005). The term zoograft refers 
to a tissue that is always transferred from an animal to a human while a xenograft can be 
used either for the transplant of tissue from animal to animal or animal to human 
(Grove, 2008).  
 
Stem cells are undifferentiated cells, which originate from two different sources, 
embryonic and adult stem cells. These cells can be found in all multicellular organisms. 
Stem cells have the ability to renew themselves through mitotic cell division and divide 
in culture to give rise to different forms of specialized cells (Becker, 1963, Marolt, 
2012). In a developing embryo stem cells are able to differentiate into all of the 
specialized embryonic tissues, whilst in an adult stem cells play a role in the repair and 
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maintainance of tissues in regenerative organs such as skin, blood or intestinal tissues. 
Currently stem cells can be grown and differentiated into specific cells through cell 
culture in vitro. Embryonic cell lines and autologous embryonic stem cells are two 
important candidates for future therapies (Tuch, 2006). Self renewal and potency are 
two properties of stem cells. Self-renewal is the ability to go through various stages of 
cell division while maintaining the undifferentiated state (Hans, 2007). Potency is the 
capability and potential to differentiate into various and certain cell types. In terms of 
potency stem cells may be totipotent, pluripotent, multipotent, unipotent or oligopotent 
(Hans, 2007). In the case of totipotent cells  the stem cell has the capability to 
differentiate into any embryonic cell type, thus, can construct a complete organism 
(Hans, 2007). Pluripotent stem cells are dependent on totipotent cells and can 
differentiate into a large number of cell types including bone (Mitalipov, 2009). In the 
case of multipotent, the stem cell can differentiate into a closely related family of cells. 
Some stem cells can also differentiate into only a few cells, such as lymphoid or 
myeloid stem cells known as oligopotent stem cells (Hans, 2007), and finally unipotent 
cells can only produce their own cells like muscle stem cells (Ulloa-Montoya, 2005).  
  
Gene therapies and the harvesting of tissue/organ or cells from cloned transgenic 
animals are relatively new technologies aimed to help many patients without using 
conventional therapies (Kofron, 2006, Carbonaro, 2012). These two new methods are 
still not practical for many different diseases due to limitations such as ethical, 
economical, technical, scientific and political issues (Vorburger, 2002). Conventional 
cell culture consists of growing cells in an environment outside the body but cells are 
not able to differentiate easily due to a lack of natural signals present in the body. 
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Signals such as mechanical, structural, electrical and chemical are normally present in 
the body but not outside the body in the cell culture environments (Freshney, 1994). 
These signals guide the cell and influence cell behaviour via cell signalling pathways 
(Clarkin, 2012). Thus, lack of these signals in vitro may result in cells exhibiting non-
normal behaviours (Haj, 1990, Aoudjit, 2012). These structural signals in the body are 
derived from interactions between cells and cell-ECM. The communication between the 
cell and ECM affect the cell’s shape and function (Einhorn, 1998). Gene therapy or 
genetic engineering, on the other hand, is a technique to deliver small DNA or RNA 
sequences to cells or tissues to correct a genetic defect or replace a mutated gene in the 
treatment of a disease (Marie, 2011). The potential use of gene therapy for bone 
regeneration is the delivery of physiological levels of therapeutic protein using the 
natural cellular mechanism (Kofron, 2006). Experimental investigations have verified 
this approach to yield bone healing equivalent to that achieved via the administration of 
a recombinant factor or use of bone graft (Laurencin, 1999). Currently the majority of 
gene therapies focus on adding genetic information to cells rather than alteration of the 
genome (Lieberman, 1998, Kofron, 2006).   
 
Drug therapy is another treatment option for patients with orthopedic disorders. Non-
steroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammation and severe 
pain (Kurmis, 2012, Pountos, 2012). Aspirin, Difunisal, Ibuprofen, Fenoprofen, 
Flurbiprofen, Ketoprofen and many other drugs are common examples of mild NSAIDs 
(Munson, 1996). NSAID therapy possesses many disadvantages and limitations 
(Amadio, 1993) and has a temporary effect instead of permanent cure. Chronic dosing 
with these agents is necessary and they all share a potential for causing serious adverse 
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effects such as peptic ulceration, bleeding from both the upper (Tamblyn, 1997) and 
lower digestive tract (Holt, 1991), damage to the liver and promotion of renal 
impairment, especially in the elderly (Tamblyn, 1997). Bone disorder drugs such as 
Alendronate can also interact with other drugs stopping them from working correctly 
(Watts, 2004).  
  
1.4  TISSUE ENGINEERING  
Tissue engineering is a field that seeks to replace/repair or enhance the biological 
function of a tissue or an organ by manipulating cells via their extra-cellular 
environment (Laurencin, 1999, Ikada, 2006, Rosa, 2012). In reality tissue engineering 
has a multi-disciplinary approach consisting of cell engineering, molecular biology, 
biomaterial engineering, design, imaging, etc, to develop materials in order to 
replace/repair diseased or damaged tissue and restore and improve their function 
(Parikh, 2002). 
 
1.4.1   Origin of Tissue Engineering and its definition 
The concept of directly engineering tissue was articulated in detail in 1985 (Fung, 
1985). The term “tissue engineering” was first used during a meeting sponsored by the 
National Science Foundation (NSF) in 1987. The first true tissue engineering 
symposium was held in 1988, where a working definition was proposed (Skalak, 1988) 
in which tissue engineering was defined as “the application of the principles and 
methods of engineering and life sciences toward the fundamental understanding of 
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structure-function relationships in normal and pathological mammalian tissue and the 
development of biological substitutes to restore, maintain, or improve tissue function” 
(Skalak, 1988). 
 
1.4.2  The need for bone tissue engineering  
Bone and joint diseases cause many people to suffer for years with crippling effects. 
With the progressive aging of the population, the need for functional tissue substitutes is 
increasing (Vunjak-Novakovic, 2006). According to new research the cost of fractures 
in the UK is ~£5.1 billion each year (Strom, 2011). Large bone defects resulting from 
trauma, tumors, infections or congenital abnormalities often require reconstructive 
surgery to restore function (Crana, 1995, Sikavitsas, 2002). Organ transplantation and 
mechanical devices have revolutionised medical practice but have limitations. New 
bone tissue engineering strategies have been proposed that promise greater bone 
restoration without many of the limitations of the current therapies (Mooney, 1999). 
Bone tissue engineering is a different method of treatment as compared to drug therapy, 
gene therapy or permanent implants since engineered bone becomes incorporated within 
the patient, giving rise hopefully to a permanent cure for the patients suffering from 
various bone disorders.  
 
1.4.3  Bone Tissue Engineering 
Bone tissue engineering is a promising area in the field of medicine and involves 
principles of biology and biomedical engineering with the aim of developing a viable 
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tissue substitute that can restore the function of human bone tissue (Rosa, 2012, 
Hollinger, 2004). Bone cells (osteoblast, osteocyte, osteoclast), osteoconductive factor 
(three-dimensional matrices or scaffold) and osteoinductive factor (recombinant 
signalling molecules or growth factors) are the three main key elements (See Figure 1.3) 
in the tissue engineering of bone (Ramoshebi, 2002).  
 
Figure 1.3 Three main elements of bone tissue engineering (Sefat, 2010a). 
 
One popular approach in bone tissue engineering involves seeding bone cells in a highly 
porous biodegradable scaffold in the shape of the required bone. In this system bone 
cells are grown with growth factors in a bioreactor in which in vivo mechanical stresses 
are mimicked. Once cultured these replacement tissues can then be implanted into the 
defect site in order to induce and direct the growth of new bone (Jeffrey O. Hollinger, 
2004, Vunjak-Novakovic, 2006, Salter, 2012). As a result of this process it is hoped that 
bone cells from the intact tissue will also grow into the implanted tissue thus allowing 
full integration of the implant and potentially repair the damaged bone with a high 
degree of structural integrity. Key in this process is the non-toxic degradation of the 
implanted scaffold (Hutmacher, 2000, Kawakita, 2012). 
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Bone repair and regeneration by the method of bone tissue engineering takes place in a 
series of cellular events that are affected by various biological and mechanical factors. 
All new formed tissue requires a group of cells known as osteoprogenitor cells capable 
of forming bone (Fleming, 2000). Cells used for bone tissue engineering are derived 
from a pluripotent population. These cells are capable of differentiation to different 
tissue types. Osteoprogenitor cells can be harvested from many sites and can undergo 
population expansion in in vitro cell culture (Freshney, 1994). Bone cells need to be 
delivered to a bone defect.  The bone healing response starts when newly formed bone 
cells integrate with the surrounding tissue. Bone cells then grow either in a natural 
matrix or synthetic 3- dimensional scaffolds (Hutmacher, 2000). In this system the 
natural matrix or synthetic scaffolds are used to support cell attachment, proliferation 
and differentiation. Growth factors and adhesion molecules are present in or on the 
surface of the implanted matrix or secreted by cells incorporated in the matrix. Growth 
factors and adhesion molecules function by controlling cell migration, differentiation 
and subsequent tissue formation (Ramoshebi, 2002). The stimuli from these growth 
factors and adhesion molecules are known as osteoinductive signals. These are capable 
of determining the osseous nature of the tissue produced at the graft site (Fleming, 
2000). Mechanical stimulation (environment) is also used to assist bone formation. 
Distraction osteogenesis (DO) is the process by which application of a tensile force at 
an optimal rate and frequency controls new bone formation, and this has been used 
successfully in bone repair (McCarthy, 2001). 
 
The use of a bioreactor is very important. Fully functional tissues cannot be grown in 
conventional cell culture systems because although they may expand cell numbers they 
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may also promote inappropriate cell differentiation or de-differentiation (Freshney, 
1994, Schnabel, 2002, Salter, 2012). Moreover, cells require external signals or cues 
before being implanted in the body to grow into functional 3D tissue (Burridge, 1996, 
Barrientos, 2008). These signals in the body can be mechanical, electrical, chemical or 
topographic (Logeart-Avramoglou, 2005). Structural cues involve the interaction 
between cells with their ECM. Firstly, bone cells cause remodelling of the ECM and, in 
turn, this remodelling of the ECM functions in a feedback mechanism modifying cell 
function. Thus, the physical communication between cells and ECM impacts cell shape 
and function (Akiyama, 1990). Cell actions and their responses to different signals 
(chemical, electrical, mechanical and structural) are mediated by protein based 
molecules known as growth factors (GF). GFs regulate cell migration, cell 
morphogenesis (from one cell type to another) and mitogenesis (cellular proliferation) 
(Ramoshebi, 2002). Growth factors are produced locally and systematically and can 
have different effects such as autocrine, paracrine, juxtacrine and endocrine effects in 
terms of the source of secretion, distance they travel in the body and the specific target 
where they can be effective. Beside their functions such as growth development and 
bone tissue maintenance, growth factors are also mobilized during bone remodelling 
and repair (Solheim, 1998).  
 
1.4.4  Integrin receptors and cell adhesion 
The interaction of bone cells with their extracellular matrix is of major importance in 
bone development, repair, and disease (Brighton, 1992, Tosounidisa, 2009). The 
interaction of bone cells with their surrounding ECM environment influences 
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physiological functions and pathological processes (Albelda, 1990). These 
physiological functions are normal skeletal development and bone matrix production. 
The interaction of bone cells with ECM are mediated by integrins, a family of cell 
surface receptors (Akiyama, 1990, Aoudjit, 2012). Integrins are a group of membrane 
spanning receptor proteins which bind to components of the extracellular matrix 
(Hynes, 1992) and they play key roles in the assembly of the actin cytoskeleton as well 
as in modulating signal transduction pathways (Srichai, 2010) that control biological 
and cellular functions including cell adhesion, migration, proliferation, cell 
differentiation, and apoptosis (Hynes, 1992, Worthington, 2011, Aoudjit, 2012). The 
physical link between integrins and actin is required for local regulation of actin 
polymerization as well as for global control of cytoskeletal dynamics. 
 
Integrins exist as two non-covalently bound α and β subunits (Saito, 2004, Srichai, 
2010). There are 18α and 8β known subunits which combine to form at least 24 distinct 
integrin heterodimers (see Figure 1.4) (Hynes, 2002). The α chain conveys ligand 
specificity and the β chain provides linkage to the cytoskeleton via talin, vinculin, or α 
actinin. The α and β chains have similar tertiary structures and are linked via their 
extracellular globular domains (Albelda, 1990, Worthington, 2011). Integrins can be 
divided into two groups. The first group contains integrins that bind to matrix proteins 
found in basement membranes. In this group the receptor binds to proteins such as 
collagen and laminin (Stephansson, 2002). The second group contains integrins that 
bind to matrix proteins such as fibronectin, vitronectin, osteopontin and fibrinogen, all 
of which are found during inflammation, wound healing or the development process 
(Saito, 2004). When integrins are inserted into the leading edge of the cell then cell 
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surface coupling will predominate in this region, which prevents membrane retraction 
and provides adhesive traction for cell movement.  
 
Figure 1.4 Classification of integrin family of heterodimers. The nine a domains with 
inserted (I) domains (1, 2, 10, 11, D, L, M, X, E) are indicated in red. Image adapted 
from (Srichai, 2010). 
 
Figure 1.5 shows an integrin of the fibronectin receptor with two named subunits. These 
transmembrane polypeptides associate non-covalently with each other to form a binding 
site for the ligand on the outer membrane surface and a binding site for a specific 
cytoskeletal protein on the inner membrane surface. The fibronectin receptor has a 
binding site for fibronectin on the outer surface and a binding site for talin on the 
cytoplasmic side of the membrane. In this integrin the alpha subunit is split into two 
segments held together by a disulfide bond. 
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Figure 1.5 Schematic representation of the integrin subunit structure, showing how 
both an  and  sub-unit combine to form a matrix binding domain and a cytoskeleton 
binding domain. Image adapted from (Alberts, 2002) 
 
Several parallel researches have been carried out for about two decades towards an 
understanding of the role played by integrins in the growth, maintenance, and repair of 
bone. For instance, it has been shown that osteoclast isolated from human bone 
expresses the αVβ3 integrin complex, which constitutes the classic vitronectin receptor 
(Davies, 1989), and α2 integrin, which combines with β1 integrin to form the (very late 
activation) VLA-2 complex, (Davies, 1988) a type I collagen receptor (Staatz, 1989 ). 
There is evidence to suggest that the bone matrix protein osteopontin is the ligand for 
αVβ3 expressed on osteoclasts (Reinholt, 1990). The human osteosarcoma-derived cell 
line MG63 has been shown to express α5β1 and αVβ3 integrins (Dedhar, 1987, Freed, 
1989) and a variant of this line showing osteoblastic differentiation expresses increased 
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levels of cell surface α5β1 but not αVβ3 (Dedhar, 1987, Dedhar, 1989a). Furthermore, 
interleukin-1β induction of osteoblastic differentiation of MG63 osteosarcoma cells 
results in an induction of expression of α5β1 (Dedhar, 1989b). Inhibition of α5β1 function 
with subunit-specific monoclonal antibodies inhibits this osteoblastic differentiation 
(Dedhar 1989c). In order to identify the expression of integrins by bone cells more 
precisely in vivo immunocytochemical studies involving the use of antibodies against 
β1-4 , α1-6 and αV integrins, and the αVβ3 dimer (Hughes, 1993) have shown that all cell 
types present in bone expressed β1 and α5 integrins and a subpopulation of osteoblastic 
cells expressed α4. The αV was uniformly expressed by osteoblasts but was 
heterogeneously expressed by osteocytes. Osteoclasts also expressed α2, αV and αVβ3. 
These results (Hughes, 1993) demonstrate differential expression of a restricted range of 
integrins in bone. This supports the possibility that integrins may mediate the differing 
interactions of cells of the osteoblast and osteoclast lineages with the matrix of bone 
(Hughes, 1993). More recent studies have also identified integrins on human bone cells 
(Saito, 2004). Minced fragments of trabecular bone obtained during total knee 
arthroplasty were grown in culture until confluent. Bone cells were assayed for alkaline 
phosphatase activity. Results showed different percentages of attachment for each group 
of substrates. 60-70% adhered to type I collagen, fibronectin, vitronectin and poly-D-
lysine, 40-50% adhered to type-IV collagen, laminin and gelatine and only 10% adhered 
to fibrinogen (Saito, 2004). It was found that human bone cells revealed high levels of 
α1β1, α3β1, α5β1 and αvβ5 integrins and lower levels of α2β1, α4β1, αvβ1 and αvβ3 
integrins (Saito, 2004). This study also demonstrated that cultured human bone cells 
adhere to a wide variety of ECM proteins and possess a unique repertoire of integrin 
receptors that includes relatively large amounts of collagen/laminin receptors (α1β1, 
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and α3β1 integrins) and fibronectin/ fibrinogen/vitronectin receptors (α5β1, αvβ3, and 
αvβ5 integrins) (Saito, 2004).  
 
1.4.5  Cell adhesion proteins 
The morphology of cells is determined by a sequence of dynamic interactions that are 
mediated by a heterogeneous population of transmembrane adhesion molecules (Lodish, 
2000, Yang, 2010). Besides mediating cell–cell and cell–extracellular-matrix 
attachment, cell-adhesion molecules facilitate cytoskeletal–membrane interaction and 
signal-transduction processes, which control some cell’s function including, 
cytoskeletal organisation, cell motility, cell viability and receptor activation. Cell 
adhesion proteins like selectins and cadherins are often transmembrane receptors. 
Transmembrane cell adhesion proteins expand across the cell surface membrane and 
have domains that extend into both the extracellular space and the intracellular space.  
The extracellular domain of a cell adhesion protein can attach to other molecules that 
might be either on the surface of neighbouring cells (cell-to-cell adhesion) or part of the 
ECM (cell-to-ECM adhesion) (Lodish, 2000).   
 
Cell adhesion proteins bind to specific ligands. There are families of cell adhesion 
proteins that can be categorized in terms of the structure of the adhesion proteins and 
their ligands.  Homophilic binding is an adhesion between similar adhesion protein 
while heterophilic binding is an adhesion between an adhesion protein and some other 
molecule. Table 1.1 shows the major cell adhesion proteins (Saito, 2004).  
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Table 1.1 Major cell adhesion protein families and the corresponding ligands (Saito, 
2004). 
Major Cell Adhesion Protein Families 
Family ligands interactions 
Selectins Carbohydrates heterophilic 
Integrins Extracellular matrix heterophilic 
 Ig superfamily proteins heterophilic 
Ig superfamily proteins Integrins heterophilic 
 Ig superfamily proteins homophilic 
Cadherins Cadherins homophilic 
 
1.4.6  Role of Micro-contact Printing (MCP) 
Biomaterials can be used to modify the surfaces in cell culturing and so modify cell 
adhesion, but the complexity and fragility of a biomaterial is an important issue to 
consider when engineering tissue. Protein patterning can be achieved using a range of 
techniques (Crozatier, 2005). In the micrometer and sub-micrometer range photo 
lithographical methods can be used to create patterns, but materials such as organic 
solvents, UV light and photo resist developer may denature proteins (Tan, 2004). 
Micro-contact printing (MCP) is a strategy to overcome these problems (Jang, 2012) 
that was initially used for the creation of alkanethiol patterns on gold. Versatility is the 
main advantage of this method, since a wide range of biomolecules can be printed onto 
a variety of different background materials (Offenhäusser, 2007). Collagen type I is the 
main component of the extracellular matrix (ECM) in bone which acts as a cell adhesion 
protein and is an ideal candidate for micro-contact printing as it functions by directing 
cellular adhesion, migration, differentiation and network formation in vivo. Fibronectin 
is present in bone after wounding at the site of injury (Han, 2008). Fibronectin and 
heparin released from cells during tissue injury participate in blood clotting and play 
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important roles in initiating tissue repair. In this respect fibronectin provides adhesion 
sites for tissue repair cells and constitutes a connector for the fibrin glue and heparin 
(Han, 2008). Despite evidence suggesting that bone cells express laminin receptors, 
bone ECM contain little laminin and there is little evidence that bone cells adhere to 
laminin (Colucci, 1996, Gentili, 2009). Thus, laminin was used in this study (as a 
negative control) in order to compare with main proteins that exist in bone such as 
collagen type I and fibronectin.   
 
1.4.7  Osteoinductive Factors (Role of Cytokines) 
There are various techniques to enhance tissue regeneration via the application of 
growth factors to the site of regeneration to induce cells to proliferate, differentiate and 
regenerate. Generally, direct application of growth factors has little effect (Khan, 2000) 
because the growth factor diffuses out from the site of regeneration very quickly. This is 
a problem that can be solved by a controlled release of growth factor at the site of action 
over a long period of time by use of a bioabsorbable scaffold. Growth factors are protein 
based molecules in the body which are produced by cells and attach to the cell surface. 
Growth factors bind to membrane receptors, which in turn activate an intracellular 
signalling pathway. This will activate or inhibit a gene causing either an up regulation 
or down regulation of a gene product, which then alters the cells behaviour. Growth 
factors mediate cell actions and their response to different environmental cues. Growth 
factors may be produced in different ways with different effect such as autocrine effect 
(growth factors act directly on the cell that produced them), paracrine effect (growth 
factors act on neighbouring cells surrounding the growth factor), juxtacrine effect 
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(growth factor communication signal received by one cell to neighbouring cells due to 
cell-cell interaction), endocrine effect (growth factors act on a cell a distance away from 
the growth factor by travelling through the blood stream) (Smith, 2003a). Growth 
factors, therefore, have an important role in growth, development, day-to-day 
maintenance, mobilised remodelling and injury. Bioabosrbable scaffolds may be seeded 
with DNA coding for growth factors. Tissue regeneration can be achieved if a growth 
factor gene is transferred into the cells at the site of regeneration and cause cells to 
secrete growth factor (Centrella, 1994). Bone cells can be isolated from the recipient 
(bone marrow/connective tissue), expanded in tissue culture, exposed to bioactive 
factors, combined with the scaffold and finally implanted into the donor site in order to 
persuade regeneration. Specific growth factors are synthesized and secreted by 
developing cell lines and combined with a delivery system for implantation in the 
skeletal site. Cell differentiation occurs due to the influence of the secreted growth 
factor (Solheim, 1998).   
   
1.4.8  Previous studies on osteoinductive factor (Cytokines) 
Growth factors have direct effects on cell activities such as cell adhesion, proliferation, 
differentiation, and migration by modulating the synthesis of proteins, other growth 
factors and receptors (Johnson, 1988). Each growth factor such as bone morphogenetic 
protein (BMP) (Croteau, 1999), transforming growth factor beta (TGF-β) (Khan, 2000), 
fibroblast growth factor (FGF) (Hurley, 1993), insulin-like growth factor (IGF) (Thaller, 
1993) and platelets-derived growth factor (PDGF) (Solheim, 1998) have different 
effects on bone cells (Ramoshebi, 2002). For instance, BMP belongs to a group of non-
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collagenous glycoproteins that in turn belongs to the TGF-β super family (Guiqian, 
2012). BMP is synthesized locally and 15 types of BMP have been discovered (Croteau, 
1999). Many studies have been carried out in order to see the effect of BMP on different 
bone defects (Laflamme, 2008). Research on BMP-2 (Cho, 2002) showed early 
response genes in the cascade of healing one day after fracture. These discoveries 
indicate that the BMP family of proteins are actively involved in fracture healing 
(Matthews, 2005).  
 
Insulin-like growth factor (IGF) makes use of the anabolic effect on bone metabolism. 
There are two types of IGF known as IGF1 and IGF2 which stimulate osteoblast, 
osteoclast cell proliferation and matrix synthesis (Khan, 2000). Its ability to promote the 
healing of critically sized calvarial defects in rats has been studied (Thaller, 1993). Rats 
receiving IGF-1 subcutaneously showed repair within one week of treatment and 
complete bone formation by the end of week six. In contrast, controls showed delay 
osseous repair after eight weeks. The effectiveness of IGF-1 with TGF-β1 compared to 
autologous bone grafts in cervical fusion (Kandziora, 2002), C3 and C4, under 
discectomy and stabilisation was achieved by using a titanium cage with IGF-1 and 
TGF-β1. These results showed that animals treated with IGF-1 and TGF-β1 had 
significantly higher fusion rates compared with bone grafted animals.  
 
1.4.9  Transforming growth factor-beta (TGF-β)  
The TGF-β super family include different proteins such as BMPs, nodals, activins, 
TGF-β and inhibins (Derynck, 2008). TGF-β is a cytokine produced by different cell 
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types inside the body and exists in three isomers TGF-β1, 2 and 3 (Worthington, 2011). 
These isomers can act as either paracrine or endocrine hormones. These isomers are 
structurally similar and encoded by three distinct genes in mammalian species (Mehta, 
2007). The TGF-β superfamily includes a large group of soluble extra-cellular proteins, 
which regulate development in both vertebrates and invertebrates (Raftery, 2002a). The 
TGF-β family of cytokines regulate cell functions such as migration, apoptosis, 
proliferation and differentiation (Krauss, 2006a). It is important to know where the 
target cells are located as TGF-β can have different effects in different cell 
environments. For example, in skin cells when fibroblasts are grown in a monolayer in 
the presence of epidermal growth factor, TGF-β1 causes a decrease in proliferation. In 
comparison, when these cells are grown in a semi-solid medium, TGF-β1 induces 
growth (Border, 1994). TGF-β influences a number of cell activities such as 
differentiating, stimulating mesenchymal stem cell (MSC) growth, acting as a 
chemotactic factor and also enhances bone cells and ECM production and secretion 
(Khan, 2000). It has also been used to stimulate bone regeneration (Lind, 1993). Using 
an animal model and TGF-β2 administered for a period of six weeks in the case of tibial 
defects it was shown that TGF-β2 had positive effects on fracture repair (Lind, 1993). 
The effects of TGF-β on bone repair are dependent on the mechanical stability at the 
site of fracture (Critchlow, 1995). Unilateral tibial fractures were produced in a rabbit 
animal model and a plate (plastic /steel) was used in order to immobilise the fracture 
site. TGF-β2 was applied into the calluses 4 days after fracture. Results demonstrated 
that in an animal with unstable fixation TGF-β2 did not show an effect on callus 
formation, but the sample with a stable fixation developed enlarged calluses (Critchlow, 
1995). The presence of BMP-7 enhanced bone formation when combined with low 
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dosage of TGF-β1 (Ripamonti, 1997). Mixtures of these two growth factors showed an 
increase (about 2-3 times) in the cross sectional area of newly generated ossicles 
compared to BMP-7 alone.  
 
1.4.10  TGF-β signalling 
The effects of TGF-β1, 2 and 3 are mediated by a range of signalling pathways (Kale, 
2004a, Aoudjit, 2012). Activation of the same signalling cascade follows ligand-
receptor interactions at the cell surface. The TGF-β receptor complex is made up of 
serine-threonine kinase receptor types I and II. These bind to a third receptor, type III; 
also known as betaglycan. This membrane-anchored proteoglycan binds to the TGF-β 
ligand and presents it to the type I/II receptor complex allowing signal transduction to 
occur (Shi, 2003). This betaglycan has been shown (Lo´pez-Casillas, 1994) to act as 
dual modulator of TGF-β activity. The soluble form of this protein, no longer anchored 
to the cell membrane, acts as an inhibitor of TGF-β signalling (Lo´pez-Casillas, 1994, 
Shi, 2003). Furthermore, all TGFβ superfamily members bind to heterodimeric receptor 
isomers that belong to the same family, i.e. dimeric complexes of various type I receptor 
serine/threonine kinases (ALK 1-7) and type II receptor proteins (5 isoforms) (Euler-
Taimor, 2006). These receptors subsequently activate different intra-cellular Smad 
proteins to elicit various biological responses (Euler-Taimor, 2006). Besides activation 
of Smads, TGF-β mediates its effects via activation of a number of signals including 
mitogen-activated protein kinases (p38 MAPK), extracellular-signal-regulated kinases 
(Erk), c-Jun N-terminal kinase (JNK), and Transforming growth factor β–activated 
kinase 1 (TAK1) (Bujak, 2007).  
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Apart from TGF-β itself, the biological functions of the other TGF-β superfamily 
ligands are poorly understood such as BMP which share the same signalling cascade. 
To initiate intracellular signaling, BMP binds as a dimer to a complex of two 
transmembrane receptors (type I and II) and starts a phosphorylation cascade 
upregulating bone-specific differentiation genes (e.g., runx2, osteocalcin, bone 
sialoprotein, type I collagen, and alkaline phosphatase). Interestingly, BMP-2 receptors 
type I and II are cascaded by two independent signalling pathways (Hollinger, 2005, 
Massague, 1996, Palcy, 1999, Kale, 2004a). 
 
The first pathway involves BMP-2 dimerization and binding to a preformed receptor 
complex, initiating a phosphorylation cascade. The type I receptor phosphorylates 
Smad1, Smad5, and Smad8. A complex of these three is formed with Smad4 in the 
cytoplasm. The complex translocates to the nucleus and functions as a transcriptional 
regulator of bone-specific genes. In contrast Smad6 and Smad7 have an inhibitory effect 
for such formation by bending to type I receptor and blocking the phosphorylation of 
Smad1, Smad5, and Smad8 (See Figure 1.6). The second signalling pathway is 
activated when the BMP-2 dimer binds to receptor type II only. This binding event 
recruits receptor type I and initiates a phosphorylation cascade via the MAPK pathway 
involving p38 and Erk1/2. This pathway culminates with activation of AP-1 in the 
nucleus.  
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Figure 1.6 Two different pathways characterized for Runx2 activation via BMP’s 
(Hollinger, 2004). 
 
TGF-βs are among the most multi-functional cytokines known; they affect a variety of 
cell types and modulate multiple biological processes (Mehta, 2007). The overall effect 
of TGF-β depends on the cytokine milieu and the state of cell differentiation 
(Souchelnytskyi, 1996). Previous studies regarding the effects of different TGF-β 
families and their combinations in the wound healing of bone are poorly understood or 
have only been partly addressed (Khan, 2000). For instance, many studies have been 
carried out in the presence of bone with various growth factors such as bone 
morphogenetic protein (BMP) (Croteau, 1999), platelets-drived growth factor (PDGF), 
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insulin-like growth factor (IGF) (Thaller, 1993) and fibroblast growth factors (FGF) 
(Hurley, 1993). The current work, related to the use of TGF-βs, investigates the effect 
of different TGF-β isomers and their combinations on bone cell detachment via the 
trypsinization process in addition to their effect on the wound closure response on dish-
cultured bone monolayers, using a simple scratch assay.  
 
In order for TGF-β to be administered exogenously it needs to be dissolved with HCl 
and with BSA as carrier of TGF-β. It is suggested that HCl also contributes to the rate 
of wound repair (Centrella, 1988). This is particularly important since there is evidence 
that the pH of injured bone can decrease and that this may play a role in activating TGF-
β (Oursler, 1994, Dallas, 2002). Thus, it is important to investigate the role played by 
HCl in wound closure in a simple bone cell culture model. It is also very important for 
the growth factor to be delivered properly to ensure a stable form and without losing its 
bioactivity. To overcome these problems HCl is added to the TGF-β to stabilize the 
solution and reconstitute it from the powder form. Upon cell culturing further HCl is 
added to TGF-β, which prevents losses allowing a final concentration ranging from 
0.1ng/ml to 10ng/ml in most culture systems (Lind, 1993). Other groups have also 
investigated that latent TGF-β1 can be activated by heat, acidification, alkalinisation or 
the action of chaotropic agents in vitro (Annes, 2003). The Zamora research group 
compared the effectiveness of acidification versus heat treatment in activating latent 
TGF-β1 in a cell-free system. ELISA assay was carried out using recombinant human 
latent TGF-β1 (Zamora, 2007). It was found that while both heat and HCl led to the 
activation of latent TGF-β1, heat treatment was significantly more effective than 
acidification (Zamora, 2007). On the other hand ascorbic acid has been reported to 
 40 
 
increase collagen deposition and tensile strength in experimental models of wound 
repair (Wendt, 1997). The role of ascorbic acid in the healing of injured tissues has been 
investigated in a variety of studies (Cevikel, 2008). Other groups have shown that the 
administration of ascorbic acid expedites wound healing in rats (Kamer, 2010). 
Ascorbic acid could bestow benefits to tissue healing by significantly enhancing tissue 
hydroxyproline levels, neovascularization, fibroblast maturation, and collagen 
deposition. It is therefore important to examine the role played by HCl in wound closure 
of bone. Previous studies have shown (Khan, 2000) an overall poor understanding 
regarding the use of TGF-β isomers in bone cells in terms of fracture repair and healing 
compared to other cell type, for example, keratinocyte, and, also, compared to other 
growth factors such as bone morphogenetic protein (BMP) (Croteau, 1999), platelets-
derived growth factor (PDGF), insulin-like growth factor (IGF) (Thaller, 1993) and 
fibroblast growth factors (FGF) (Hurley, 1993). It is therefore important to examine the 
role of each TGF-β isomer in cultured bone cell monolayers. 
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1.5 AIMS AND OBJECTIVES 
The overall aim of this study was to investigate the role of ECM proteins (collagen type 
I, fibronectin and laminin), transforming growth factor beta isomers (TGF-β1, 2 and 3), 
and HCl/BSA in cellular adhesion, cell behaviour and wound healing in cultured bone 
cell monolayers.  
 
The main objectives of this work were to: 
1) Compare Collagen type I, Fibronectin and Laminin in the adhesion and alignment 
of the human bone (MG63) cell to these proteins printed via micro-contact printing 
with various widths (sizes).  
2) Investigate the effects of different transforming growth factor beta isomers (TGF-
β1, 2 and 3) on bone cell detachment via a trypsinization assay. This will provide 
information about the degree of cell surface attachment.  
3) Investigate and compare the wound closure properties of bone cell monolayers 
using different TGF-β isomers, HCl and BSA/HCl in cultured dish environments by 
creating a simple 2D wound model. This will provide information about how 
different TGF-β isomers influenced wound repair. Also, to identify various 
integrins that may inhibit wound repair, it was necessary to examine the 
combination of TGF-βs and use specific antibodies. This has the potential for 
therapeutic combinations of cytokines and cell attachment inhibitors in the in vivo 
wound. 
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4) Examine the effect of HCl on cell behaviour used as TGF-β solvent and to 
distinguish its effect compared to the actual growth factor effects on wound 
healing. 
5) Investigate other cellular responses such as proliferation and detachment along with 
different stages of cell behaviour and morphology (cell length and cell number) 
during wound healing. 
6) Use immunostaining to identify which integrins are up or down regulated and how 
TGF-β modified ECM production. It is hoped the above investigation will allow the 
identification of the major integrins that influencing wound repair. To have a better 
understanding about cell-surface interfacial interactions, a newly developed WSPR 
microscope will used for imaging and analysing the cell surface interactions. 
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CHAPTER TWO 
2. STUDYING BONE CELL INTERACTIONS 
WITH MICROPATTERNED ECM PROTEINS 
 
2.1  INTRODUCTION 
Micro-contact printing (MCP) is a strategy that enables a surface to be readily 
functionalised with a material such as an extra cellular matrix (ECM) protein, in a 
defined pattern (Sefat, 2010a, Ricoult, 2012, Sefat, 2008, Berends, 2009, Khaghani, 
2008). MCP also allows control of cell adhesion geometry on a surface. Micro-contact 
printed substrates may be used to examine cell behaviour in relation to a wide range of 
extracellular matrix (ECM) molecules including collagen type I, fibronectin and laminin 
(Kumar, 1994). These cell adhesion proteins are the main components of ECM and 
ideal candidates for MCP as they can direct cellular adhesion, migration, differentiation 
and network formation in vitro (Carter, 1965). These cellular behaviours may then be 
used to aid in deciphering the cell signalling pathways associated with the control of 
cell surface interactions (Kleinman, 1990).  Collagen is a group of naturally occurring 
proteins and one of the most important structural proteins of the extracellular matrix. It 
is the major element of connective tissue and is the most abundant protein in mammals 
(Viguet-Carrin, 2006). 25 to 35% of the entire body consists of collagen protein. 
Collagen in the form of elongated fibril is typically found in skin, tendon and ligament, 
which are known as fibrous tissue. Collagen is also plentiful in bone, cartilage, cornea, 
blood vessels, intervertebral disc and the gut. Fibronectin is a transmembranous 
glycoprotein that is found naturally in its soluble form in plasma and its insoluble form 
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in connective tissue and the basal lamina (Pankov, 2002). It is a high molecular weight 
protein that binds to collagen, fibrin, fibroblasts in the ECM and the plasma membrane 
of the cells. This protein plays a major role in cell adhesion and re-organiation of the 
ECM (Salber, 2007). Fibronectin and collagen can bind together at the region called 
FN1/2, while the FN3 region takes up contact with the respective cells (Pankov, 2002). 
The contact point consists of the amino acid sequence RGD (Arg-Gly-Asp) which binds 
to integrins. The 5β1-integrin has a particularly high affinity for fibronectin. 
Completely different kinds of fibronectin are formed by alternative splicing. The liver, 
for example, builds fibronectin, which then circulates as a dissolved component of the 
serum.  However, stationary fibronectin is also formed in different tissues (Pankov, 
2002).  
 
Laminin is another important protein present in the body and a major protein in basal 
lamina. Laminins are large molecules, which occur mainly in the basement membrane 
of the epithelium. Laminin is very important in influencing cell differentiation, 
migration, adhesion as well as phenotype and survival (Timpl, 1979). It consists of α, β 
and γ chain. Laminin can bind to two groups as it has a binding site for the cell receptor 
and a binding site to other components of ECM. The laminin molecules are named by 
looking at their chain composition, e.g. laminin-511 contains α5, β1 and γ1 chains 
(Aumailley, 2005). This protein has a cross shape with three shorter arms and a long 
arm at the bottom. The shorter arms are suitable for binding to other laminin molecules 
in order to form a sheet, while the long arm can bind to cells (Haralson, 1995). Laminin 
is not normally found in the ECM of bone (Colucci, 1996, Gentili, 2009). 
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The major ECM components of bone consist of collagen type I, fibronectin and 
individual proteoglycans (Gentili, 2009). This is an interactive natural scaffold that 
provides mechanical stability and cell anchorage, and is also able to control cell 
functions.  There is not enough laminin in bone and therefore poorely expressed. We 
were motivated to use laminin in this study (as a control) to enable a comparison of this 
protein with other ECM proteins such as collagen type I and fibroenctin, (Sefat, 2010a). 
The aim of this study was to compare osteoblast behaviour grown on micro-contact 
printed laminin against collagen type I and fibronectin. Therefore, osteoblast responses 
to these three ECM proteins were investigated.  
 
In natural skeletal tissues, such as bone, ligaments and tendons, the cells and the 
structures are found to align at spatial and oriented geometries and patterns (Zhu, 2005). 
When designing an implant material, it is important to mimic natural bone tissue, where 
cells are orientated at specific directions, by providing directional cues in regulating the 
cell alignment in a preferential direction and in specific locations to create organized 
structures (Zhang, 2011). In recent years, considerable efforts have been made to 
understand cell surface interaction and cell guidance for applications in biomedical 
systems (Feinberg, 2008, Hamilton, 2006). The potential applications of such systems 
include the micro-textures that have been introduced to enhance tissue integration and 
wound healing (Dalby, 2003, Khang, 2006, Berends, 2009, Khaghani, 2008). On the 
other hand, many polymer and metal materials have been commercially developed as 
implants for bone and cartilage repair. These materials often exhibit poor and 
uncontrolled interactions with proteins and cells, making them difficult to integrate into 
the body tissues. Therefore, efforts have been made to deposit bioactive coatings onto 
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implant surfaces to improve the bioactivity and biocompatibility. For instance, the uses 
of chemical guidance cues have been shown to promote “contact guidance” (Folch, 
1998, Clark, 1990), which is a phenomenon that involves the alignment of cells, as they 
spread across micro-patterns. Another investigator (Su, 2007) studied the effects of 
micro-patterned geometries on cell alignment. Polydimethylsiloxane (PDMS) has been 
extensively used in microfluidic devices, BioMEMS and lab-on-a-chip applications 
(Whitesides, 2006, Cecchini, 2008, Yea, 2006). The increasing attention on PDMS has 
been due mainly to its excellent combination of biocompatibility and mechanical 
properties (Peterson, 2005, Griscom, 2002). Some investigators also studied the effects 
of micro-pattern on cell spreading and alignment on PDMS (Chaw, 2007, Salber, 2007).  
 
Recently collagen type I and gelatin were stamped on modified glass and titanium 
surfaces to create patterns with varying shapes and sizes (Zhang, 2011). Osteoblast-like 
cells were seeded onto these patterned surfaces and the cell attachment, proliferation, 
and spatial alignment were investigated. Their results showed that the alignment of cells 
was dependent on the width of the protein stripes and the spacing distance between the 
stripes. Their results also showed that the osteoblast-like cells exhibited a precise 
alignment along the stripe patterns at low stripe widths of 10, 25, and 50μmAs the 
width of the stripes increased to 100, 150 and 200μm, the cells on the protein stripes 
tended to become more randomly orientated (Zhang, 2011).  
 
This method can be used to modify implantable medical devices to provide an ECM-
mimicking environment for better cell attachment, proliferation and tissue growth. 
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Creation of precise surface patterns on the glass, polymer or metal materials could 
provide entirely new insights into the factors that control cell adhesion onto material 
surfaces, cell proliferation, differentiation and molecular signalling pathways (Ogaki, 
2010, Diener, 2005). It is expected that these surface-engineered materials will have the 
ability to control the shape of the attached cells and the cell-cell contacts through the 
formation and dimensions of the cell-adhesive patterns. The methods and results in the 
present study could find applications in surface engineering of implant materials for 
bone replacement and repair (Zhang, 2011, Sefat, 2010a).  
 
The aims of this chapter is to investigate the effect of micro-contact printed ECM 
proteins, namely fibronectin, collagen type I and laminin, with different pattern width 
(5, 10, 25, 50 and 100m), on cell alignment, attachment, density and morphology of 
MG63 bone cells cultured in vitro. ECM proteins were stamped on plain (un-modified) 
glass cover slips to create patterns with varying sizes. Our approach to cell patterning 
has the advantages of simple preparation, high stability, tunable pattern sizes and 
facilitation of controlling the cell alignment, and this could find wide applications in 
tissue engineering, such as in bone implants, where precise control of cell structures 
would be preferable. 
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2.2  MATERIALS AND METHODS 
2.2.1  Cell Culture 
Bone cells were cultured in a low glucose (1g/L-D-Glucose) HEPES (25mM) buffered 
DMEM (Dulbecco's Modified Eagle Media, Sigma Aldrich) culture media 
supplemented with L-glutamine (2.5 mM U/mL), Penicillin (100 U/mL), Streptomycin 
(0.1 mg/mL), Amphotericin B or a fungizone (250µg/ml), (Sigma Aldrich-UK)  and 
10% FCS v/v (fetal calf serum- PromoCell - UK). The bone cells were plated in 25cm
2
 
tissue culture grade cell culture flasks at a cell density of 250,000 cells/culture flask and 
bathed in the culture media. All supplements were purchased from Sigma Aldrich-UK 
except those mentioned. Media was changed every 2 days for normal cell culture 
procedure. Cells were incubated at 37°C and split upon reaching confluency, usually 
every 3-4 days (Vunjak-Novakovic, 2006). Sterilisation was a key aspect in performing 
the experiment, and therefore a sterilised environment was essential when working with 
cell culture to avoid contamination by using 70% ethanol. Cells were seeded on glass 
surface patterned 5, 10, 25, 50 and 100μm wide repeat gratings of collagen type I, 
fibronectin or laminin in order to identify the role of these proteins in the adhesion and 
alignment of the human bone cell (MG63) to different micro-contact printed ECM 
patterns.    
 
2.2.2 Type of cell used  
Human bone cell line MG63 (Osteoblast-like cells originally isolated from a human 
osteosarcoma) was used in this study (Sefat, 2008, Sefat, 2010a). MG63 human 
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osteoblasts, is a widely used cell line (Morris, 2006) because of its ability to retain a 
differentiated phenotype in culture conditions (Declercq, 2004). MG63 cells have also 
been used previously in the study of the integrin-mediated cell-matrix interactions and 
regulated by cytokines and hormones (Broberg, 1996, Riikonen, 1995). Moreover, the 
MG63 cell line has been used as a convenient source for purification and identification 
of known and novel osteoblast transcription factor complexes (Newberry, 1997).  
 
2.2.3 Stamp Fabrication 
Master stamps (glass template) repeat gratings consisting of 5, 10, 25, 50 and 100m 
wide ridges (width) with 5m deep channels were micro-fabricated by the Department 
of Electronics and Electrical Engineering, at University of Glasgow. 
Polydimethylsiloxane (PDMS) stamps were then produced at the University of 
Bradford from these templates by firstly coating the templates with 2% 
dimethylchlorosilane mixed with 98% trichloroethylene. This mixture made the 
surface hydrophobic. Next, 9ml of sylgard (silicon-based elastomer gel) and 1ml of 
curing agent were poured onto the templates and allowed to cure overnight. Vacuum 
processing was carried out to remove any trapped gases. After curing, the sylgard gel 
was removed from the template enabling sylgard stamps exhibiting a negative relief of 
the template to be produced. These stamps were then used to functionalize plain glass 
slides and gold coated test substrates with different proteins.      
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2.2.4 Micro contact printing (MCP) Technique 
Prior to MCP all working environments (surfaces), stamps and coverslips were 
sterilized with 70% ethanol and left to dry completely in a laminar airflow cabinet. 
Plain glass coverslips and gold coated glass coverslips were then micro-contact printed 
with collagen type I, fibronectin and laminin. The dilution used for collagen, 
fibronectin and laminin was 3mg/ml (SIGMA). The following stamping method was 
then employed: stamps were inked by dipping in each protein solution for duration of 
60 seconds (Tan, 2004, Khaghani, 2008). The stamp was then removed from the 
protein solution and air-dried for 30 seconds and placed immediately in contact with 
the substrate and pressed slightly using another glass cover slip for 60 seconds. This 
allowed the substrate to be patterned with 5, 10, 25, 50 and 100m wide protein 
coated tracks separated by 5, 10, 25, 50 and 100m wide uncoated tracks. The same 
procedure was used for stamping each ECM protein. This process has been depicted in 
Figure 2.1 and Table 2.1. MCP patterns were reasonably transferred to the substrates, 
although imperfections in the stamp and the application of manual pressure resulted in 
some variation in the track widths of the stamped extracellular matrix proteins.  
 
Figure 2.1 Illustration of the stamping process. Adapted: (Thibault, 2005). 
 
 51 
 
The following table shows a summary of the micro-contact printing process. 
Table 2.1 Illustration of the steps involved in micro-contact printing. 
Steps Process 
1 The elastomeric stamp is wet with the inking solution 
(biomolecules). 
2 Dried in flow hood, leaving a thin layer of material on the 
stamp surface. 
3 The stamp is then pressed to the substrate surface, leaving the 
biomolecules only on the regions defined by the raised 
structures of the stamp. 
4 The stamp is removed from the surface 
 
Figure 2.2 show images of the master stamps with repeat gratings of five different 
sizes (5, 10, 25, 50 and 100m width).  
 
 
Figure 2.2 Actual stamps with five different sizes (5, 10, 25, 50 and 100 m width) 
(Sefat, 2008). 
 
Figures 2.3a and 2.3b show the images of collagen protein patterns printed on 
coverslips.  
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(a) 
 
(b) 
Figure 2.3 Actual images of 50m width protein patterns printed on glass coverslip, 
(a) Show protein ridges with widths of 50m (coated) (b) 50m wide channels (un-
coated) (Scale bar=100 µm). 
 
 53 
 
The stamp consisted of ridges with widths of 50m separated by 50m wide channels 
(uncoated). This allowed the substrate to be patterned with 50μm wide collagen coated 
tracks separated by 50μm wide uncoated tracks. The distances between coated and 
uncoated channels have been marked by the yellow arrows in Figures 2.3a and 2.3b. 
However, in applying the stamps to the surface the pattern was distorted by the 
stamping process probably because of nanometric scale stamp imperfections causing 
the point of contact between the stamp and the surface to decrease in some places. 
 
2.2.5 Plating of cells on Patterned Coverslips 
The glass slides micro-contact printed with 5 different gratings were then seeded with 
bone cells (50,000 cells/coverslip) for 18hrs. Figure 2.4 shows the method of cell 
seeding on stamped coverslips. After 18hrs, cells were then fixed with 0.1% 
formaldehyde diluted in Hank’s Balanced Salt Solution (HBSS, SIGMA) for 5 
minutes and imaged with standard phase contrast light microscope. The effects of 
initial cell attachment on different substrates were investigated by recording cell 
images up to 18hrs after cell culture using Image J software. Cell alignment to the 
patterns was measured by measuring the angle of the long axes of the cells in relation 
to the stamp pattern, such that an angle of 0° represents 100% alignment to the pattern 
(Figures 2.5 and 2.6). Figure 2.6 shows cells attached to a 100µm stamped protein 
pattern. The stamp pattern is clearly shown by arrows for areas without bone cells. 
Stamp pattern may not be visible in the some areas as it is coverd by bone cells. The 
actual pattern is visible as a very fine line which is shown by an arrow in Figure 2.6. 
Image J software were also used to measure cell length, width and number of cells. 
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Figure 2.4 schematic drawing showing the method of cell seeding on stamp patterned 
coverslips. 
 
 
Figure 2.5 Measuring the angle between cell axis and 50µm collagen stamp patterned 
coverslip (glass); image taken with standard phase contrast microscope, (Scale 
bar=100 µm) (Sefat, 2010a). 
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Figure 2.6 angles measured between cell axis and stamp patterned glass cover slip. The 
edges of the stamp pattern are indicated by the arrows (Scale bar=100 µm) (Sefat, 
2008). 
 
 
2.2.6  Control experiment 
Cells were also seeded on three ECM coated substrates (collagen type I, fibronectin, 
laminin) and plain un-coated substrates as control. These four substrates either ECM 
coated or un-coated provided were used to compare to different micro-contact printed 
ECM patterns. All experiment either controls or micro-contacted printed were repeated 
three times. In each repeat 10 fields of view were captured. Cell number, cell alignment 
and cell length were measured from 10 fields of view. We were motivated to use 
laminin in this study as a control due to the lack of laminin present in bone. Therefore, it 
enabled a comparison of this protein with other ECM proteins such as collagen type I 
and fibroenctin (Sefat, 2010a, Colucci, 1996).  Finally, the degree of cell alignment on 
un-coated/un-patterend substrates was measured (using image J software) by measuring 
the angle of the long axes of the cells in relation to the parallel lines drawn on each field 
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of view such that an angle smaller than 45° represents good alignment to the parallel 
lines (See Figure 2.7).  
 
Figure 2.7Angles measured between cell axis and parralle lines drawn by image J 
software on un-patterend/un-coated glass cover slip (Scale bar=100 µm). 
 
2.3  STATISTICAL ANALYSIS 
Mean angle of cell alignment and cell length were tested for normality using a 
Kolmogorov Smirnov test. Results that showed normal distribution (p > 0.05) were 
analysed using SPSS via a Oneway Analysis of Variance (ANOVA) followed by a post 
Hoc Bonferroni test. Kruskal-Wallis test and serial Mann Whitney tests were used for 
non-normally distributed results (p < 0.05).  Statistical tests were performed such that a 
p value of < 0.05 was considered as indicating a significant difference.   
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2.4  RESULTS 
2.4.1 Effect of ECM protein coating on cell morphology 
Figure 2.8 shows the morphology of bone cells on four different substrates including 
ECM coated substrates (collagen type I, fibronectin, laminin) and plain un-coated 
substrates as control. These four substrates either ECM coated or un-coated provided a 
negative control to compare different micro-contact printed ECM patterns in the next set 
of results. Although, these four coverslips are similar in terms of initial cell number and 
passage number, they show different cell adhesion capacity. There seems to be a very 
poor cell adhesion and cell number on laminin coated coverslips (mean cell number ~ 
62.00/field of view ± 3.96SD) while fibronectin coverslips show better adhesion (with 
mean cell number ~ 150.73 ± 3.65SD). According to the collected data (See Tables 2.4 
and 2.5) bone cells on laminin coated coverslips show poor attachment with not much 
elongation (with mean cell length ~ 67.10m ± 2.16SD). There were also lots of 
rounded cells which imply bone cells with less attachment to this type of ECM protein 
while substrates with fibronectin showed better attachment with larger number of 
attached and elongated cells (with mean cell length ~ 92.09m ± 6.02SD). Collagen 
coated and un-coated (control) substrates show similar result to fibronectin in terms of 
cell number, but the cell morphology was different. Cells grown on collagen coated 
coverslip had a more elongated morphology (with mean cell length ~ 84.10m ± 2.17 
SD), while bone cells on un-coated control substrates had shorter lengths of ~ 77.33m 
± 2.05SD). Tables 2.2-2.5 show the descriptive statistics and statistical test for bone cell 
number and cell length of three proteins coated substrates (collagen type I, fibronectin 
and laminin) and un-coated substrate. 
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Table 2.2 Descriptive statistics of bone cell number of various substrates with addition 
of protein coated (collagen, fibronectin, laminin) and un-coated (n= 3times, 10 samples 
for each repeat). 
Treatment 
(Coating) 
Mean Cell Number  
± Std. Deviation (SD) 
Std. Error 
(SE) 
Collagen 73.13 ± 2.29 0.59 
Fibronectin 150.73 ± 3.65 0.94 
Laminin 62.00 ± 3.96 1.02 
Plain (Un-coated) 78.53 ± 2.38 0.61 
 
Table 2.3 P value derived from pair wise comparisons of bone cell number for various 
substrates with addition of protein coated (collagen, fibronectin, laminin) and un-coated 
(n=3, 10 samples/repeat). Pairs that are significantly different from one another are 
marked by an asterisk (*) whereas * P<0.05, ** P<0.01 and *** P<0.001. 
Treatment 
(Coating) 
p-value p-value 
(significant difference) 
Collagen – Fibronectin 0.001 *** 
Collagen – Laminin 0.001 *** 
Collagen – Plain (Un-coated) 0.001 *** 
Fibronectin – Laminin 0.001 *** 
Fibronectin – Plain (Un-coated) 0.001 *** 
Laminin – Plain (Un-coated) 0.001 *** 
 
In all cases the data acquired regarding cell length was found to be normaly distributed 
and were thus analysed using a Oneway Analysis of Variance (ANOVA) followed by a 
post Hoc Bonferroni test (See Tables 2.4 and 2.5). Results showed that there are 
significant differences in cell length between fibronectin and laminin coated substrates 
(p<0.01). These results indicate that MG63 cells respond better to fibronectin coated 
substrates with the highest cell length (with mean cell length ~92.09 ± 6.02SD), which 
indicate the cells attach mostly via fibronectin specific integrins. 
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Figure 2.8 Initial attachment and cell morphology evaluated with collagen, fibronectin, 
laminin coated glass coverslips and un-coated (control) at 18hrs of seeding; scale 
bar=100m. 
 
Table 2.4 Descriptive statistics of bone cell length of various substrates with addition of 
protein coated (collagen, fibronectin, laminin) and un-coated (n= 3times, 10 samples for 
each repeat). 
Treatment 
(Coating) 
Mean Cell Length  (m) 
± 
Std. Deviation (SD) 
Std. Error 
(SE) 
Collagen 84.10 ± 2.17 7.01 
Fibronectin 92.09 ± 6.02 1.55 
Laminin 67.10 ± 2.16 0.55 
Plain (Un-coated) 77.33 ± 2.05 7.50 
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Table 2.5 P values derived from pair wise comparisons for bone cell length of various 
substrates with addition of protein coated (collagen, fibronectin, laminin) and un-coated 
(n= 3times, 10 samples for each repeat). Pairs that are significantly different from one 
another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 and *** P<0.001. 
Treatment 
(Coating) 
p-value p-value 
(significant difference) 
Collagen - Fibronectin 0.699  
Collagen - Laminin 0.108  
Collagen – Plain (Un-coated) 0.794  
Fibronectin - Laminin 0.007 ** 
Fibronectin – Plain (Un-coated) 0.198  
Laminin – Plain (Un-coated) 0.511  
 
2.4.2  Studying Bone Cell Interactions with Micro-patterned ECM 
Proteins 
 
The aim of this study was to identify the role of collagen type I, fibronectin and laminin, 
in the adhesion and alignment of the human bone cell (MG63) to different micro-
contact printed ECM patterns (Sefat, 2010a). An additional plain (un-coated/un-
patterend) coverslip was seeded with cells as a control. As described earlier an angle of 
45° suggests no alignment. i.e., random orientation to the pattern, whilst mean angles of 
alignment less than 45° suggest alignment to the pattern such that a mean angle of 0° 
indicates complete alignment to the pattern. Figure 2.9 shows photomicrographs of 
MG63 bone cells after 18hrs of seeding on 5, 10, 25, 50 and 100m micro-contact 
printed substrates with three ECM proteins. Patterned cells exhibited an elongated 
morphology in the direction of the patterned guidance cue. It was found that after 18hrs 
in culture cells grown on the patterned coverslips show more elongation (and better 
adhesion) on fibronectin-patterned substrates than substrates patterned with collagen 
and Laminin. The cells aligned well on fibronectin patterned coverslips especially to 50 
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and 100m with a mean angle of 7.87˚ 3.06SD and 6.45˚  5.08SD, respectively. 
Poorly aligned cells were evident on laminin patterns where some cells still remained 
rounded even after 18hrs (50 and 100m with a mean angle of 14.36˚  1.57SD and 
15.58˚  1.94SD, respectively). By comparison, cells on almost all fibronectin patterns 
attached and elongated at early stages (after about 2hrs of seeding), whereas with 
collagen and laminin patterns, cells did not adhere readily and appeared more rounded 
until about 18hrs after seeding. The best cell alignment to collagen and laminin patterns 
occurred after 18hrs in culture on the 50µm wide patterns (mean angle of 9.66˚  
4.18SD and mean angle 14.36˚  1.57SD, respectively). Photomicrographs of MG63 
bone cells after 18hrs of culture on 10 and 25m showed very poor cell alignment in the 
presence of all three types of proteins, e.g. the angle of alignment for the 10m 
patterned collagen, fibronectin and laminin was 31.24˚  5.6SD, 20.82˚  5.7SD and 
33.83˚  4.36SD, respectively, and in the case of 25m patterned collagen, fibronectin 
and laminin was 26.03˚  16.29SD, 23.33˚  9.03SD and 32.19˚  11.54SD, 
respectively. MG63 bone cells showed no alignment on control (Un-patterend) 
coverslip with mean angle of 46.11˚  3.96SD. Overall, of the three ECM proteins and 
five stamped patterns bone cells, the best response was obtained for the 50µm and 
100µm wide stamp patterns. Statistical results showed (See Tables 2.6-2.8) that there 
are highly significant differences in cell alignment between larger (50 and 100m) and 
smaller (5, 10 and 25m) stamp sizes (p<0.001).  Mean angle of alignment versus 
stamp size is shown in Figure 2.10 which confirms that fibronectin patterns with 50 and 
100 m width gave the best cell alignment. 
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Table 2.6 Descriptive statistics of mean angle of alignment for three ECM proteins 
(Collagen, Fibronectin and Laminin) and un-coated (control) versus stamp sizes (5, 10, 
25, 50 and 100m) of MG63 bone cells after 18hrs of seeding (n= 3times, 10 samples 
for each repeat). 
Treatment Stamp Size 
(µm) 
Mean Angle of Alignment  
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
Collagen 
5µm 22.33⁰ ± 4.34 1.37 
10µm 31.24⁰ ± 5.60 1.77 
25µm 26.03⁰ ± 6.29 5.15 
50µm 9.66⁰ ± 4.18 1.32 
100µm 19.12⁰ ± 5.77 1.82 
 
 
Fibronectin 
5µm 17.11⁰ ± 9.00 2.84 
10µm 20.82⁰ ± 5.70 1.80 
25µm 23.33⁰ ± 9.03 2.85 
50µm 7.87⁰ ± 3.06 0.97 
100µm 6.45⁰ ± 5.08 1.60 
 
 
Laminin 
(Control) 
5µm 24.27⁰ ± 6.35 2.00 
10µm 33.83⁰ ± 4.36 1.37 
25µm 32.19⁰ ± 11.54 3.64 
50µm 14.36⁰ ± 1.57 0.49 
100µm 15.58⁰ ± 1.94 0.61 
Un-patterend 
(Control) 
 
-------------- 
46.11⁰ ± 3.96  1.25 
 
Table 2.7 P values derived from pair wise comparisons of mean angle of alignment for 
three ECM proteins (Collagen, Fibronectin and Laminin) and un-coated/un-patterend 
(control) versus stamp sizes (5, 10, 25, 50 and 100m). Pairs that are significantly 
different from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 
and *** P<0.001.  
Treatment Collagen  Fibronectin  Laminin 
5µm - 10µm 0.155  0.059  0.012 * 
5µm - 25µm 0.869  0.028 * 0.054  
5µm - 50µm 0.015 * 0.001 *** 0.009 ** 
5µm - 100µm 0.918  0.001 *** 0.028 * 
10µm - 25µm 0.656  0.762  0.977  
10µm - 50µm 0.001 *** 0.001 *** 0.001 *** 
10µm - 100µm 0.022 * 0.001 *** 0.001 *** 
25µm - 50µm 0.001 *** 0.001 *** 0.001 *** 
25µm - 100µm 0.385  0.001 *** 0.001 *** 
50µm - 100µm 0.116  0.597  0.992  
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Table 2.8 P values derived from pair wise comparisons of mean angle of alignment for 
three ECM proteins (Collagen, Fibronectin and Laminin) and un-coated/un-patterend 
(control) versus stamp sizes (5, 10, 25, 50 and 100m). Pairs that are significantly 
different from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 
and *** P<0.001.  
Treatment 5µm  10µm 25µm 50µm 100µm 
Collagen – Fibronectin 0.002** 0.002** 0.762 0.290 0.001*** 
Collagen – Laminin 0.002** 0.001*** 0.123 0.001*** 0.001*** 
Collagen – Control 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Fibronectin – Laminin 0.002** 0.001*** 0.019* 0.001*** 0.001*** 
Fibronectin – Control 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Laminin – Control 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
 
Differences in cell length mirrored those of alignment, with cells acquiring the greatest 
length when showing the greatest degree of alignment (see Figure 2.11) (Sefat, 2010a). 
Tables 2.6-2.11 show descriptive statistics and statistical test results comparing the 
mean angle of alignment and cell length for three ECM proteins (Collagen type I, 
Fibronectin and Laminin) versus stamp sizes (5, 10, 25, 50 and 100m) of MG63 bone 
cells after 18hrs of seeding. In the case of 5m micro contact printed substrates 
fibronectin compared to collagen induced better cell elongation (mean cell length ~ 
121.6m ± 5.61SD and 115.23m ± 5.11SD, respectively). Cells grown on the 
patterned coverslips after 18hrs showed more elongation for fibronectin followed by 
collagen and laminin (see Figure 2.9 for details). Statistical results showed that there are 
significant differences between 5m and all others stamp sizes (p<0.001). 
Photomicrographs of MG63 bone cells after 18hrs of culture on 10 and 25m showed 
very poor cell elongation in the presence of all three types of proteins, e.g. the cell 
length for the 10m patterned collagen, fibronectin and laminin was 85.86m  
7.73SD, 98.31m  6.60SD and 80.78m  6.55SD, respectively, and in the case of 
25m patterned collagen, fibronectin and laminin was 81.22m  5.99SD, 88.65m  
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8.46SD and 77.42m  5.05SD, respectively. Mean cell length was tested statistically 
using SPSS. Results demonstrated that there are significant differences in cell length 
between 10µm-50µm and 10m-100m stamp sizes (p<0.001). Photomicrographs of 
MG63 bone cells after 18hrs of culture on 50 and 100m showed better cell elongation 
in the presence of all three types of proteins, e.g. the cell length for the 50m patterned 
collagen, fibronectin and laminin was 138.23m  5.53SD, 160.85m  8.18SD and 
122.58m  9.88SD, respectively, and in the case of 100m patterned collagen, 
fibronectin and laminin was 153.26m  7.91SD, 162.37m  6.62SD and 124.19m  
5.68SD, respectively (Sefat, 2010a). 
Table 2.9 Descriptive statistics of mean cell length for three ECM proteins (Collagen, 
Fibronectin and Laminin) and un-coated (control) versus stamp sizes (5, 10, 25, 50 and 
100m) of MG63 bone cells after 18hrs of seeding (n= 3, 10 samples/repeat). 
 
Treatment 
 
Stamp Size (µm) 
 
Mean cell length(µm) 
± Std. Deviation (SD) 
 
Std. Error 
(SE) 
 
 
Collagen 
5µm 115.23 ± 5.11 0.89 
10µm 85.86 ± 7.73 1.34 
25µm 81.22 ± 5.99 1.04 
50µm 138.23 ± 5.53 0.96 
100µm 153.26 ± 7.91 1.37 
 
 
Fibronectin 
5µm 121.6 ± 5.61 0.97 
10µm 98.31 ± 6.60 1.15 
25µm 88.65 ± 8.46 1.47 
50µm 160.85 ± 8.18 1.42 
100µm 162.37 ± 6.62 1.15 
 
 
Laminin 
(Control) 
5µm 101.0 ± 7.06 1.23 
10µm 80.78 ± 6.55 1.14 
25µm 77.42 ± 5.05 0.88 
50µm 122.58 ± 9.88 1.72 
100µm 124.19 ± 5.68 0.98 
Un-
patterned 
(Control) 
 
------------------------ 77.33 ± 2.65 0.46 
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Table 2.10 P value derived from pair wise comparisons of mean cell length for three 
ECM proteins (Collagen, Fibronectin and Laminin) and un-coated/un-patterend 
(control) versus stamp sizes (5, 10, 25, 50 and 100m). Pairs that are significantly 
different from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 
and *** P<0.001. 
Treatment Collagen  Fibronectin  Laminin 
5µm - 10µm 0.001 *** 0.001 *** 0.001 *** 
5µm - 25µm 0.001 *** 0.001 *** 0.001 *** 
5µm - 50µm 0.001 *** 0.001 *** 0.001 *** 
5µm - 100µm 0.001 *** 0.001 *** 0.001 *** 
10µm - 25µm 0.013 * 0.001 *** 0.305  
10µm - 50µm 0.001 *** 0.001 *** 0.001 *** 
10µm - 100µm 0.001 *** 0.001 *** 0.001 *** 
25µm - 50µm 0.001 *** 0.001 *** 0.001 *** 
25µm - 100µm 0.001 *** 0.001 *** 0.001 *** 
50µm - 100µm 0.001 *** 0.248  0.887  
 
Table 2.11 P value derived from pair wise comparisons of mean cell length for three 
ECM proteins (Collagen, Fibronectin and Laminin) and un-coated/un-patterend 
(control) versus stamp sizes (5, 10, 25, 50 and 100m). Pairs that are significantly 
different from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 
and *** P<0.001. 
Treatment 5µm  10µm 25µm 50µm 100µm 
Collagen – Fibronectin 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Collagen – Laminin 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Collagen – Control 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Fibronectin – Laminin 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Fibronectin – Control 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Laminin – Control 0.001*** 0.005** 0.573 0.001*** 0.001*** 
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Figure 2.9 Photomicrographs of MG63 bone cells after 18hrs of seeding on 5, 10, 25, 
50 and 100m micro-contact printed glass substrates: (a) Collagen, (b) Laminin, and 
(c) Fibronectin; Images taken with standard phase contrast microscope; (Scale 
bar=100 m) (Sefat, 2010a). 
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Figure 2.10 Comparison between three patterned ECM proteins (Collagen, fibronectin 
and laminin) in terms of cell alignment on five different stamp sizes (5, 10, 25, 50 and 
100m). (Error bar= Standard error) (Sefat, 2008, Sefat, 2010a). 
 
Figure 2.11 Comparison between three patterned ECM proteins (Collagen, fibronectin 
and laminin) in terms of cell elongation with five different stamp sizes (5, 10, 25, 50 and 
100m). (Error bars = Standard error) (Sefat, 2008, Sefat, 2010a). 
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2.5  DISCUSSION  
2.5.1  Effect of MCP on bone cell behaviour 
The results indicate that cells align, elongate and attach better along specific patterns 
depending on their width and make-up in terms of ECM protein. In the last decade or so 
the effects of surface micro- and nano-textures on cell adhesion, alignment, migration 
and morphology have attracted much attention and various models/mechanisms exist to 
explain alignment and attachment (Clark, 1990, Curtis, 1997, Flemming, 1999, 
Teixeira, 2006, Lim, 2007, Feinberg, 2008, Zhang, 2011). Substrates printed with fine 
chemical cues cause various cell responses such as cell alignment and migration along 
the cues (Dalton, 2001, Diehl, 2005, Su, 2007, Sefat, 2010a, Sefat, 2008, Khaghani, 
2008), they promote adhesion of osteoblast (Hasenbein, 2002, Charest, 2006) and, more 
recently patterned substrates have been found to enable differentiation of stem cells 
(Charest, 2007). Many researchers have assessed cell alignment after cells have been 
fixed in formaldehyde, methanol or glutaraldehyde (Fischer, 2008). Static/fixed 
observations are useful for visualizing intracellular protein fiber alignment in detail, but 
they provide little information about dynamic/live cell behaviour on surfaces with MCP 
or nanopatterns. Present studies were carried out on both fixed and time-lapse dynamic 
cell behaviours and hence more detailed information on the mechanism of cell 
alignment on MCP patterns was obtained. Figure 2.9 shows that the differentiation 
direction of cells can be controlled by the surface chemistry of cell culture substrates 
with a major effect on the morphology of cells. In this study the time dependence of cell 
alignment was analysed to study the mechanism of the chemical guidance effect of the 
substrate on cell responses. It was found that fibronectin, rather than collagen and 
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laminin, promoted MG63 cells adhesion (Sefat, 2010a). Cell orientation angles were 
also quantified by the analysis of low-magnification time-lapse phase contrast images 
using image J software. The orientation angle of an individual cell was determined as 
the angle between the pattern direction and the direction of the longer axis of each cell. 
It was found that cells on the MCP plate started to align along the patterns within a few 
hours (or even less) of cell seeding, depending on the type of MCP protein, as seen in 
Figure 2.9. Cells extended/elongated in parallel with the MCP pattern and aligned with 
each other during the subsequent 18hrs of culture. Cell alignment was maintained for at 
least 3-4 days following this period. To express cell alignment quantitatively, the 
orientation angles of individual cells against the pattern direction were measured 
together with standard deviation (SD) and the distribution of the orientation angles at 
each time point. After 18hrs in culture (Figure 2.9) cells were poorly aligned to the 
5µm, 10µm and 25µm wide repeat patterns of collagen, fibronectin and laminin, but at 
widths of 50µm and 100µm alignment improved significantly, particularly for cells 
cultured on the fibronectin patterns (See Tables 2.6-2.11 for full statistical analysis). 
However, cells seemed to align to the edge of these larger patterns indicating that they 
were in fact responding to the small feature of the interface between the fibronectin 
patterned region and the fibronectin free regions. 
 
A large number of studies have examined the effects of surface chemistry on cell 
behaviour or contact guidance. One group (Teixeira, 2003) employed human corneal 
epithelial cells and they found that filopodia aligned along the patterns and that cells 
attached to the ridge and aligned along the nano-patterns. From these findings, they 
speculated that filopodia sense differences in surface chemistry and induce cell 
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alignment. In their other report, however, filopodia aligned perpendicular to the 
guidance cues (Teixeira, 2006). They concluded that these two contradictory results 
reflected a difference in culture media. Also it was reported (Wo´jciak-Stothard, 1996) 
that filopodia extending perpendicular to the groove direction were more frequently 
observed than those along the pattern, even though they were in cells that had aligned 
along the pattern. The role of filopodial probing remains controversial. MCP have also 
been used (Hasenbein, 2002) to pattern circles with N [3-(trimethoxysilyl) propyl] 
diethylenetriamine (DETA) in presence of osteoblasts. Diameters of 10, 50, 100, and 
200µm were used with inter-pattern spacings of 10µm in the study.  The DETA 
patterned regions were further modiﬁed by cell-adhesive peptides Arginine–Glycine–
Aspartic Acid–Serine (RGDS) and Lysine–Arginine–Serine–Arginine (KRSR) or non-
adhesive peptides Arginine–Aspartic Acid–Glycine–Serine (RDGS) and Lysine–
Serine–Serine–Arginine (KSSR). After four hours under standard cell culture 
conditions, adhesion of either osteoblasts or ﬁbroblasts on surfaces patterned with the 
non-adhesive peptides was random and low (Hasenbein, 2002). In contrast, both 
osteoblasts and fibroblasts adhered and formed clusters onto circles modified with the 
adhesive peptide RGDS, whereas only osteoblasts adhered and formed clusters onto the 
circles modified with KRSR, a peptide that selectively promotes adhesion of 
osteoblasts.These results provide evidence that patterning of selected peptides can direct 
adhesion of speciﬁc cell lines exclusively to predetermined regions on material surfaces 
(Hasenbein, 2002). Another group also presented a hot embossing imprint lithography 
technique to form mechanical topography and microcontact printing to surface chemical 
patterns on polymer cell substrates in order to investigate the response of osteoblast 
cells to these surface patterns (Charest, 2006). The resulting substrate had surface 
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features consisting of micro-contact printed adhesive lanes 10µm wide with spacing that 
ranged from 10 to 100µm. Results showed that the cells signiﬁcantly aligned to the 
pattern presented. As the chemical pattern spacing was increased, osteoblasts remained 
aligned to the mechanical topography (Charest, 2006). However, at this moment in 
time, it is difficult to identify what is the major mechanism in cell alignment on the 
MCP patterns. However, our results suggest that guidance to ECM proteins such as 
fibronectin and collagen with good cell alignment represent great attachment to the edge 
of micor-contact printed area which means there are high levels of integrins present and 
expressed in this region. It has been reported that human bone cells revealed high levels 
of α1β1, α3β1, α5β1 and αvβ5 integrins and lower levels of α2β1, α4β1, αvβ1 and αvβ3 
integrins (Saito, 2004). This study also demonstrated that cultured human bone cells 
adhere to a wide variety of ECM proteins and possess a unique repertoire of integrin 
receptors that includes collagen/laminin receptors (α1β1, and α3β1 integrins) and 
fibronectin/fibrinogen/vitronectin receptors (α5β1, αvβ3, and αvβ5 integrins) (Saito, 
2004). Therefore, in chapter 7, we have tried to examine some important intgrins such 
as α3 and β1 in order to see which integrins are most important for the attachment and 
migration of bone cells.  
 
On the other hand, laminin is not normally expressed in bone (Colucci, 1996) and our 
results show that bone cells poorly aligned to the laminin, but however, to verify that 
laminin has little effect on bone cell behaviour additional experiment was performed 
without using any ECM protein (control). Our results show a significant difference 
between laminin micro-contact printed and un-patterend (control). Cells showed a better 
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alignment to laminin than the unpatterned surface which indicates either a response to 
laminin or a response to the nanoscale topography.  
The natural process of healing a fracture starts when the injured bone and surrounding 
tissues bleed, forming a fracture hematoma. The blood coagulates to form a blood clot 
situated between the broken fragments. It is well established that collagen type I, major 
ECM protein, mainly exist in intact bone (Tosounidisa, 2009). After few days of injury 
blood vessels develop into the matrix of the blood clot. The blood vessels bring 
fibroblasts in the walls of the vessels and these multiply and produce collagen fibres. 
Therefore, the blood clot is replaced by a matrix of collagen. However, collagen type I 
is not the only ECM protein present in bone while fibronectin accumulates in the site of 
injury (Canavan, 2005b). This further supports this finding in which MG63 cells 
responded mostly to the fibronectin patterns suggesting that these cells attach mostly via 
fibronectin specific integrins. This in term suggests that cells take on a more migratory 
phenotype when cultured on fibronectin. This, therefore, suggests that specific integrins 
associated with attachment to fibronectin could be important in bone wound repair. 
 
2.5.2  Effect of various substrates and topography on cell 
behaviour 
There has been a challenge in recent years to understand the principle of surface 
chemistry and topography. Techniques of protein patterning can be used to produce 
patterns that guide cell movement (Clark, 1990, Britland, 1992a, Britland, 1996). Since 
these protein patterns have edges, it is possible to reverse the criticism and then ask 
whether cells can react to edges which may be a single molecule in height or are simply 
 73 
 
discontinuities in molecular ordering. This problem has been answered by Pritchard et 
al who used patterning systems to fill adjacent spaces with different proteins to level up 
the surface so that any step at the junction is less than a molecule in height (Pritchard, 
1995). Result shows that extending cells appear to be localized more frequently at the 
region of junction or discontinuity than would be expected if cell attachment to the 
patches of protein was random. Laminin protein was used by Britland et al as a 
chemical cue which oriented at right angles to a topographic one (Britland, 1996). When 
the grooves were 500nm deep or less, the cells reacted mostly to the chemical cue. On 
deeper grooves the topographic cue over-rode the chemical one and at 5µm depth the 
topographic effect oriented about 80% of the cells and the chemical one 7%. Curtis et al 
created a method for applying very small areas of chemically specified substratum to a 
cell using a bead technique. Although these cues often modified or activated cells 
leading to increased neurite extension, they did not lead to a polarized extension or any 
other obvious reaction resembling a topographic one (Curtis, 1997). Den Braber et al 
modified silicone grooved and plane surfaces by exposure to UV light, which affected 
surface energies but did not alter topographic reaction (Den Braber, 1995). This result 
suggests that surface chemistry plays a small role in topographic phenomena. It is also 
consistent with the findings that cells react to topography in a broader similar way on 
very many different materials bearing topographic features.  
 
It is always useful to bear in mind all other factors that may have effect on cell 
attachment. The ideal substrate provides a framework and initial support for the cells to 
attach, proliferate and differentiate, and form an ECM (Agrawal, 2001). It should be 
noted that substrate surface topography and chemistry (wettability, softness, stiffness 
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and roughness); microstructure (porosity, pore size, pore shape, interconnectivity, 
specific surface area) (O'Brien, 2005) and mechanical properties (Peyton, 2005, Engler, 
2006) have been shown to influence cell behaviours. When cells adhere to surface of a 
substrate, a sequence of physico-chemical reactions will happen between cells and the 
substrate. Immediately after a substrate comes into contact with cell culture 
environments, protein adsorption to its surface occurs and which mediates the cell 
adhesion, and also provides signals to the cell through the cell adhesion receptors, 
mainly integrins. The interaction between cells and substrates is called focal adhesion. 
In this study ECM proteins such as fibronectin, collagen and laminin were used in order 
to investigate adhesion, alignment and elongation of MG63 bone cells. In here we are 
going to briefly discuss the other factors which have direct effect on cell adhesion.  
 
2.5.2.1 Protein adsorption 
 
Since cell adhesion to a substrate (in-vivo or in-vitro) requires a series of cytoplasmic, 
transmembranal and ECM proteins that assemble into stable contact sites (Geiger, 
1987), cell adhesion and behaviours is likely involved the adsorption onto the material 
surface of serum and ECM proteins (Brynda, 1990). Many proteins, including 
vitronectin, fibronectin and fibrinogen adsorb onto substrate (biomaterial) surfaces 
immediately upon contact with physiological fluids and modulate subsequent 
inflammatory responses. Therefore, according to the literature various cell behaviours, 
related to different hydrophobicities, may be mediated by protein absorption. For this 
reason the effect of fibronectin, collagen and laminin were investigated in this study. 
Surface wettability also has effect on adsorption of cell adhesion molecules. 
Hydrophobic surfaces tend to adsorb more proteins, while hydrophilic surfaces tend to 
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resist protein adsorption (Xu, 2007). In this study we have used different substrates 
including plain glass and glass coated with gold in order to investigate cell alignment 
and elongation in vitro. Bone cells represented similar alignment and elongation in both 
substrates; however, as a future work it is beneficial to investigate the characteristics of 
these two surfaces in detail. Tissue culture (TC) plastic was also used in the next 
chapters. The inside surface of TC plastic provides an optimal growth surface on the 
flask base for the most varied matrix-dependent tissue cultures. TC treatment cross links 
carboxyl and amine groups and gives the plastic its net negative charge. TC surface 
modification is usually done by ionizing radiation or physio-chemical methods. 
 
2.5.2.2 Surface roughness 
Surface roughness (or topography) is another important factor influencing cell adhesion 
and behaviour. Roughness modulates the biological response of cells in contact with the 
substrates. Material surface roughness has a direct influence in vitro as well as in vivo 
on cellular morphology, proliferation, and phenotype expression. Literature papers have 
been reported that cells grown on micro-rough surfaces were stimulated towards 
differentiation in comparison with cells growing on smooth surfaces. For instance, 
primary rat osteoblasts and human foetal osteoblastic cells had higher proliferation, cell 
spreading and osteocalcin expression on the rough surface in comparison with smooth 
one (Hatano, 1999, Lim, 2007). Depending on the scale of irregularities of the material 
surface, surface roughness can be divided to macroroughness (100μm – milimeters), 
microroughness (100nm – 100μm), and nanoroughness (less than 100 nm), each with its 
specific influence (AGASKÁ, 2010). The response of cells to roughness is different 
depending on the cell type. For larger cells, such as osteoblasts (MG63), macroscopic 
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descriptions of the surface roughness could be reasonable (Donoso, 2007, Lee, 2004). It 
seems that the cell adhesion and proliferation were progressively inhibited as the 
substrate had micropores. Therefore, the selectivity of cells on surface roughness could 
be highly advantage on the development of implanted devices. In this study surface 
chemistry was mainly considered and it is also beneficial to consider surface 
topography in order to investigate more precise cell behaviour.   
 
2.5.2.3 Effects of depth 
It has been documented that on groove/ridge topography the extent of reaction is related 
to groove width as well to depth and probably also to the number of adjacent grooves 
(Clark, 1990). There is general evidence that the extent of orientation increases with 
groove depth up to about 25µm from topographies of about 1µm relief. Below this 
degree of relief results are less available, partly owing to the difficulty of quantifying 
the etch depth in earlier years and perhaps partly because of a naive belief that there 
would not be any effect on the cells. Other group have discovered that macrophage-like 
cells react down to dimensions at least as small as 44nm (Wojciak, 1995). Such small 
topographies approach the dimensions of large molecules and in the very near future the 
excitement generated by the suspicion that the sensing mechanisms of cells for 
topography are perhaps as sensitive as those of the atomic force microscope may lead to 
further discoveries.  
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2.5.2.4 Groove width  
According to the literature when the grooves or ridges are noticeably wider than the 
cells effects on orientation are not very marked, although cells may align to one edge 
(Clark, 1991). On the other hand, as the groove/ridge width is reduced to the width of 
the cells and less, effects on orientation become more marked. When more than two 
discontinuities underlay a cell, lines of actin condensation mark each discontinuity. It 
also showed that cells will react to groove/ridge topography with a pitch (repeat) of 260 
nm. These grooves were relatively deep at 500nm. No work has yet discovered the 
minimum width of topography to which a cell can react.  
 
2.6  CONCLUSIONS  
In summary, it can be concluded that human bone cells (MG63) were cultured 
successfully in the presence of different protein patterned substrates using micro contact 
printing. Cells on the fibronectin patterns attached, aligned and elongated at early stages 
(about 2hrs) after seeding. In the case of collagen and laminin cells did not adhere 
readily and appeared more rounded until about 18hrs after seeding. The results indicated 
that MG63 cells responded mostly to the edge of 50 and 100m wide fibronectin 
patterns suggesting that these cells attach mostly via fibronectin specific integrins. 
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CHAPTER THREE 
3. TRYPSINISATION ASSAY: 
THE EFFECT OF TRANSFORMING 
GROWTH FACTOR BETA (TGF-β), BSA, HCl 
AND BSA/HCl ON CELL DETACHMENT OF 
HUMAN BONE CELLS  
 
3.1  INTRODUCTION 
Cells are not found in isolation and they usually adhere to other cells or the surrounding 
extracellular matrix (ECM) environment in vivo and substrate or a surface in vitro 
(Critchlow, 1995, Freshney, 1994, Sefat, 2009a, Sefat, 2010c, Eapen, 2012, Beggs, 
2008). Osteoblasts and other bone cells produce many growth factors including TGF-β 
and this growth factor has clear functions in regulation of bone formation and their 
actions on bone formation have been examined extensively in vivo (Linkhart, 1996, 
Mohan, 1995, Chin, 2004, Kovacevic, 2011, Guiqian, 2012). Application of TGF-β 
promoted bone healing in skull defects and tibia1 fractures (Nielsen, 1994, Critchlow, 
1995) and continuous infusion of TGF-β increased bone formation and fracture healing 
(Tosounidisa, 2009), suggesting TGF-β as a potential therapeutic agent for fracture 
repair. The effect of TGF-β is mediated by a range of signalling pathways (Hollinger, 
2004) and the interaction of bone cells with their surrounding ECM environment 
influence physiological functions and pathological processes (Erlebacher, 1996). These 
physiological functions are normal skeletal development and bone matrix production 
(Tosounidisa, 2009(Guiqian, 2012). These interactions are mediated by integrins, which 
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are capable of transducing the signals from ECM to the cells which results in migration, 
differentiation and specific protein synthesis. Bone repair and wound healing comprises 
an ordered sequence of events including cell migration and proliferation, synthesis of 
extracellular matrix, angiogenesis and remodelling. TGF-β regulates many of these 
processes such as cell migration during bone repair. Degree of cell attachment in 
presence of different isomers of TGF-β is also important issue that needs to be 
considered because enhanced cell migration is associated with decresed attachment and 
there is evidence that TGF-may promote decreased attachment in some cell types 
(Loeser, 1994). For instance, Boland et al. investigated the effects of TGF-1 on rabbit 
tracheal epithelial cells in primary culture, with respect to cell proliferation and 
differentiation (Boland, 1996). TGF-β1 treatment produced a negative effect on cell 
proliferation, but in contrast, promoted a marked enhancement of cell migration and 
increase in cell spreading (Boland, 1996). Therefore, degrees of cell detachment using 
different TGF-β isomers is an important issue that needs to be consided in order to 
understand how fast cells are able to migrate to the site of injury during wound healing. 
This can be easily measured by a process called “Trypsinisation”. This is a technique in 
cell culture to detach the cells from the culture flask. Trypsin is an enzyme which can be 
used to digest the proteins that assist adhesion between culture flask and cells 
(Freshney, 1994). Therefore, the aim of this study was to investigate the effect of 
different TGF-β isomers (TGF-β1, TGF-β2, and TGF-β3), TGF-β combinations, BSA, 
HCl and BSA/HCl on bone cell detachment via a trypsinisation assays (Sefat, 2009a, 
Sefat, 2010c). HCl and BSA were also tested, as they are the solvent and carrier for 
TGF- and thus it was important to investigate if these carriers have positive effect on 
cell detachment.  
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3.2  MATERIALS AND METHODS 
3.2.1  Cell culture 
Bone cells were cultured in a low glucose (1g/L-D-Glucose) HEPES (25mM) buffered 
DMEM (Dulbecco's Modified Eagle Media, Sigma Aldrich) culture media 
supplemented with L-glutamine (2.5 mM U/mL), Penicillin (100 U/mL), Streptomycin 
(0.1 mg/mL), Amphotericin B or a fungizone (250µg/ml), (Sigma Aldrich-UK)  and 
10% FCS v/v (fetal calf serum- PromoCell - UK). The bone cells were plated in a 12 
multiwell plates at a cell density of 50,000 cells/well and bathed in the culture media. 
All supplements were purchased from Sigma Aldrich-UK, except those otherwise 
mentioned.  
 
3.2.2  Reconstitutions 
TGF-β1 was reconstituted in a 10mM HCl solution containg 2mg/ml BSA to give a 
stock solution containing 50ng/ml TGF-β1. Further dilutions were made into PBS 
containing 2 mg/ml albumin to give a working concentration of 5ng/ml. This solution 
was then stored at working aliquate at -20°C. TGF-β2 is a multifunctional peptide soluble 
in acid solvent. It is also soluble in water; however, the solution would be sticky and 
difficult to aliquot and utilise. It is also evident that TGF-β2 requires a carrier molecule 
such as BSA to enable cell uptake. Thus a stock solution of 5 μg/ml TGF-β2 was made by 
dissolving 2μg of TGF-β2 in 400 μl of sterile 4mM HCl containing 2 mg/ml BSA to give a 
working concentration of 10ng/ml. This solution was then stored at working aliquate at 
-20°C. TGF-β3 was diluted, according to supplier recommendation, with HCl and BSA. 
10mg BSA was dissolved in 10ml of 4mM HCl to obtain 1mg/ml HCl/BSA. Following 
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this, the solution was sterilised, using a 0.22μm filter. 2μg of TGF-β3 was dissolved in 
0.4ml of 1mg/ml HCl/BSA to give a working concentration of 50ng/ml and aliquoted 
into forty 10μl vials and stored at -20ºC. Combinations of TGF-β1, 2 and 3 along with 
solutions of HCl (4mM), BSA (2mg/ml) and distilled water were prepared. A total of 
5ng/ml of TGF-β1 and 10ng/ml of TGF-β2 were added to 5ml cell suspension and 
incubated at 37°C. A total of 5ng/ml of TGF-β1 and 50ng/ml TGF-β3 were added to 
another 5 ml cell suspension. Similar manipulation process was performed to produce 
5ml of cell suspensions containing TGF-β (2+3) and TGF-β (1+2+3). All culture flasks 
were labelled and incubated at 37°C. Final concentrations of 50ng/ml (80µM) were 
used for HCl and BSA (as a control). 
 
3.2.3  Trypsinisation Method 
Bone cells were cultured in a 12 well petridish (50,000 cells/well) and left for 3 days to 
become confluent. Cells were checked after 3 days to observe their confluency. The 12 
well cultured dishes were imaged using an inverted phase contrast microscope (Optika, 
XDS-2). Old media was aspirated and cells were washed with Hank’s balanced salt 
solution (HBSS) and trypsin (0.5ml) was added to each well. Cells were imaged every 
20 second for a duration of 14 minutes (42 frames in total). This method was repeated 
for bone cell monolayer treated with BSA, HCl, HCl/BSA, TGF-1, TGF-2, TGF-3, 
TGF-(1+2), TGF-(1+3), TGF-(2+3), TGF-(1+2+3) and bone with media as 
negative control (Sefat, 2009a, Sefat, 2010c). Detatchment was measured over 14 
minutes as 100% cell detachment was recorded in control culture flask (with no 
treatment) and this time frame is good enough to compare with other treatments. The 
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aim of this study was to investigate the effect of the named solutions on cell 
detachment. Cells detaching from a surface take on a spherical morphology (Canavan, 
2005a). Thus, the degree of cell detachment was determined by counting the number of 
rounded cells at each timepoint and expressing this as a percentage of cells in the field 
of view. HCl and BSA were used, as they are solvent and carrier for TGF-. This 
method was repeated three times and the mean % of rounded cells was determined at 
each timepoint. Figures 3.1, 3.2a and 3.2b show the schematic of the 12 well petridish 
for different TGF-β isomers, TGF-β combinations, BSA, HCl, HCl/BSA and bone cell 
only as control.  
 
Figure 3.1 – 12 well culture dish for trypsinisation of (A1-A3) Control; (B1-B3) 
HCl/BSA; (C1-C3) HCl and (D1-D3) BSA (Sefat, 2009a, Sefat, 2010c). 
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(a)                                                   (b) 
 
Figure 3.2a: 12 well culture dish for trypsinisation of different TGF-β isomers: (E1-E3) 
Control; (F1-F3) TGF-β1; (G1-G3) TGF-β2; (H1-H3) TGF-β3; Figure 3.2b: 12well 
culture dish for trypsinisation of different TGF-β combinations: (I1-I3) TGF-β(1+2); 
(J1-J3) TGF-β(1+3); (K1-K3) TGF-β(2+3) and (L1-L3) TGF-β(1+2+3). 
 
3.3  STATISTICAL ANALYSIS 
The mean % of rounded cells was tested for normality using a Kolmogorov Smirnov 
test. Results that showed normal distribution (p > 0.05) were analysed using SPSS via a 
Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni test. 
Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed results (p < 0.05).  Statistical tests were performed such that a p value of < 
0.05 was considered as indicating a significant difference.   
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3.4  RESULTS 
3.4.1  Trypsinisation Assessment: Control, HCl, BSA, BSA/HCl  
Figures 3.3-3.6 show the trypsinisation process for control, BSA/HCl, HCl and BSA 
over a period of 14 minutes. In the case of control, cells start detaching from the surface 
about 6 minutes after applying trypsin. Cell detachment was 43% ± 2.23SD after 6 
minutes, which suggests that control cells detached relatively slowly during the 
trypsinisation process. Cells in the presence of BSA/HCl started detaching from the 
surface faster than control cells, about 4-5 minutes after applying trypsin. Cell 
detachment was about 63.20% ± 5.89SD after 6 minutes which is faster as compared to 
the control. Figure 3.5 shows the trypsinisation process for bone cells cultured with HCl 
alone which shows that cells started to detach from the surface about 2 minutes after 
application of trypsin. Cell detachment was about 46% ± 6.14SD after 4 minutes, which 
is faster when compared to the control and BSA/HCl (with mean % rounded cells ~ 
19% ± 2.54SD and 41.6% ± 3.50SD, respectively). Cell detachment was about 59.20% 
± 12.13SD after 6 minutes which was faster as compared to the control. Figure 3.6 
shows the trypsinisation process for bone cells cultured with BSA indicated that cells 
started to detach from the surface about 4 minutes after application of trypsin but that 
detachment occurred at a very slow rate. Cell detachment was 11% ± 3.56SD after 4 
minutes and 13.00% ± 3.16SD after 6, which is slower when compared to all other 
treatments. Complete detachment was achieved for cells cultured with HCl and un-
treated (control) after 14 minutes while cells remained attached to culture flask treated 
with BSA and BSA/HCl with mean percentage rounded cells about 22.20% ± 3.27SD 
and 88.40% ± 2.40SD, respectively. 
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Figure 3.3 Trypsinisation process for the control over a period of 14 minutes; (Scale 
bar=100 m) (Sefat, 2009a, Sefat, 2010c). 
 
 
Figure 3.4 Trypsinisation process in the presence of BSA/HCl for the period of 14 
minutes; (Scale bar=100 m) (Sefat, 2009a, Sefat, 2010c). 
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Figure 3.5 Trypsinisation process in the presence of HCl for the period of 14 minutes; 
(Scale bar=100 m) (Sefat, 2009a, Sefat, 2010c). 
 
 
Figure 3.6 Trypsinisation process in the presence of BSA for the period of 14 minutes; 
(Scale bar=100 m) (Sefat, 2009a, Sefat, 2010c). 
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Table 3.1 Descriptive Statistics for trypsinisation (Percentage of rounded cells) of bone 
cell treated with control, BSA, HCl and BSA/HCl over period of 14 minutes. 
 
Treatment Trypsinisation 
Time (min) 
Mean % Rounded Cells 
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
 
Control 
0min 0.00 0.00 
2min 14.00 ± 1.58 0.71 
4min 19.00 ± 2.54 1.14 
6min 43.00 ± 2.23 1.00 
8min 57.00 ± 3.80 1.70 
10min 79.00 ± 4.52 2.02 
12min 87.40 ± 2.88 1.28 
14min 100.00 0.00 
 
 
 
 
HCl 
0min 0.00 0.00 
2min 24.20 ± 7.04 3.15 
4min 46.20 ± 6.14 2.74 
6min 59.20 ± 12.13 5.42 
8min 74.60 ± 11.19 5.00 
10min 87.60 ± 4.15 1.86 
12min 96.20 ± 2.16 0.96 
14min 100.00 0.00 
 
 
 
 
BSA 
0min 0.00 0.00 
2min 5.20 ± 1.30 0.58 
4min 11.00 ± 3.56 1.59 
6min 13.00 ± 3.16 1.41 
8min 17.20 ± 2.04 0.91 
10min 20.00 ± 2.44 1.09 
12min 21.60 ± 2.50 1.12 
14min 22.20 ± 3.27 1.46 
 
 
 
 
BSA/HCl 
0min 0.00 0.00 
2min 14.00 ± 2.23 1.00 
4min 41.60 ±  3.50 1.56 
6min 63.20 ± 5.89 2.63 
8min 81.60 ± 3.97 1.77 
10min 81.00 ± 4.63 2.07 
12min 85.40 ± 1.67 0.74 
14min 88.40 ± 2.40 1.07 
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Table 3.1 shows descriptive statistics of percentage of rounded cells during 
trypsinisation process treated with control, BSA, HCl and BSA/HCl.  
 
Figure 3.7 Comparison between percentages rounded cells during trypsinisation 
process treated with control, HCl, BSA and BSA/HCl (Error bars represent standard 
deviation) (Sefat, 2009a, Sefat, 2010c). 
 
3.4.2  Trypsinisation - Different TGF-β Isomers 
In the previous section, it was observed that HCl and BSA as a solvent and carrier for 
TGF-β influenced cell detachments compared to the control (p < 0.05). In this section 
the effect of TGF-β isomers (TGF-β1, TGF-β2 and TGF-β3) on cell detachment were 
investigated. Figure 3.8 shows the trypsinisation process for bone cells cultured with 
TGF-1 which shows that cells started to detach from the surface about 1 minute after 
application of trypsin and majority of cells were detached by the forth minute (with a 
mean % rounded cells ~ 77.60 ± 5.54SD). In comparison, as seen in previous Figures 
(e.g. Figure 3.3-3.6), a completely different response was recorded with the bone cells 
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plated in negative controls (without any TGF-), i.e. the rate of detachment was much 
slower in control even after 6-8 minutes. In the case of TGF-β1, cell detachment was 
about 84% after 6 minutes, which was significantly faster when compared to the 
controls (p < 0.001), BSA (p < 0.001), HCl (p < 0.001) and HCl/BSA (p < 0.001). 
Figure 3.9 shows the trypsinisation process for bone cells cultured with TGF-2 which 
shows that cells started to detach from the surface about 1 minute after application of 
trypsin and even more cells were detached by the forth minute compared to the TGF-1. 
In the case of TGF-β2 cell detachment was approximately 88% after 4 minutes, which 
was faster as compared to the control (p<0.001), BSA (p<0.001), HCl (p<0.001) and 
HCl/BSA (p<0.001). TGF-β2 also induced faster cell detachment after 4 minutes 
compared to TGF-1 (p=0.463) but there was not significance differences in cell 
detachment. Figure 3.10 shows the trypsinisation process for bone cells cultured with 
TGF-3 which shows that cells started to detach from the surface about 1 minute after 
application of trypsin and were mostly detached by the third minute. In comparison, as 
seen in the previous Figures (e.g. Figure 3.3-3.6), a completely different response was 
recorded with the bone cells plated without TGF-3, i.e. the rate of detachment was 
much slower in control even after 6-8 minutes. Cell detachment with TGF-3 was about 
85% after 4 minutes, which is faster as compared to the control, BSA, HCl and 
HCl/BSA. For comparison, as seen in Table 3.2, it was found that treatment with TGF-
1, TGF-2 and TGF-3, enhanced the bone cell detachment rate by statistically similar 
amounts when applied in islolation. 
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Table 3.2 Descriptive statistics for trypsinisation (Mean percentage of rounded cells) of 
bone cells monolayer treated with TGF-β1, TGF-β2 and TGF-β3 over period of 14 
minutes. 
 
Treatment Trypsinisation Time 
(min) 
Mean % Rounded Cells 
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
 
TGF-β1 
0min 0.00 0.00 
2min 22.20 ± 1.92 0.86 
4min 77.60 ± 5.54 2.48 
6min 84.20 ±  1.30 0.58 
8min 92.00 ± 4.35 1.94 
10min 95.40 ± 1.14 0.50 
12min 100.00 0.00 
14min 100.00 0.00 
 
 
 
 
TGF-β2 
0min 0.00 0.00 
2min 39.40 ± 3.71 1.66 
4min 88.40 ± 3.04 1.36 
6min 91.00 ± 1.22 0.54 
8min 95.00 ± 5.24 2.34 
10min 96.00 ± 3.08 1.37 
12min 100.00 0.00 
14min 100.00 0.00 
 
 
 
 
TGF-β3 
0min 0.00 0.00 
2min 21.40 ± 4.61 2.06 
4min 85.60 ± 3.43 1.53 
6min 96.00 ± 3.08 1.37 
8min 96.00 ± 3.08 1.37 
10min 96.60 ± 2.50 1.12 
12min 98.20 ± 0.83 0.37 
14min 100.00 0.00 
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Figure 3.8 Trypsinisation process in the presence of TGF-β1 for the period of 14 
minutes; (Scale bar=100 m). 
 
 
Figure 3.9 Trypsinisation process in the presence of TGF-β2 for the period of 14 
minutes; (Scale bar=100 m). 
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Figure 3.10 Trypsinisation process in the presence of TGF-3 for the period of 14 
minutes; (Scale bar=100 m) (Sefat, 2009a, Sefat, 2010c). 
  
3.4.3  Trypsinisation - Different TGF-β Combinations: 
In vivo  it is unlikely that cells will be exposed to just one cytokine, thus the aim of this 
part of the thesis was to determine the  effects of different TGF-β combinations such as 
TGF-(1+2), TGF-(1+3), TGF-(2+3) and TGF-(1+2+3) on cell detachment. Figure 
3.11 shows the trypsinisation process for bone cells treated with TGF-(1+2). In 
response to treatment with TGF-(1+2) cells started to detach from the surface about 1 
minute after application of trypsin but not much detachment was observed upto 6 
minutes 30.20 ± 2.48SD, which was extremely slow compared to all three isomers of 
TGF-β (p<0.01). After treatment with TGF-(1+2) cell detachment was not completed 
even after 14 minute (with a mean % rounded cells ~ 85.80% ± 2.86SD).  
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Figure 3.11 Trypsinisation process in the presence of TGF-β(1+2) for the period of 14 
minutes; (Scale bar=100 m). 
 
Figure 3.12 shows the trypsinisation process for bone cells cultured treated with TGF-
(1+3), which shows that cells started to detach from the surface about 2 minute after 
application of trypsin and good detachment were observed from up to 4 minutes (cell 
detachment was 16% ± 2.54SD after 2 minutes and suddenly increased to 67.6% ± 
2.70SD at 4 minute). Cell detachment was unchanged after 8 minutes and no more cell 
detachments were observed even after 14 minutes (cell detachment was 88%). TGF-
β(1+3) showed better cell detachment compared to TGF-β(1+2) (p < 0.01) but complete 
detachment was not observed even after 14 minutes.  
 94 
 
 
Figure 3.12 Trypsinisation process in the presence of TGF-β(1+3) for the period of 14 
minutes; (Scale bar=100 m). 
 
Figure 3.13 shows the trypsinisation process for bone cells cultured treated with TGF-
(2+3), which shows that cells started to detach from the surface about 1 minute after 
application of trypsin and great detachment were observed up to 4 minutes (cell 
detachment was 30% after 2 minutes and increased to 74% at 4 minutes). Cell 
detachment continued after 4 minutes and complete detachment was observed at 12 
minutes (100% cell detachment). Petridish treated with TGF-β(2+3) showed the best 
result in terms of cell detachment compared to all other TGF-β combinations.  
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Figure 3.13 Trypsinisation process in the presence of TGF-β(2+3) for the period of 14 
minutes; (Scale bar=100 m). 
 
Figure 3.14 shows the trypsinisation process for bone cells cultured treated with TGF-
(1+2+3), which showed that cells started to detach from the surface about 2 minutes 
after application of trypsin and good detachment was observed up to 4 minutes (cell 
detachment was 18% after 2 minutes and increased to 64% after 4 minutes). Cell 
detachment was increased gradually after 4 minutes but complete detachment was not 
achieved even after 14 minutes (cell detachment was 85%).  TGF-β(1+2+3) showed 
similar results to TGF-β(1+3).  
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Figure 3.14 Trypsinisation process in the presence of TGF-β (1+2+3) for the period of 
14 minutes; (Scale bar=100 m). 
 
Table 3.3 shows mean percentage of rounded cells during trypsinisation process for all 
TGF-β combinations (these experiments were repeated three times). Table 3.4 also 
shows P values derived from pair wise comparisons of different treated TGF-βs, HCl, 
BSA, BSA/HCl and control for trypsinisation of bone cell monolayer over period of 14 
minutes. For comparison, as seen in Figures 3.8-3.14, it was found that treatment with 
TGF-1, TGF-2 and TGF-3, enhanced the bone cell detachment rate by statistically 
similar amounts when applied in islolation but when applied in combination induced 
statistically different rates of detachment (See Table 3.4). 
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Table 3.3 Descriptive statistics for trypsinisation (Mean percentage of rounded cells) of 
bone cell monolayer treated with TGF-β combinations over period of 14 minutes. 
 
Treatment Trypsinisation 
Time (min) 
Mean % Rounded Cells 
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
 
TGF-β1+2 
0min 0.00 0.00 
2min 4.60 ± 1.14 0.50 
4min 10.00 ± 1.58 0.70 
6min 30.20 ± 2.48 1.11 
8min 46.60 ± 3.04 1.36 
10min 63.60 ± 2.30 1.02 
12min 72.40 ± 3.20 1.43 
14min 85.80 ± 2.86 1.28 
 
 
 
 
TGF-β1+3 
0min 0.00 0.00 
2min 16.00 ± 2.54 1.14 
4min 67.60 ± 2.70 1.20 
6min 79.20 ± 3.34 1.49 
8min 88.60 ± 1.51 0.67 
10min 88.00 ± 1.58 0.70 
12min 88.20 ± 3.42 1.52 
14min 88.20 ± 1.30 0.58 
 
 
 
 
TGF-β2+3 
0min 0.00 0.00 
2min 30.00 ± 2.23 1.00 
4min 74.20 ± 1.64 0.73 
6min 83.00 ± 3.80 1.70 
8min 87.20 ± 1.78 0.80 
10min 97.40 ± 1.51 0.67 
12min 100.00 0.00 
14min 100.00 0.00 
 
 
 
 
TGF-β1+2+3 
0min 0.00 0.00 
2min 18.00 ± 2.23 1.00 
4min 64.20 ± 3.11 1.39 
6min 72.80 ± 1.64 0.73 
8min 76.40 ± 2.07 0.92 
10min 81.00 ± 2.54 1.14 
12min 83.60 ± 4.82 2.15 
14min 85.20 ± 2.16 0.96 
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Table 3.4 P values derived from pair wise comparisons of different treated TGF-βs, HCl, BSA, BSA/HCl and 
control for trypsinisation of bone cell monolayer over period of 14 minutes. Pairs that are significantly different 
from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 and *** P<0.001. 
 
Treatment 0min 2min 4min 6min 8min 10min 12min 14min 
Control  -  HCl 1.000 0.001*** 0.001*** 0.001*** 0.036* 0.002** 0.008** 1.000 
Control  -  BSA 1.000 0.004** 0.047* 0.001*** 0.009** 0.001*** 0.008** 0.001*** 
Control  -  BSA/HCl 1.000 1.000 0.001*** 0.001*** 0.008** 0.992 0.239 0.001*** 
Control  -  TGF-β1 1.000 0.010* 0.001*** 0.001*** 0.009** 0.001*** 0.005** 1.000 
Control  -  TGF-β2 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 1.000 
Control  -  TGF-β3 1.000 0.028* 0.001*** 0.001*** 0.009** 0.001*** 0.008** 1.000 
Control  -  TGF-β1+2 1.000 0.002** 0.011* 0.004** 0.009** 0.001*** 0.008** 0.001*** 
Control  -  TGF-β1+3 1.000 0.996 0.001*** 0.001*** 0.009** 0.001*** 0.589 0.001*** 
Control  -  TGF-β2+3 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 1.000 
Control  -  TGF-β1+2+3 1.000 0.681 0.001*** 0.001*** 0.009** 0.992 0.112 0.001*** 
HCl  -  BSA 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.009** 0.001*** 
HCl  -  BSA/HCl 1.000 0.001*** 0.640 0.956 0.169 0.040* 0.009** 0.001*** 
HCl  -  TGF-β1 1.000 0.996 0.001*** 0.001*** 0.009** 0.007** 0.005** 1.000 
HCl  -  TGF-β2 1.000 0.001*** 0.001*** 0.001*** 0.012* 0.003** 0.005** 1.000 
HCl  -  TGF-β3 1.000 0.950 0.001*** 0.001*** 0.009** 0.001*** 0.088 1.000 
HCl  -  TGF-β1+2 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.009** 0.001*** 
HCl  -  TGF-β1+3 1.000 0.010* 0.001*** 0.001*** 0.009** 1.000 0.009** 0.001*** 
HCl  -  TGF-β2+3 1.000 0.181 0.001*** 0.001*** 0.021* 0.001*** 0.005** 1.000 
HCl  -  TGF-β1+2+3 1.000 0.119 0.001*** 0.002** 0.675 0.040* 0.009** 0.001*** 
BSA  -  BSA/HCl 1.000 0.004** 0.001*** 0.001*** 0.008** 0.001*** 0.009** 0.001*** 
BSA  -  TGF-β1 1.000 0.001*** 0.001*** 0.001*** 0.008** 0.001*** 0.005** 0.001*** 
BSA  -  TGF-β2 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 0.001*** 
BSA  -  TGF-β3 1.000 0.001*** 0.001*** 0.001*** 0.008** 0.001*** 0.008** 0.001*** 
BSA  -  TGF-β1+2 1.000 1.000 1.000 0.001*** 0.009** 0.001*** 0.009** 0.001*** 
BSA  -  TGF-β1+3 1.000 0.001*** 0.001*** 0.001*** 0.008** 0.001*** 0.009** 0.001*** 
BSA  -  TGF-β2+3 1.000 0.001*** 0.001*** 0.001*** 0.008** 0.001*** 0.005** 0.001*** 
BSA  -  TGF-β1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.009** 0.001*** 
BSA/HCl  -   TGF-β1 1.000 0.010* 0.001*** 0.001*** 0.015* 0.001*** 0.005** 0.001*** 
BSA/HCl  -   TGF-β2 1.000 0.001*** 0.001*** 0.001*** 0.015* 0.001*** 0.005** 0.001*** 
BSA/HCl  -   TGF-β3 1.000 0.028* 0.001*** 0.001*** 0.008** 0.001*** 0.008** 0.001*** 
BSA/HCl  -   TGF-β1+2 1.000 0.002** 0.001*** 0.001*** 0.008** 0.001*** 0.009** 0.363 
BSA/HCl  -   TGF-β1+3 1.000 0.996 0.001*** 0.001*** 0.025* 0.023* 0.173 1.000 
BSA/HCl  -   TGF-β2+3 1.000 0.001*** 0.001*** 0.001*** 0.044* 0.001*** 0.005** 0.001*** 
BSA/HCl  -   TGF-β1+2+3 1.000 0.681 0.001*** 0.076 0.026* 1.000 0.292 0.124 
TGF-β1  -  TGF-β2 1.000 0.001*** 0.001*** 0.463 0.401 1.000 1.000 1.000 
TGF-β1  -  TGF-β3 1.000 1.000 0.038* 0.011* 0.202 1.000 0.005** 1.000 
TGF-β1  -  TGF-β1+2 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 0.001*** 
TGF-β1  -  TGF-β1+3 1.000 0.119 0.003** 0.838 0.07 0.013* 0.005** 0.001*** 
TGF-β1  -  TGF-β2+3 1.000 0.017* 0.916 1.000 0.035* 0.992 1.000 1.000 
TGF-β1  -  TGF-β1+2+3 1.000 0.617 0.001*** 0.016* 0.009** 0.001*** 0.005** 0.001*** 
TGF-β2  -  TGF-β3 1.000 0.001*** 0.976 0.838 0.916 1.000 0.005** 1.000 
TGF-β2  -  TGF-β1+2 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 0.001*** 
TGF-β2  -  TGF-β1+3 1.000 0.001*** 0.001*** 0.011* 0.115 0.005** 0.005** 0.001*** 
TGF-β2  -  TGF-β2+3 1.000 0.002** 0.001*** 0.240 0.059 1.000 1.000 1.000 
TGF-β2  -  TGF-β1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 0.001*** 
TGF-β3  -  TGF-β1+2 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.009** 0.001*** 
TGF-β3  -  TGF-β1+3 1.000 0.263 0.001*** 0.001*** 0.008** 0.002** 0.009** 0.001*** 
TGF-β3  -  TGF-β2+3 1.000 0.005** 0.001*** 0.003** 0.009** 1.000 0.005** 1.000 
TGF-β3  -  TGF-β1+2+3 1.000 0.847 0.001*** 0.001*** 0.009** 0.001*** 0.008** 0.001*** 
TGF-β1+2  -  TGF-β1+3 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.009** 0.480 
TGF-β1+2  -  TGF-β2+3 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.005** 0.001*** 
TGF-β1+2  -  TGF-β1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.009** 0.001*** 0.009** 1.000 
TGF-β1+3  -  TGF-β2+3 1.000 0.001*** 0.159 0.968 0.163 0.001*** 0.005** 0.001*** 
TGF-β1+3  -  TGF-β1+2+3 1.000 0.996 0.916 0.552 0.009** 0.023* 0.116 0.184 
TGF-β2+3  -  TGF-β1+2+3 1.000 0.001*** 0.003** 0.046* 0.009** 0.001*** 0.005** 0.001*** 
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HCl and HCl/BSA induced similar rates of detachment for up to 8 minutes with no 
significant differences (P < 0.05) compared to the control. TGF-β1, TGF-β2 and TGF-
β3 treatments were significant differences (P < 0.05) in term of cell detachment 
compared to the control, BSA and BSA/HCl. Multiple comparisons with respect to 
different treatments at each time point were performed (See Table 3.4). TGF-β3 treated 
cells appeared to detach faster than did HCl/BSA and BSA treated cells, although TGF-
β3 and HCl induced detachment times were not significantly different (P = 0.088) after 
12 minutes of trypsinisation. Tables 3.1-3.4 show that there are no significant 
differences between all TGF- isomers with TGF-(2+3) (p=1.000) which means 
combination of TGF-2 and TGF-3 induce responses similar to those associated with 
the treatment of cells with the different TGF- isomers in isolation. However, there are 
significantly difference in percentage rounded cells between cells treated with TGF- 
isomers in isolation and other TGF- combinations (p<0.05). It can be concluded that 
combination of TGF-3 with any other TGF- isomer other than TGF-2 causes better 
cell detachment whilst a lack of TGF-3 decreased cell detachment. Exceptionally, 
TGF-(1+2+3) caused less detachment compared to those with TGF-3 (p<0.01).  Also 
in all cases with addition of TGF- isomers better cell detachments were observed 
compared to the control, BSA, HCl and BSA/HCl. These results suggest that the 
application of TGF-3 at 50ng/ml decreased the degree of cell attachment on surface as 
also shown graphically in Figure 3.7. BSA represented slowest degree of cell 
detachment compared to all other solutions (p<0.05).  
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Figure 3.15 Comparison between mean percentages rounded cells during trypsinisation 
process treated with TGF-β1, TGF-β2, TGF-β3, TGF-(1+2), TGF-(1+3), TGF-
(2+3), TGF-(1+2+3)and un-treated as control (Error bars represent standard 
deviation). 
 
3.5  DISCUSSION 
The natural process of healing a fracture starts when the injured bone and surrounding 
tissues bleeds, forming a fracture hematoma. The blood coagulates to form a blood clot 
situated between the broken fragments. It is well established that collagen type I, the 
major ECM protein of bone, mainly exist in intact bone (Tosounidisa, 2009). Within a 
few days of injury blood vessels develop into the matrix of the blood clot. The blood 
vessels bring fibroblasts in the walls of the vessels and these multiply and produce 
collagen fibres. Therefore, the blood clot is replaced by a matrix of collagen. However, 
collagen type I is not the only ECM protein present in bone and fibronectin also 
accumulates in the site of injury (Canavan, 2005b). This further supports the finding in 
the previous chapter in which MG63 cells responded mostly to the fibronectin patterns 
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suggesting that these cells attach mostly via fibronectin specific integrins. This is in 
term represents that cells take on a more migratory phenotype when cultured on 
fibronectin. This indicates that specific integrins associated with attachment to 
fibronectin could be important in bone wound repair. For this reason trypsinisation 
assay were carried out in this chapter in order to assess the effect of various TGF-βs 
treatment on cell detachment. Cell detachment using the trypsinisation assay has been 
investigated for different purposes in many cell types; however, in the case of 
osteoblasts the amount of information for cell detachment behaviour is limited. For 
instance, MG63 cell adhesion was measured using a trypsinisation assay (Abed, 2009). 
MG63 cells were seeded in 12-well plates for 4 days and treated with platelet-derived 
growth factor (PDGF) for 16hrs. Then cells were incubated with 1 ml of 0.05% trypsin-
EDTA for 4 minute to promote cell detachment. Detached cells were collected by 
adding media. The number of detached cells under limited trypsinisation was then 
manually counted using a haemocytometer. Results showed that cell adhesion induced 
by PDGF was prevented when cells were transfected with melastatin-like transient 
receptor potential 7 (TRPM7) compared to the control (Abed, 2009). Another group 
also showed osteoblast-like cell adhesion on bioactive glasses (Foppiano, 2007a, 
Foppiano, 2007b). Surface reactions and resistance to trypsinisation have been studied. 
Osteoblast attachment and detachment phenomenon were also investigated for the 
successful integration of an orthopaedic implant into bone (Moutzouri, 2010). Human 
osteoblast was used to study the development of attachment for coated and uncoated 
surfaces. Current literature, or similar research, showed adhesion assay of osteoblast 
cells without the presence of any treatment and it was necessary for our research studies 
to know the detachment rate of MG63 over a period of time with the presence of various 
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TGF-βs treatments. In addition, many cell types such as osteoblast take on a migratory 
phenotype during wound repair and this can be associated with a change in the degree 
of cell surface attachment (Boland, 1996, Moutzouri, 2010). However, a decrease in cell 
surface attachment may be beneficial to changes in cell behaviour during wound healing 
and repair with the presence of different TGF-β isomers. Trypsinisation was also carried 
out in order to investigate its effect on cell detachment in the presence of HCl, BSA, 
BSA/HCl (as a TGF-β solvent and carrier) (Sefat, 2009a, Sefat, 2010c). HCl decreased 
cell attachment and this could be associated with cells taking on a migratory phenotype. 
This is supported in the literature by Dong et al, 2005. The aim of their study was to 
investigate the effect of taspine hydrochloride (TA/HCl) on skin wound healing in rats 
(Dong, 2005). The closure time of the skin wounds was significantly shorter in the 
TA/HCl treated groups than that in the control. TA/HCl has the ability of promoting 
skin wound healing in rats, and it can also accelerate the angiogenesis and raise the 
production of collagen in wound tissue. It has also been proposed (Oreffo, 1989) that 
TGF-β may not be the only reason for increasing the rate of wound repair in bone. In 
order for TGF-β to be administered exogenously it needs to be dissolved with HCl and 
BSA used as the carriers of TGF-β. It is suggested that HCl also contributes to the rate 
of wound repair (Centrella, 1988, Sefat, 2010b). This is particularly important seeing as 
there is evidence that the pH of injured bone can decrease and that this may play a role 
in activating TGF-β (Oursler, 1994, Dallas, 2002). These results also suggest that the 
application of TGF-3 and HCl decreases the degree of cell attachment. It can be 
concluded that combination of TGF-3 with any other TGF- isomer decreases cell 
attachment whilst a lack of TGF-3 increases cell attachment. This could be associated 
with changes in integrin expression. For this reason we will investigate the effects of 
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various TGF-βs and HCl in wound closure in a simple bone cell culture model in the 
next two chapters.  
 
3.6  CONCLUSIONS 
In conclusion, TGF-β3, HCl and HCl/BSA enhanced the rate of cell detachment in 
relation to the negative controls indicating perhaps that TGF-β3 does not act alone in 
cell detachment, but instead functions synergistically with signalling pathways that are 
dependent on the availability of hydrogen ions. Such a mechanism would depend on 
signalling molecules undergoing a conformational change on binding hydrogen ions, 
which is not a new concept. For comparison, a completely different response was 
recorded with the bone cells plated with TGF-1, TGF-2 and TGF-3 as all three 
TGF- isomers enhanced the cell detachment rate on their own, but induced different 
rates of detachment when combined together. It can also be concluded that the 
combination of TGF-3 with any other TGF- isomer causes better cell detachment, 
while TGF-3 absence showed less cell detachment. 
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CHAPTER FOUR 
4. EFFECTS OF DIFFERENT 
TRANSFORMING GROWTH FACTOR BETA 
(TGF-β) ISOMERS ON WOUND CLOSURE OF 
BONE CELL MONOLAYERS 
 
4.1  INTRODUCTION 
Bone repair can be modulated by different stimuli including growth factors (Hollinger, 
2004, Guiqian, 2012). TGF-β is a cytokine known to be associated with the scarless 
healing of skin (Khan, 2000) and it is highly probable that it may play a role in the 
repair of other tissues including bone (Sefat, 2009b, Sefat, 2010d, Beggs, 2010). TGF-β 
can be found in three isomers: TGF-β1, TGF-β2 and TGF-β3. TGF-β has also been used 
to stimulate bone regeneration (Lind, 1993). TGF-β2 has been administrated for a 
period of 6 weeks in animal models with tibial defects (Lind, 1993). It was shown that 
TGF-β2 induced a higher healing rate compared to the control (Lind, 1993). The 
anabolic effects of TGF-β on bone repair are also dependent on the mechanical stability 
at the site of fracture (Critchlow, 1995). Unilateral tibial fractures were produced in a 
rabbit animal model and a plate (plastic /steel) was used in order to immobilise the 
fracture site. TGF-β2 was applied to the calluses 4 days after fracture. Results 
demonstrated that in animals with unstable fixation, TGF-β2 did not show an anabolic 
effect on callus formation, but animals with stable fixation enlarged calluses were 
developed (Critchlow, 1995). It is not clear whether or not TGF-β2 will  always induce 
a positive response since different dosages of TGF-β2 have different effects (Duque, 
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2007). However, some believe that the anabolic effect of TGF-β may be due to its 
potentiation of bone morphogenic protein (BMPs) (Centrella, 1994). BMP-7 has been 
reported (Ripamonti, 1997) as having positive effects on bone formation when co-
administered with low dosages of TGF-β1. Mixing these two growth factors induced a 
2-3 fold increase in the cross sectional area of newly generated ossicles compared to 
treatment with BMP-7 alone. Previous studies have shown (Khan, 2000, Tosounidisa, 
2009) that there is limited research regarding the use of TGF-β isomers in bone cells in 
terms of fracture repair and healing compared to other cell types such as keratinocytes 
(Sun, 2009, Shirakata, 2010, Mauvie, 2009), and also compared to other growth factors 
such as BMP (Croteau, 1999), platelets-derived growth factor (PDGF), insulin-like 
growth factor (IGF) (Thaller, 1993) and fibroblast growth factors (FGF) (Hurley, 1993). 
Therefore, there is a need to carry out further research on the effect of different TGF-β 
isomers and their combinations on bone repair and its related mechanism. 
 
4.2  AIMS AND OBJECTIVES 
The main objective of this chapter was to investigate the effect of different TGF-β 
isomers and their combinations on wound closure in cultured monolayers of MG63 
bone cells. The lab-based experimental work investigated and compared the wound 
closure properties of three TGF-β isomers, HCl and BSA/HCl in cultured monolayers of 
human bone cells. Other cellular responses such as proliferation and detachment were 
also investigated along with morphology changes during wound closure in an in vitro 
model wound. 
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4.3  MATERIALS AND METHODS  
4.3.1  Cell Culture 
Bone cells were cultured in a low glucose (1g/L-D-Glucose) HEPES (25mM) buffered 
DMEM (Dulbecco's Modified Eagle Media, Sigma Aldrich) culture media 
supplemented with L-glutamine (2.5 mM U/mL), Penicillin (100 U/mL), Streptomycin 
(0.1 mg/mL), Amphotericin B or a fungizone (250µg/ml), (Sigma Aldrich-UK) and 
10% FCS v/v (fetal calf serum- PromoCell - UK). The bone cells were plated in 25cm
2
 
tissue culture grade cell culture flasks at a cell density of 250,000 cells/culture flask and 
bathed in the culture media. All supplements were purchased from Sigma Aldrich-UK, 
except those otherwise mentioned. 
 
4.3.2  Creating wound on cell monolayers 
MG63 human bone cells were cultured and when confluent the cell monolayer was 
wounded (scratched) using a disposable plastic pipette of 1mm diameter. The tip was 
bent downwards so that it could be inserted into the flasks. The tip was then drawn 
across the cells on the cultured surface creating the wound. The underside of the flask 
was then marked with 3 parallel lines using a water resistant marker pen such that the 
lines intersected with the wound drawn in the monolayer of cells at 90
o
. These markings 
facilitated orientation and allowed the same points to be repeatedly monitored and 
photographed every 5hrs (see Figure 4.1). A ‘test experiment’ was performed in order to 
determine the time frame of wound closure in the wounded cultures. The duration of 
this test experiment was 30hrs. This was similar to another experiment on wound 
closure using NIH/3T3 fibroblast monolayers (Hollinger, 2004, Sefat, 2009b) for which 
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wound closure was achieved after ~300 minutes. In their study, cell monolayers were 
wounded with “the corner of a piece of Mylar film which is commonly used in copy 
machines”. 
 
Figure 4.1 Marked line determining point of reference on cultured monolayer for 
scratch assay. 
 
Scratching the cell monolayer resulted in wounds of approximately 300μm; however, 
there was some variability in wound widths. To normalise for this the mean starting 
wound width was calculated per treatment and each starting wound width was 
expressed as a percentage of that mean starting wound width. Wound width at each time 
point was in turn expressed as a percentage of the mean starting wound width per 
treatment. During our ‘test experiment’ (20hrs), it became clear that complete wound 
closure was not achieved during this time frame and thus the time frame for our 
experiment was set to 30hrs with data collection every 5hrs. Figure 4.2 (a-c) 
diagrammatically shows the steps involved in these experiments. All experiments in this 
chapter were repeated three times.  
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Figure 4.2 Growth of human bone cells (MG63) in culture flask: (a) after cell seeding 
(b) confluence cell monolayer (after 3 days in culture) and (c) wounded cells ready for 
treatment; X100 magnification (Scale bar = 100 μm). 
 
Different TGF-β isomers (TGF-β1, TGF-β2 and TGF-β3) and their combinations (TGF-
(1+2), TGF-(1+2+3), TGF-(1+3), TGF-β(2+3)) were applied with the same 
concentrations described in Chapter 3 to investigate their effect on wound healing 
(Sefat, 2009b, Sefat, 2010d). The same method was applied for culturing the cells with 
HCl and BSA/HCl as TGF-β solvent (HCl) and carrier (BSA) with working 
concentrations of 50ng/ml, and without growth factor as a control.  
 
4.3.3  Data acquisition 
After wounding, culture flasks were stored inside the incubator and wound width was 
imaged and measured every 5hrs over a 30hrs period. The cells were photographed 
using a phase contrast light microscope and a digital camera. Pictures were captured and 
stored as tif images. Image J software was used in order to measure the distance 
between the wound edges. Ten vertical lines at approximately equal distances apart and 
the distances between the intersections of the lines with the wound edges were 
measured as shown in Figure 4.3. The measurements began at a scratch width of 300µm 
± 10-30µm at 0mins. Graphs of percentage wound closure versus time were plotted for 
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the different TGF-β treatments and control (with no treatment). Comparison was made 
in terms of percentage wound closure. The whole procedure was repeated three times 
and the data acquired was combined to acquire mean % wound width at each timepoint. 
 
Figure 4.3 Measurement of wound closure width on cultured MG63 bone cell 
monolayer using ‘Image J’ software; (Scale bar = 100µm)(Sefat, 2009b, Sefat, 2010d). 
 
4.4  STATISTICAL ANALYSIS 
Mean % of wound remained open was tested for normality using a Kolmogorov 
Smirnov test. Results that showed normal distribution (p > 0.05) were analysed using 
SPSS via a Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni 
test. Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed results (p < 0.05).  Statistical tests were performed such that a p value of < 
0.05 was considered as indicating a significant difference. There was some variability in 
initial wound widths therefore, % wound closure was normalised as described 
previously.  
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4.5  RESULTS 
4.5.1  The wound closure properties of HCl, BSA/HCl and control 
in cultured human bone cell monolayer 
Figure 4.4 shows the entire wounded bone cell monolayers together during 30hrs of 
healing treated with HCl, BSA/HCl and control. Results for the control showed that 
there were only small changes in % wound remained open even after 10hrs (Sefat, 
2009b, Sefat, 2010d). Cell morphology changes could be observed only in the cells at 
the wound edges after 15hrs (with mean % of wound remained open ~ 85.67% ± 
1.31SD). These cells had elongated but without migration to the wound site. After 20hrs 
there were still gaps between the cells in the wound site. The cells in the control flask 
did not seem to form bridges with cells from the opposite wound margin to stabilize the 
wound site until about 25hrs (with mean % of wound remained open ~ 63.47% ± 
0.56SD). Cells met each other after 25hrs and started making bridges but without 
complete closure. It was clear that wounds remained open even after 25hrs and that after 
30hrs 57.86% ± 0.62SD of the wound still remained open (See Table 4.1). For the HCl 
treatment, it was found that after 10hrs wound size had decreased by 50%. After 20hrs 
the cells treated with HCl showed a high percentage of wound closure (only 15.17% ± 
0.40SD remained open). By comparison between control and HCl treated cultures, it 
became clear that after 30hrs the wound in the control remained open by  57.86% ± 
0.62 whereas HCl treated cultures seemed to almost reach full closure (p<0.001). This 
indicates that HCl even in buffered media had a significant effect on the wound healing 
process compared to the control. Treatment with BSA/HCl induced a similar wound 
closure response to treatment with HCl. From figures 4.4 and 4.5, it can be seen that 
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after 15hrs, the cells had migrated into the wound site and had started to meet cells from 
the opposite side of the wound similar in a way similar to those cells treated with HCl 
previously. These cells then formed bridges to connect the wound edges and closed the 
wound. As soon as the bridges were formed in the wound site the wound closed quite 
rapidly. During bridge formation the cells a distance away from the wound edge aligned 
behind those bridges to organize the cell structure and this seemed to aid wound closure 
after 25hrs (Sefat, 2009b, Sefat, 2010d).   
Table 4.1 Descriptive statistics for mean % of wound remaining open against time for 
wounded monolayers treated with HCl, BSA/HCl and control. 
 
Treatment 
Wound 
Closure 
Time (hrs) 
Mean % of Wound Remaining 
Open ± Std. Deviation 
(SD) 
Std. Error 
(SE) 
 
 
 
Control 
0hrs 100.00 ±  1.10 0.34 
5hrs 94.13 ± 0.64 0.20 
10hrs 92.25 ± 0.9 0.28 
15hrs 85.67 ± 1.31 0.41 
20hrs 82.15 ± 0.73 0.23 
25hrs 63.47 ±  0.56 0.17 
30hrs 57.86 ± 0.62 0.19 
 
 
 
HCl 
0hrs 100.01 ± 1.48 0.46 
5hrs 93.44 ± 0.80 0.25 
10hrs 48.69 ± 0.6 0.18 
15hrs 31.87 ± 0.61 0.19 
20hrs 15.17 ± 0.40 0.12 
25hrs 6.19 ±1.00 0.31 
30hrs 0.00 0.00 
 
 
 
 
BSA/HCl 
0hrs 100.00 ± 1.32 0.42 
5hrs 71.49 ± 0.61 0.19 
10hrs 49.83 ± 0.89 0.28 
15hrs 41.92 ± 0.41 0.13 
20hrs 17.68 ± 0.52 0.16 
25hrs 9.96 ± 0.85 0.27 
30hrs 0.00 0.00 
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Figure 4.4 Images of the wound healing process for the bone cell monolayers treated 
with 50ng/ml of HCl, BSA/HCl and un-treated as control for the period of 30hrs (Scale 
bar=100m)(Sefat, 2009b, Sefat, 2010d). 
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Figure 4.5 Graph of normalised % wound remaining open against time for wounded 
bone cell monolayers treated with HCl, BSA/HCl, and un-treated as control (Error bars 
represent standard deviation). 
 
However, the control culture flasks did not perform well with 82.15% ± 0.73SD of the 
wound remaining open after 20hrs. In contrast, the HCl treated culture flask had only 
15.17% ± 0.40SD of the wound still open. This indicates that HCl had significant effect 
on wound closure (p<0.001, See Table 4.1). Also, in cultures treated with BSA/HCl the 
% of wound remained open was 17.68% ± 0.52D after 20hrs. Statistical analysis shows 
that there were a significant differences between HCl and BSA/HCl treated flasks at 15, 
20 and 25hrs (p<0.001).   
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4.5.2  The Wound Closure Properties of TGF-β1, TGF-β2 and 
TGF-β3 in Cultured Human Bone Cell Monolayer 
Figure 4.6 shows all of the wounded bone cell monolayers together during 30hrs of 
healing treated with TGF-1, TGF-2, TGF-3 and un-treated as control. In the case of 
TGF-β1 it was observed that after 5hrs wound closure was faster compared to the 
control (with mean % wound remained open ~ 77.48% ± 1.11SD for TGF-β1 and 
94.13% ± 0.64SD for control) (Sefat, 2009c). Cells from both wound edges had 
elongated in order to contact the opposite cells and form bridges after ~15hrs of healing 
process (with mean % wound remained open ~ 48.92% ± 1.38SD). Cells had migrated 
along these bridges and a distance away from the wound edge they were aligned to 
reorganize the cell structure. These cells had elongated in order to fill the gaps created 
by the migrated and elongated cells at the wound edges. After 20hrs, cells covered the 
wound site, but there were still some gaps between cells. It was observed that after 
20hrs all the cells treated with TGF-β1 showed a high percentage of wound closure 
(with mean % of wound remained open ~ 29.77% ± 1.20SD). Elongation and bridging 
of the cells inside and outside the wound site was also observed and wound healing still 
continued even after 30hrs. The remaining wound following TGF-1 healed very fast 
after 25hrs and the percentage of wound remaining open was ~13.93% ± 2.46SD after 
30hrs which meant that wound healing was not complete even after 30hrs. The results 
indicate that TGF-β1 does indeed speed up the wound closure process in a pure cell 
culture environment. Statistical analysis show that TGF-β1 treated flasks at 25hrs has 
significantly improved the wound closure response as compared to the control 
(p<0.001) and reflected by % wound remained open (19.63% for TGF-β1 and 63.47% 
for control). 
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In the case of TGF-β2 it can be seen that after 5hrs the morphology of the cells at the 
wound edges have changed and that the cells seems to be elongated. After 15hrs the 
cells had migrated into the wound site and had begun to meet cells from the opposite 
side of the wound. As soon as the bridges formed in the wound site the wound was 
closed quite rapidly. It is useful to note that this process of wound closure is very 
similar to that following treatment with TGF-1 (Sefat, 2009c, Sefat, 2009d). After 
20hrs, cells covered the wound site (with percentage of wound remained open ~ 31.89% 
± 1.20SD) but there were still some gaps between cells. It was seen that after 25hrs all 
the culture flasks treated with TGF-β2 showed high percentage of wound closure (only 
 15.43% ± 2.76SD of the wound remained open). Wound healing was not completed 
even after 30hrs and there were still some gaps between cells (only 8.67% ± 1.34SD of 
wound remained open). Statistical results (Table 4.2) show that TGF2 treatment 
caused model wounds to heal faster than control (p<0.001), but induced a significantly 
slower rate of wound closure when compared to treated flasks with HCl (p<0.001) and 
BSA/HCl (p<0.001) (Sefat, 2009d).  
 
Despite cultures treated with TGF-β1 and TGF-β2 it was observed that cells treated with 
TGF-β3 had already elongated and started to migrate to the wound axis after 5hrs 
(62.25% ± 1.65SD wound remained open). After 10hrs the cells had already covered a 
great part of the wound site (41.95% ± 0.76SD wound remained open). It was seen that 
after 20hrs all the cells treated with TGF-β3 showed a high percentage of wound closure 
(only 16.19% ± 1.54SD wound remained open) and the remaining wound healed very 
fast after 25hrs and the percentage of wound remaining was almost zero which meant  
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Figure 4.6 Photomicrographs of the wound healing process for the bone cell 
monolayers treated with TGF-1, TGF-2, TGF-3 and control for the period of 30hrs 
(Scale bar=100m)(Sefat, 2009b, Sefat, 2009c, Sefat, 2009d). 
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Table 4.2 Descriptive statistics for % of wound remaining open against time for 
wounded monolayers treated with TGF-1, TGF-2, TGF-3 and un-treated as control. 
 
Treatment 
Wound Closure 
Time (hrs) 
Mean % of Wound Remaining 
Open ± Std. Deviation 
(SD) 
Std. 
Error 
(SE) 
 
 
 
Control 
0hrs 100.00 ±  1.10 0.34 
5hrs 94.13 ± 0.64 0.20 
10hrs 92.25 ± 0.9 0.28 
15hrs 85.67 ± 1.31 0.41 
20hrs 82.15 ± 0.73 0.23 
25hrs 63.47 ±  0.56 0.17 
30hrs 57.86 ± 0.62 0.19 
 
 
 
TGFβ1 
 
 
 
0hrs 100.00 ± 1.52 0.48 
5hrs 77.48 ± 1.11 0.35 
10hrs 63.35 ± 0.86 0.27 
15hrs 48.92 ± 1.38 0.43 
20hrs 29.77 ± 1.20 0.38 
25hrs 19.63 ± 2.82 0.89 
30hrs 13.93 ± 2.46 0.77 
 
 
 
TGFβ2 
 
0hrs 100.00 ± 1.80 0.57 
5hrs 69.86 ± 2.64 0.83 
10hrs 61.55 ± 2.27 0.72 
15hrs 48.94 ± 1.73 0.54 
20hrs 31.89 ± 1.20 0.38 
25hrs 15.43 ± 2.76 0.87 
30hrs 8.67 ± 1.34 0.42 
 
 
 
TGFβ3 
0hrs 99.99 ± 1.55 0.49 
5hrs 62.25 ± 1.65 0.52 
10hrs 41.95 ± 0.76 0.24 
15hrs 21.07 ± 0.75 0.23 
20hrs 16.19 ± 1.54 0.48 
25hrs 0.00 0.00 
30hrs 0.00 0.00 
 
that the wound healed completely after 25hrs. These results indicate that TGF-3, HCl, 
and BSA/HCl treatments show significant faster wound healing compared to the 
cultures treated with TGF-1 (p<0.001), TGF-2 (p<0.001) and un-treated as control 
(p<0.001). Table 4.2 and Figures 4.6 and 4.7 show results for the % wound remained 
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open against time for wounded bone cell monolayers treated with TGF-1, TGF-2, 
TGF-3 and un-treated as control. 
 
Figure 4.7 Graph of normalised % wound remaining open against time for wounded 
bone cell monolayers treated with TGF-1, TGF-2, TGF-3, HCl, BSA/HCl, and 
control (Error bars represent standard deviation). 
 
4.5.3  The Effect of Combinations of Transforming Growth Factor 
Beta Isomers TGF-(1+2), TGF-(2+3), TGF-(1+3) and TGF-(1+2+3) 
On Wound Closure of Bone Cell Monolayers 
Figure 4.8 shows wounded bone cell monolayers during 30hrs of healing treated with 
various combinations of three TGF-β isomers including TGF-(1+2), TGF-(1+2+3), 
TGF-(1+3), TGF-β(2+3) and untreated flask as control. In the case of TGF-(1+2) 
wound healing was not observed after 5hrs, while after 15hrs the cells replication had 
increased at the wound edge. After 20hrs the cells did not cover a great part of the 
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wound site (~ 63.19% ± 1.55SD of wound remained open) and showed slower healing 
compared to the other TGF-β combinations but closed faster than control wounds. Cells 
finally formed bridges at 30hrs and about 37.77% ± 1.90SD of wound remained open, 
for the TGF-(1+2) combination. Cells in culture flasks treated with TGF-(1+2+3) 
showed similar behaviours up to 20hrs and formed bridges 25hrs after wounding (with 
mean % of wound remained open ~ 40.83% ± 0.52SD) which was significantly faster 
compared to TGF-(1+2) (with mean % of wound remained open ~ 47.88% ± 1.94SD) 
(p<0.001). More cells could be seen in the middle of wound after 25hrs of healing but 
similar to TGF-(1+2) there were still some gaps between cells (~ 33.60% ± 1.12SD of 
the wound still remained open at 30hrs). In the case of TGF-β(1+3) it was observed that 
after 5hrs of incubation the cells had already elongated and started to migrate 
perpendicularly to the wound. After 25hrs cells started forming bridges and full wound 
closure did not occur at 30hrs but the rate of wound repair was significantly faster 
(25.33% ± 0.73SD of wound remained open at 30hrs) compared to TGF-β(1+2) 
(p<0.001) and TGF-β(1+2+3) (p<0.001). Figure 4.8 also shows the images for the 
wound closure process with TGF-β(2+3) treated culture flask. It was observed that after 
5hrs the cells had already enlarged and elongated. After 25hrs the cells had already 
covered a great part of the wound site and wound healing was not completed even after 
30hrs (23.87% ± 0.94SD of wound remained open). However, compared to all other 
TGF-β combinations, TGF-β(2+3) showed the fastest rate of wound closure. Table 4.3 
show descriptive statistics for the % wound remained open against time for wounded 
bone cell monolayers treated with TGF-(1+2), TGF-(1+2+3), TGF-(1+3), TGF-
β(2+3) and untreated as control. Results indicated that there was no significant 
difference in % wound closure between TGF-β(1+3) and TGF-β(2+3), while there were  
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Figure 4.8 Photomicrographs of the wound healing process for the bone cell 
monolayers treated with TGF-(1+2), TGF-(1+2+3), TGF-(1+3), TGF-β(2+3) and 
un-treated as control for the period of 30hrs (Scale bar=100m). 
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significance differences in % wound closure between other possible TGF-β 
combinations (p<0.001) (See Table 4.4).  The results also showed that TGF-β(2+3) 
increased the wound closure rate in a cell culture environment faster than the other 
TGF-β combinations. TGF-(1+2) showed the slowest healing rate, but it enhanced 
wound closure as compared to the control (p<0.001). Overall comparison between all 
treatments represent that cells treated with HCl and BSA/HCl induced a decrease in the 
% wound remained open compared to all TGF- combinations (p<0.001) whereas 
complete wound closure was achieved after 30hrs of healing in both HCl and BSA/HCl. 
This result also suggested that cells treated with TGF-β3, TGF-2 and TGF-1 showed 
significant faster wound healing compared to all TGF- combinations (p<0.001) (See 
Figures 4.8, 4.9 and Table 4.3). 
 
Figure 4.9 Graph of normalised % wound closure against time for wounded bone cell 
monolayers treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), 
TGF-(1+3), TGF-β(2+3) and un-treated as control (Error bars represent standard 
deviation). 
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Table 4.4 is the tabulated results to show the P value for the % of wound remained open 
against time for wounded bone cell monolayers treated with all TGF-β isomers and their 
combinations including TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-
(1+3), TGF-β(2+3), HCl, BSA/HCl and un-treated as control. 
Table 4.3 Descriptive statistics for mean % of wound remaining open against time for wounded 
monolayers treated with TGF-(1+2), TGF-(1+2+3), TGF-(1+3)and TGF-β(2+3). 
 
Treatment 
Wound 
Closure 
Time (hrs) 
Mean % of Wound Remaining 
Open ± Std. Deviation 
(SD) 
Std. Error 
(SE) 
 
 
 
TGFβ1+2 
 
0hrs 100.01 ± 1.25 0.39 
5hrs 90.92 ± 1.33 0.42 
10hrs 79.22 ± 2.07 0.65 
15hrs 73.26 ± 2.12 0.67 
20hrs 63.19 ± 1.55 0.49 
25hrs 47.88 ± 1.94 0.61 
30hrs 37.77 ± 1.90 0.60 
 
 
 
 
TGFβ1+3 
 
0hrs 99.98 ± 1.77 0.56 
5hrs 86.35 ± 0.84 0.26 
10hrs 71.98 ± 1.07 0.34 
15hrs 61.42 ± 1.18 0.37 
20hrs 50.99 ± 1.38 0.43 
25hrs 32.76 ± 1.36 0.43 
30hrs 25.33 ± 0.73 0.23 
 
 
 
TGFβ2+3 
 
0hrs 100.00 ± 2.17 0.68 
5hrs 84.60 ± 1.16 0.36 
10hrs 65.79 ± 1.2 0.38 
15hrs 60.92 ± 0.96 0.30 
20hrs 44.86 ± 1.40 0.44 
25hrs 30.95 ± 0.93 0.29 
30hrs 23.87 ± 0.94 0.29 
 
 
 
TGFβ1+2+3 
 
0hrs 99.98 ± 0.578 0.18 
5hrs 81.83 ± 1.47 0.46 
10hrs 76.24 ± 0.61 0.19 
15hrs 71.07 ± 0.83 0.26 
20hrs 58.43 ± 0.97 0.30 
25hrs 40.83 ± 0.52 0.16 
30hrs 33.60 ± 1.12 0.35 
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Table 4.4 P values derived from pair wise comparisons of treatment related % wound 
remained open. Pairs that are significantly different from one another showing marked 
by an asterisk (*) whereas * P<0.05, ** P<0.01 and *** P<0.001. 
 
Treatment Wound 
Closure  
0hrs 
Wound 
Closure  
5hrs 
Wound 
Closure  
10hrs 
Wound  
Closure  
15hrs 
Wound  
Closure  
20hrs 
Wound  
Closure 
25hrs 
Wound  
Closure  
30hrs 
Control – HCl 1.000 0.041* 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – BSA/HCl 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ1 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
HCl - BSA/HCl 1.000 0.001*** 0.587 0.001*** 0.001*** 0.001*** 1.000 
HCl - TGFβ1 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
HCl - TGFβ2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
HCl - TGFβ3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 1.000 
HCl - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
HCl - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
HCl - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
HCl - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
BSA/HCl - TGFβ1 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
BSA/HCl - TGFβ2 1.000 0.023* 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
BSA/HCl - TGFβ3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 1.000 
BSA/HCl - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
BSA/HCl - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
BSA/HCl - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
BSA/HCl - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ2 1.000 0.001*** 0.056 0.705 0.705 0.013* 0.001*** 
TGFβ1 - TGFβ3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.008** 0.008** 0.001*** 0.001*** 
TGFβ1+3 - TGFβ2+3 1.000 0.003** 0.001*** 0.226 0.226 0.005** 0.190 
TGFβ1+3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2+3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
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The overall results show that complete healing did not occur in cell cultures treated with 
four different TGF-β combinations, whereas TGF-β3 on its own induced complete 
healing in a similar time frame (Sefat, 2009b, Sefat, 2010d). TGF-β1 and TGF-β2 
showed faster rate of wound closure compared to any TGF-β combinations (p<0.001). 
In all culture flasks with combined TGF-βs, healing rate was significantly better than 
that seen in the control treatment groups (p<0.001). Figure 4.9 also showed that the 
presence of TGF-β3 in any combination caused faster closure rates when compared to 
others without presence of TGF-β3. For instance, TGF-β(1+2) had much slower rate of 
closure compared to the other combined culture flasks. The presence of TGF-β1 in any 
TGF-β combination reduced the healing rate, while presence of TGF-β2 or TGF-β3 
showed increase in bridge formation and wound healing. It was also seen that even after 
30hrs none of the cells treated with TGF-β1, either alone or combined showed complete 
closure. These results suggested that presence of TGF-β1 had some inhibitory effect on 
bone cell elongation, proliferation and healing, while TGF-β3 did not show these effects 
in a pure cell culture environment. The data in Figure 4.9 showed that as time of the 
healing increased up to 25hrs, the rate of wound closure increased in the case of all 
TGF-β isomers either alone or in combined form. There are also significant differences 
between TGF-3 and the other two isomers (p<0.001) while there were no significant 
difference in % wound closure between TGF-1 and TGF-2 (See Tables 4.2 and 4.4). 
However, there were significant differences in % wound closure between TGF-β1, 2 
and 3 with all TGF-β combinations (P < 0.001), (See Table 4.4). These results suggest 
that wound healing took place in all culture flasks but at different rates while TGF-3 
caused the fastest wound closure followed by HCl (p<0.001) and BSA/HCl (p<0.001) 
whereas control induced the slowest rate of healing. All TGF combinations resulted in 
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faster healing particularly those treated with TGF (2+3) (p<0.001). TGF1 and TGF2 
treated culture flasks induced faster healing compared to all TGF combinations but 
complete closure were not achieved. In summary, TGF-3 had the most significant 
effect followed by HCl, BSA/HCl, TGF-2, TGF-1, TGF-(2+3), TGF-(1+3), TGF-
(1+2+3), TGF-(1+2) and control. 
 
4.6  DISCUSSION 
Following scratching of the bone cell monolayers, and after 5 hrs of incubation, the % 
wound remained open showed different rates of healing depending on different 
treatments. This rate was significantly higher for all TGF-β isomer treated cells 
compared to un-treated controls. There is significant enhancement in the % of wound 
remaining open for TGF-β3 (P < 0.001) and TGF-β2 (P < 0.001). As the time of healing 
increased up to 25 hrs, the rate of wound closure also increased in the case of TGF-β1 
and TGF-β2 compared to TGF-β3. There were no significant differences in the % 
wound remaining open between TGF-β1 and TGF-β2 for the first 20 hrs. These rates 
increased and then became gradually similar to each other in the case of TGF-β3, HCl 
and HCl/BSA. In the case of combined TGF-β isomer treated cells this rate was 
significantly higher (P < 0.001) (See Table 4.4) compared to the un-treated control. 
However, the wound width showed a significant increase in healing rate for TGF-
β(2+3) (P < 0.001) and TGF-β(1+3) (P < 0.001) compared to the control and other 
TGF-β combinations. As the time of healing increased up to 25 hrs the rate of wound 
closure increased in all cases of TGF-β isomers, however, there were highly significant 
differences in % wound closure between TGF-β1, 2  and 3 with all TGF-β combinations 
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(P < 0.001) (See Table 4.4). It is important to know why cell monolayers respond 
differently to each TGF-β. Cytokines are known as potent biomolecules that regulate 
cellular functions and play multiple roles in the initiation and inhibition of disease 
(Hynes, 1992, Solheim, 1998). The transforming growth factor-beta (TGF-β) 
superfamily is a group of cytokines (Lawrence, 2001) which are actively involved in the 
control of some cellular activities such as cellular proliferation, cell migration, adhesion 
and apoptosis. TGF-β isomers are involved in signal transduction between the 
extracellular environment and the nucleus. Some of these isomers are potent regulators 
in cellular development (Raftery, 2002b). TGF-β was initially identified in 1978 
(Derynck, 2008) and is produced by almost all cell types in an inactive/latent form 
(Schwartz, 1993) suggesting that they play a regulatory role in most tissues. Although 
the function of the TGF-βs in various cell types has been investigated their function in 
bone repair is, as yet, not fully understood. There have been studies on the effect of 
TGF-β on bone (Solheim, 1998, Zande, 2007, Dallas, 2002), the majority of these 
studies are not related to the bone’s wound repair. The TGF-β seems to influence 
changes in cell behavior by up and down regulatory membrane proteins (Spangoli 2007) 
and, consequently, inducing cell adhesion, proliferation, differentiation, activation, 
migration and apoptosis (Krauss, 2006b). TGF-β has been used to stimulate bone 
regeneration (Lind, 1993). Using an animal model with TGF-β2 administered for a 
period of 6 weeks, in the case of tibial defects, it was shown that TGF-β2 had a positive 
effect on fracture repair (Lind, 1993). In terms of wound healing, cells can behave 
differently under various conditions. It is important to note that the interaction of cells 
(via membrane receptors) with ligands expressed by neighboring cells, and cell-cell 
signaling play an important role in cell proliferation (Fox, 2008). In fact, cell-cell 
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communication can stimulate cell proliferation (Celeste, 2002). Interestingly our studies 
indicated that the bone monolayers treated with TGF-β (mainly TGF-β3, TGF-β2+3, 
TGF-β1+2+3) demonstrated a rapid decrease in wound width during 25hrs of wound 
healing. This may be related to TGF-β3 increasing the secretion of ECM molecules at 
the wound edge, which functions by capturing cells via the integrin ECM interactions at 
the wound edge, thus helping migration into the wound site (Celeste, 2002). Such a 
mechanism may be useful in therapeutic procedures by filling a wound site with a large 
number of bone cells, which would presumably enable the deposition of ECM across 
the wound surface enabling cell migration and proliferation into the wound. The results 
of this study (Sefat, 2009b, Sefat, 2009c, Sefat, 2009d, Sefat, 2010d) together with the 
results in chapter 3 (Sefat, 2009a, Sefat, 2010c) also suggest that TGF-β2 and TGF-β3 
do not stimulate bone-ECM adhesion. Bone cells cultured in a medium with TGF-β2 
and TGF-β3 supplementation separately displayed a greater degree of cell/surface 
detachment. In contrast, the degree of cell surface attachment was increased in bone 
cells cultured with TGF-β1. However, the negative effect of this cytokine in the wound 
repair of bone suggests the hypothesis that the inhibition or activation of TGF-β1 may 
induce bone repair (Davidson, 2005, Sefat, 2009a). TGF-β1 induced a slower healing 
effect in vitro compared to TGF-β3 and TGF-β2 suggesting that the TGF-β1 down-
regulates cell proliferation and cell migration. The healing process of a scratched bone 
monolayer started after 2 hrs, which was mainly due to what appears to be a stress 
shock effect or stress responsive delay in cell activation. Similar results have been 
reported with chondrocytes and keratinocytes cells (Bordeleau, 2008, Khaghani, 2009a, 
Khaghani, 2009b). TGF-β1 in chondrocytes plays a very important role in rapid 
formation of fibroblast like chondrocyte cells in vitro (Chi, 2004). This could be linked 
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to an up-regulation in the production of extracellular matrix and extended collagen type-
I fibres causing the cells to flatten and occupy a larger area, which prohibits cells 
migration and consequently reduces cell proliferation (Annes, 2003, Chin, 2004).  
 
Growth factors can also be combined in order to target specific cell types, which results 
in certain functions such as proliferation, differentiation and migration. Previous studies 
(Zande, 2007) have used a similar approach with different growth factors in order to 
stimulate osteogenic expression in vitro by using a combination of different cytokines 
such as TGF-β1 and BMP-2. It is well established that the TGF-β super-family, mainly 
TGF-β1, 2 and 3, fulfil specific roles in the formation of new bones (Zande, 2007). It is 
therefore important to understand the effect of a combination of TGF-β isomers in 
wound closure response. This work concurs with what was found in the literature 
(Ackermann, 2011). This research group evaluated that combinations of growth factors 
such as VEGF, bFGF and PDGF have been shown to improve wound healing in 
streptozotocin-induced Diabetes in mice. Results showed that complete closure was 
reached in combined growth factors whereas the PDGF alone needed more time for 
complete closure. However, no clinical research has yet been undertaken on TGF-β3, 
thus this work was a first step for evaluating the effects of TGF-β3, HCl and HCl/BSA 
in vitro in relation to wound closure and the healing process for bone cell monolayers. 
Interestingly, there was little difference on the rate of wound repair between cells 
treated with TGF-β3 and HCl. It is possible that HCl directly influences bone cell 
behaviour or that HCl/free hydrogen ions could activate latent signalling proteins in the 
serum within the culture media. The availability of hydrogen ions could be essential for 
these signalling pathways to accelerate wound repair through administration of HCl. For 
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this reason the effect of different HCl concentrations on wound healing of bone cell 
monolayer were investigated in the next chapter.    
 
4.7  CONCLUSIONS 
In terms of wound healing, all TGF-β treatments caused different rates of wound 
closure in vitro. TGF-β3 gave the best wound closure (with 0% of the wound remaining 
open after 30hrs), followed by TGF-β2 (with 8.67% ± 1.34SD of the wound remaining 
open after 30hrs) and TGF-β1 (with 13.93% ± 2.46SD of the wound remaining open 
after 30hrs). Also, complete wound closure was achieved after 30 hrs by the presence of 
HCl as the solvent and BSA/HCl as the carrier and solvent, whereas the wound in 
control remained open within the same time period. This indicated that TGF-β3 does 
have a significant effect on the wound healing process and its healing rate was found to 
be higher than the control (p<0.001), TGF-β1 (p<0.001), TGF-β2 (p<0.001), BSA/HCl 
(p<0.001) and HCl (p<0.001) in ascending order. Combinations of TGF-β isomers 
behaved similarly in vitro but with different rates of wound closure. All TGF-β 
combinations showed a faster healing rate than the control (p<0.001). It was expected 
that the healing rate following treatment with TGF-β combinations would be greater 
than those healing rates following treatments with TGF-β isomers alone, but this was 
not the case. No complete wound closure occurred after treatment with any TGF-β 
combinations while TGF-β3 on its own induced complete healing in a similar time 
frame. TGF-β1, TGF-β2 and TGF-β3 showed a significantly faster rate of wound 
closure compared to a culture flask treated with TGF-β combinations (P < 0.001). 
Combining TGF-β3 with any other TGF-β isomer also resulted in a faster closure rate 
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(p<0.001) while the presence of TGF-β1 in any TGF-β combination reduced the healing 
rate (P<0.001). It can therefore be concluded that the presence of TGF-β1 has some 
inhibitory effect on bone wound healing while TGF-β3 had the opposite effect and 
increased the rate of wound closure in a pure cell culture environment. There was a 
significant difference in the rate of wound repair between cells treated with TGF-β3 and 
HCl (P < 0.001). For this reason the effect of different HCl concentrations on wound 
healing of bone cell monolayer were investigated in the next chapter. Changes in wound 
closure could be associated with variations in cell proliferation, elongation and 
migratory phenotype of cells in the presence of different TGF-β isomers which carried 
out in chapter 6. 
 
 
 
 
 
 
 
 
 
 
 131 
 
CHAPTER FIVE 
5. THE EFFECTS OF DIFFERENT HCl 
CONCENTRATION ON WOUND CLOSURE 
OF CULTURED HUMAN BONE CELL 
MONOLAYER 
 
5.1  INTRODUCTION  
Bone is unique in nature since it has the ability to heal without the development of a 
fibrous scar (Centrella, 1988, Glowacki, 1998, Guiqian, 2012). The regeneration of 
bone follows a complex set of four overlapping phases, which are characterised by 
specific molecular and cellular events (Gerstenfeld, 2003, Einhorn, 1998, Bolander, 
1992). The four phases include: haematoma formation/inflammatory phase, soft callus 
formation, hard callus formation and the remodeling process. Bone has the ability to 
repair itself using different methods depending on the biophysical environment. 
Ultimately bone synthesis is achieved through osetoblasts via woven and/or lamellar 
matrix. Investigations have shown that with an increased ageing population healthcare 
in the United Kingdom is set to cost millions of pound each year and a large percentage 
of that will go towards the treatment of orthopedic problems (Strom, 2011, Sefat, 
2010b). According to new research presented at the European Congress on Osteoporosis 
and Osteoarthritis the cost of fractures and different orthopeadic problems in six major 
European countries shows that the UK loses £5.1 billion as a result of the problem 
(Strom, 2011). 
 132 
 
There are many factors that affect bone repair including age, nutrients, hormones, and 
growth factors, etc. The transforming growth factor-Beta (TGF-β) superfamily has been 
reported as a bone formation stimulus (Janssen, 2005). They also showed that TGF-β 
has detrimental effects on bone construction and resorption. Other groups have claimed 
that bone formation is induced in vivo by osteoblasts in response to TGF-β injected into 
the fracture site (Noda, 1989, Marcelli, 1990). TGF-β has been identified in the fracture 
haematoma and surrounding periosteal mesenchymal cells with staining techniques 
(Joyce, 1990), and may orchestrate the cascade of cellular events resulting in fracture 
repair. All three isoforms (TGF-β1, -β2, -β3) have been found (Sodeka, 1994) to have 
overlapping functions in vivo with different biological activities in vitro. TGF-β1 is 
more potent throughout adult development, whereas TGF-β3 is more potent in tissues 
with mesenchymal origin. The three isoforms signal through the same kinase receptor 
with different binding abilities (Massague, 1996, Barrientos, 2008, Sefat, 2010b). In 
order to understand how TGF-β regulates bone repair and formation, in vitro 
experiments using osteoblast cell lines, which are mainly derived from osteosarcomas, 
and share phenotype similarities to osteoblast cells, can be performed. In vitro 
experiments have indicated that TGF-β stimulates osteoblast chemotaxis, DNA 
synthesis, cell division, and promotion of bone matrix proteins (Rodan, 1987, Janssen, 
2005).  
 
TGF-β is difficult to manufacture due to its poor physical and chemical stability in 
aqueous solution and in powder form. When TGF-β is ready to be administered it is 
reconstituted into a liquid form before use. A number of problems can exist with TGF-β 
in liquid formulations, e.g. aggregation can take place under certain conditions in which 
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TGF-β can lose its biological activity due to oxidation. Also, TGF-β has a high binding 
affinity for the surfaces of containers, which will reduce the percentage of TGF-β that 
will be administered reducing the actual dose delivered (Sefat, 2010b). It is, therefore 
very important for the growth factor to be delivered properly to ensure a stable form and 
prevent loss of its bioactivity. To overcome these problems HCl is added to the TGF-β 
to stabilise the solution and reconstitute it from the powder form. Upon cell culturing 
further HCl is added to TGF-β, which prevents losses allowing a final concentration 
ranging from 0.1ng/ml to 10ng/ml in most culture systems (Lind, 1993). A 
physiological carrier is also added, e.g. Bovine Serum Albumin (BSA), which acts as a 
carrier for the TGF-β hindering adherence to the surfaces of equipment. There are many 
different delivery systems by which TGF-β can be administered to a wound site, e.g. by 
gradual release from a scaffold (usually biodegradable which releases TGF-β 
intermittently) or it can be administered directly by injection into the wound site. 
Administration of TGF-β adjacent to the periosteum has been found to increase bone 
thickness and chondrogenesis (Marcelli, 1990, Joyce, 1990). TGF-β can be secreted 
from bone in its latent form where TGF-β can be found in abundance. The latent form 
of TGF-β has a non-covalent association with LAP (Latency Associated peptide). 
Activation of the TGF-β can be achieved through acidification with dissociation of the 
LAP protein that unmasks TGF-β binding receptors and hence activates the TGF-β 
mechanism (Lawrence, 1985). Other groups showed that latent TGF-β in a medium 
conditioned by cultured cells can be activated by transient treatment with either acids, 
bases, heat, or chaotrophic agents (Lawrence, 1985, Flaumenhaft, 1993).  
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This post-translational control of TGF-β1 through activation is arguably the most potent 
regulatory mechanism for this cytokine (Annes, 2003). Once activated, TGF-β1 binds to 
its signalling receptor complex (type I, type II, and type III in concert) (Shi, 2003). An 
enzyme-linked immunosorbent assay (ELISA) is a routine method for the detection of 
TGF-β1, which detects active TGF-β1 after activation by transient acidification or 
treatment with urea (Danielpour, 1989). 
 
Due to its simplicity, specificity and sensitivity this method is the best option when 
working on a cell-free system (Zamora, 2007). Other groups also mentioned that latent 
TGF-β1 can be activated by heat, acidification, alkalinisation or the action of chaotropic 
agents in vitro (Annes, 2003), but some discrepancies can be found in the literature 
regarding this process. The Zamora research group compared the effectiveness of 
acidification vs. heat treatment in activating latent TGF-β1 in a cell-free system. The 
ELISA assay was carried out using recombinant human latent TGF-β1 (Zamora, 2007). 
It was found that, while both heat and HCl lead to activation of latent TGF-β1, heat 
treatment was significantly more effective than acidification. Interestingly, neither 
treatment induced full activation and the mechanism of activation is not fully 
understood (Zamora, 2007).  However, it has been proposed (Oreffo, 1989) that TGF-β 
may not be the only reason for increasing the rate of wound repair in bone. In order for 
TGF-β to be administered exogenously it needs to be dissolved with HCl and BSA used 
as the carriers and solvent of TGF-β. It is suggested that HCl also contributes to the rate 
of wound repair (Centrella, 1988, Sefat, 2010b). This is particularly important seeing as 
there is evidence that the pH of injured bone can decrease and that this may play a role 
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in activating TGF-β (Oursler, 1994, Dallas, 2002). Thus it is important to investigate the 
role played by HCl in wound closure in a simple bone cell culture model.  
 
5.2  SCOPE 
Wound closure experiments were carried out using MG63 bone cells in the presence of 
different HCl concentrations, i.e. 20µM, 40µM, 80µM, 160µM and in control cultures 
without HCl. The experiments were all repeated three times for each concentration. 
Each culture flask was incrementally photographed every 5hrs.  
 
5.3  WORKING HYPOTHESIS 
HCl as the solvent is believed to bind to serum proteins (Kohn, 2002, Sefat, 2010b) that 
will change their molecular structure possibly turning the serum protein into a signalling 
molecule assisting in the bone repair process. The Null Hypothesis to be tested in this 
work is that administered of HCl to a wounded MG63 bone cell monolayer has no 
impact on rate of wound repair compared to wound repair in control cultures. 
 
5.4  AIMS AND OBJECTIVES 
The purpose of this chapter was, therefore, to investigate the effect of different HCl 
concentrations on wound closure in cultured monolayers of MG63 bone cells. This 
work investigated and compared the wound closure properties of various HCl 
concentrations in the cultured dish environment using in the cultured monolayers of 
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human bone cells. Other cellular responses such as proliferation, differentiation and 
detachment were also investigated. 
 
5.5  MATERIALS AND METHODS 
5.5.1  Cell Culture 
Bone cells were cultured in a low glucose (1g/L-D-Glucose) HEPES (25mM) buffered 
DMEM (Dulbecco's Modified Eagle Media, Sigma Aldrich) culture media 
supplemented with L-glutamine (2.5 mM U/mL), Penicillin (100 U/mL), Streptomycin 
(0.1 mg/mL), Amphotericin B or a fungizone (250µg/ml) (Sigma Aldrich-UK) and 10% 
FCS v/v (fetal calf serum- PromoCell - UK). The bone cells were plated in 25cm
2
 tissue 
culture grade cell culture flasks at a cell density of 250,000 cells/culture flask and 
bathed in the culture media. The cells attached to form a layer at the bottom of the 
culture flasks. Once confluent, a ‘wound’ was made using a disposable long nosed 
plastic pipette of 1mm diameter as described in the previous chapter.  
 
5.5.2  Treatment with HCl Dilutions 
This in vitro work examined and compared wound closure properties of the TGF-β 
solvent “HCl” in various concentrations. The wound healing response was investigated 
in TC grade culture flasks by creating a wound (with average scratch width of 
300μm10-30μm SD, 2.1-8μm SEM) on confluent monolayer of MG63 human bone 
cells. After wounding, cultures were then treated with 20µM, 40µM, 80µM and 160µM 
final bathing concentrations of HCl. As a control wound healing was monitored in 
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cultures without HCl treatment. After wounding, culture flasks were stored inside the 
incubator and wound width was imaged and measured every 5hrs over a 30hrs period as 
described previously. The whole procedure was repeated three times. Wound widths 
were normalised as percentages and then mean percentage wound widths were plotted 
against time for each HCl treatment. Addition to the percentages of wound closure, the 
rate of wound closure was also calculated. 
 
5.6  STATISTICAL ANALYSIS 
Mean % and mean rate of wound closure were tested for normality using a Kolmogorov 
Smirnov test. Normaly distributed data (p > 0.05) were analysed using SPSS via a 
Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni test. 
Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed data (p < 0.05).  Statistical tests were performed such that a p value of < 0.05 
was considered as indicating a significant difference.     
 
5.7  RESULTS 
5.7.1  Wound healing 
Images of the wound closure process for the 80µM and 160µM HCl (see Figure 5.1) 
showed that after 5hrs the morphology of the cells at the wound edges had changed and 
that the cells had elongated, spread and migrated into the wound site perpendicularly to 
the wound axis (% wound remained open 93.00% ± 7.39SD and 91.38% ± 2.31SD, 
respectively). The vertically elongated cells looked different (more elongated) to the 
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cells a distance away from the wound edges (more rounded). The cells seemed to be less 
dense and more spread out at the wound edges. After 15hrs the cells had migrated into 
the wound site and elongated in order to meet cells from the opposite side of the wound. 
Observations induced that bone cells replicated and divided forming daughter cells that 
form a complete and new wound margin (Sefat, 2010b). It also appeared that bone cells 
migrate to the centre of the wound as shown in Figure 5.1 below. 
 
Figure 5.1 Bone cells migration to the centre of the wound; magnification X50, (Scale 
bar=100m). 
 
The daughter cells then form a component of the wound margin and seem to be subject 
to a partial contact inhibition and then divide again to form a new wound margin. It also 
appeared that bone cells migrate to the centre of the wound. These cells then formed 
bridges to connect the wound edges and close the wound gap. As soon as the bridges 
formed in the wound site the wound was closed quite rapidly. The 20µM and 40µM 
concentrations of HCl and control induced slower wound closure rates compared to the 
higher HCl concentrations with full confluency not achieved even after 30hrs. Images 
and collected data for the wound closure process in the 20µM and 40µM HCl culture 
flasks (Figure 5.2 and Table 5.1) showed that there were small changes in wound width 
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even after 10hrs (% wound remained open 85.29% ± 9.83SD and 82.73% ± 10.64SD, 
respectively). Wound closure changes could be observed after 15hrs. The percentage of 
wound remained open after 15hrs of culture was 69.05% ± 11.82SD in the case of cells 
treated with 20µM HCl and 58.25% ± 13.22SD in those trated with 40µM HCl. After 
20hrs there were still huge gaps between the cells in the wound site, for the 20µM and 
40µM of HCl (p=0.375). The cells in the 20µM and 40µM HCl culture flasks did not 
seem to form bridges with cells from the opposite wound margin to stabilise the wound 
site until about 25hrs (% wound remained open 38.03% ± 15.66SD and 34.62% ± 
10.18SD, respectively). Cells met each other after 25hrs and started making bridges but 
without complete closure. It was clear that the wound remained open even after 25hrs. 
Wound healing occurred very slowly in control culture flasks (percentage of wound 
remained open after 15hrs of culture was 56.29% ± 1.20SD) (Sefat, 2010b). Figure 5.2 
shows all four wounded bone cell monolayers during 30hrs of healing treated with 
different HCl concentrations and control. These experiments showed that cells treated 
with 80µM and 160µM concentrations of HCl did indeed speed up the wound closure 
process in a pure cell culture environment. HCl enhanced wound closure as compared to 
the control (See Figures 5.2). At higher concentrations of HCl it was noticeable that 
bone cells looked longer and elongated and had more projections than that of the 
control. 
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Figure 5.2 Images of the wound healing process for the bone cell monolayers with four 
different HCl concentrations and control for the period of 30hrs, (Scale 
bar=100m)(Sefat, 2010b). 
 
       Control             20µM HCl        40µM HCl           80µM HCl          160µM 
HCl 
 0min 
5hrs 
10hrs 
15hrs 
20hrs
 0min 
hrs
 0min 
s 
25hrs 
30hrs 
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Table 5.1 Descriptive statistics for mean % of wound remaining open against time for 
wounded monolayer treated with different concentration of HCl and control over period 
of 30 hrs. 
 
 
Treatment 
 
Wound Closure Time 
(hrs) 
 
Mean % of wound 
remaining open ± Std. 
Deviation (SD) 
 
Std. Error 
(SE) 
 
 
 
Control 
0hrs 100.00 ± 1.68 0.30 
5hrs 88.06 ± 0.91 0.16 
10hrs 82.03 ± 1.15 0.21 
15hrs 56.29 ± 1.20 0.22 
20hrs 37.97 ± 1.23 0.22 
25hrs 38.00 ± 1.22 0.22 
30hrs 20.99 ± 0.91 0.16 
 
 
20µM 
0hrs 100.00 ± 0.49 0.09 
5hrs 96.81 ± 6.54 1.19 
10hrs 85.29 ± 9.83 1.79 
15hrs 69.05 ± 11.82 2.15 
20hrs 42.67 ± 18.63 3.40 
25hrs 38.03 ± 15.66 2.85 
30hrs 24.56 ± 10.39 1.89 
 
 
 
40µM 
0hrs 99.99 ± 1.07 0.19 
5hrs 93.28 ± 3.90 0.71 
10hrs 82.73 ± 10.64 1.94 
15hrs 58.25 ± 13.22 2.41 
20hrs 46.05 ± 12.33 2.25 
25hrs 34.62 ± 10.18 1.85 
30hrs 16.03 ± 4.35 0.79 
 
 
80µM 
0hrs 100.00 ± 1.21 0.22 
5hrs 93.00 ± 7.39 1.35 
10hrs 72.03 ± 10.75 1.96 
15hrs 44.31 ± 13.76 2.51 
20hrs 27.31 ± 8.79 1.60 
25hrs 0.00 0.00 
30hrs 0.00 0.00 
 
 
160µM 
0hrs 100.00 ± 1.38 0.25 
5hrs 91.38 ± 2.31 0.42 
10hrs 48.97 ± 0.83 0.15 
15hrs 31.32 ± 0.99 0.18 
20hrs 14.59 ± 0.73 0.13 
25hrs 6.18 ± 0.54 0.09 
30hrs 0.00 0.00 
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Table 5.2 P value derived from pair wise comparisons of treatment related % wound 
remained open of bone cell monolayer over period of 30hrs. Pairs that are significantly 
different from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 
and *** P<0.001. 
 
Treatment 
Wound 
Closure  
0hrs 
Wound 
Closure  
5hrs 
Wound 
Closure  
10hrs 
Wound  
Closure  
15hrs 
Wound  
Closure  
20hrs 
Wound  
Closure  
25hrs 
Wound  
Closure  
30hrs 
Control  -  20µM 0.408 0.001*** 0.526 0.001*** 0.965 0.175 0.054 
Control  -  40µM 0.605 0.001*** 0.997 0.859 0.001*** 0.139 0.002** 
Control  -  80µM 0.647 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control  -  160µM 0.756 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
20µM  -    40µM 0.506 0.003** 0.736 0.003** 0.375 0.894 0.001*** 
20µM  -    80µM 0.399 0.069 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
20µM  -  160µM 0.515 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
40µM  -    80µM 0.848 0.352 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
40µM  -  160µM 0.657 0.032* 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
80µM  -  160µM 0.636 0.028* 0.001*** 0.001*** 0.001*** 0.001*** 1.000 
 
In Table 5.2 those pairs that are significantly different from one another are marked by 
an asterisk (*) in which *** represents highest significant difference between each pair 
(p<0.001). The experiments showed that there was no difference in the % wound width 
at the start of the experiments. However after 5hrs in culture the percentage wound 
width between the control cultures and the treatment cultures was quite different (See 
Figure 5.3). Mean percentage wound width in control cultures decreased to 88.06% ± 
0.91SD, but in HCl treated cultures this decrease was not significantly reduced in 
comparison to the control (P<0.001), with the percentage wound widths only decreasing 
to 96.81% ± 6.54SD, 93.28% ± 3.90SD, 93.00% ± 7.39SD and 91.38% ± 2.31SD in the 
20µM, 40µM, 80µM and 160µM HCl treatments groups, respectively. 10hrs after 
treatment the percentage wound widths had decreased further, however, in the 20µM 
HCl treated cultures the percentage wound width had decreased to 85.29% ± 9.83SD. 
This represented a significantly smaller decrease in wound closure compared to the 
other treatment groups. Control treated cultures and 40µM HCl treated cultures 
exhibited wound percentage wound closures of 82.03% ± 1.15SD and 82.73% ± 
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10.64SD, these wound closures were not significantly different (p=0.997). In 
comparison the percentage wound widths in the 80µM and 160µM HCl treated cultures 
were significant decreased in comparison to both the control treated cultures and the 
20µM HCl treated cultures (p<0.001). Percentage wound width in the 80µM and 
160µM HCl treated cultures decreased to 72.03% ± 10.75SD and 48.97% ± 0.83SD, 
respectively, with the percentage wound closure induced by treatment with 160µM HCl 
being significantly greater  (p<0.001) than that seen in any other treatment group. At the 
15hrs time point the trend seen after 5hrs was continued, with the 20µM HCl treatment 
group displaying the lowest degree of wound closure (69.05% ± 11.82SD) and the 
control and 40µM HCl treatment groups showing insignificantly different (p=0.859) 
mean percentage wound widths of 56.29% ± 1.20SD and 58.25% ± 13.22SD. In 
comparison the 80µM and 160µM HCl treated cultures exhibited significantly lower 
percentage wound widths of only 44.31% ± 13.76SD and 31.32% ± 0.99SD. Again the 
160µM HCl treated cultures had % wound widths that were significantly lower than any 
of the other treatment groups (p < 0.001). This treatment related pattern in percentage 
wound width was followed at the 20hrs time point although after 20hrs the percentage 
wound width had decreased to 37.97% ±1.23SD, 42.67% ± 18.63SD, 46.05% ± 
12.33SD, 27. 31% ± 8.79SD and 14.59% ± 0.73SD in the control, 20µm, 40µm, 80µM 
and 160µM HCl treatment groups, respectively. At this time point all the percentage 
wound widths were significantly different from one another, other than the wound 
widths between the controls and the 20µM HCl treated cultures (p=0.965) and the 
20µM and 40µM HCl treated cultures (p=0.894).  
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Once again treatment with 160µM HCl resulted in a significantly greater decrease in the 
% wound width when compared with the other treatments. By the 25hrs time point the 
% wound width in the 80µM HCl treated cultures had dropped to zero% whilst the % 
wound width in the 160µM had decreased further to 6.18% ± 0.54SD, and the control, 
20µM and 40µM HCl treated cultures had insignificantly different percentage wound 
widths of 38.00% ± 1.22SD, 38.03% ± 15.66SD and 34.62% ± 10.18SD, respectively. 
The cells in the control flask showed significantly slower wound closure when 
compared with the higher concentrations of HCl (p<0.001). 
 
 
Figure 5.3 Graph of % wound closure width against time for wounded bone cell 
monolayers treated with different HCl concentrations and control (Error bars represent 
standard deviation)(Sefat, 2010b). 
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5.7.2  Rate of wound closure 
In addition to the % of wound closure, the rate of wound closure was calculated. These 
results showed that wound healing took place in all five culture flasks but at different 
rates. Statistical analyses demonstrated that 80µM and 160µM HCl concentrations 
caused model wounds to heal fully after 25hrs whilst wounds with 20µM, 40µM HCl 
concentrations and control remained open even after 30hrs (with mean rate of wound 
closure ~ 7.66m/hrs ± 0.18SD, 7.91m/hrs ± 0.22SD and 11.26m/hrs ± 0.22SD, 
respectively). The rate of wound closure for each HCl concentration was calculated and 
a graph of wound closure rate vs. time was plotted (Sefat, 2010b), as presented in 
Figure 5.4 and Table 5.3. It became apparent that the higher the HCl concentration the 
faster the rate of wound closure up to a peak value after which the rate decreased.  
 
Figure 5.4 Graph of rate of wound closure width against time (µm/hrs) for wounded 
bone cell monolayers treated with different HCl concentrations and control (Error bars 
represent standard deviation)(Sefat, 2010b). 
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Table 5.3 Descriptive statistics for wound closure rate of bone cell monolayer with 
different treatments of HCl and control over period of 30hrs. 
 
 
 
Treatment 
 
Rate of Wound 
Closure (hrs) 
Mean Rate of Wound 
Closure (µm/hrs) 
± 
Std. Deviation 
(SD) 
 
Std. Error 
(SE) 
 
 
 
Control 
0min-5hrs 5.67 ± 0.26 0.11 
5hrs-10hrs 13.58 ± 0.32 0.14 
10hrs-15hrs 16.20 ± 0.27 0.12 
15hrs-20hrs 9.06 ± 0.04 0.01 
20hrs-25hrs 9.06 ± 0.04 0.01 
25hrs-30hrs 7.66 ± 0.18 0.08 
 
 
20µM 
0min-5hrs 3.13 ± 0.15 0.06 
5hrs-10hrs 6.75 ± 0.16 0.07 
10hrs-15hrs 9.53 ± 0.36 0.16 
15hrs-20hrs 15.49 ± 0.09 0.04 
20hrs-25hrs 2.72 ± 0.02 0.00 
25hrs-30hrs 7.91 ± 0.22 0.10 
 
 
 
40µM 
0min-5hrs 3.45 ± 0.20 0.08 
5hrs-10hrs 6.39 ± 0.1 0.04 
10hrs-15hrs 14.84 ± 0.20 0.09 
15hrs-20hrs 7.39 ± 0.18 0.08 
20hrs-25hrs 6.93 ± 0.23 0.10 
25hrs-30hrs 11.26 ± 0.22 0.09 
 
 
80µM 
0min-5hrs 4.70 ± 0.19 0.08 
5hrs-10hrs 12.46 ± 0.07 0.03 
10hrs-15hrs 16.48 ± 0.10 0.04 
15hrs-20hrs 10.10 ± 0.31 0.14 
20hrs-25hrs 16.24 ± 0.11 0.05 
25hrs-30hrs --------- ----------- 
 
 
160µM 
0min-5hrs 4.25 ± 0.22 0.09 
5hrs-10hrs 25.87 ± 0.20 0.09 
10hrs-15hrs 10.76 ± 0.14 0.06 
15hrs-20hrs 10.20 ± 0.29 0.13 
20hrs-25hrs 5.12 ± 0.15 0.07 
25hrs-30hrs 3.77 ± 0.06 0.02 
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Table 5.4 P values derived from pair wise comparisons of treatment related wound 
closure rate. Pairs that are significantly different from one another are marked by an 
asterisk (*) whereas * P<0.05, ** P<0.01 and *** P<0.001. 
 
 
Treatment 
Wound 
Closure 
Rate 
0min- 
5hrs 
Wound 
Closure 
Rate 
5hrs- 
10hrs 
Wound 
Closure  
Rate  
10hrs- 
15hrs 
Wound 
Closure 
Rate 
15hrs-
20hrs 
Wound 
Closure 
Rate 
20hrs-
25hrs 
Wound 
Closure 
Rate 
25hrs-
30hrs 
Control  -  20µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.147 
Control  -  40µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.001*** 
Control  -  80µM 0.001*** 0.001*** 0.372 0.009** 0.009** 0.001*** 
Control  -  160µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.001*** 
20µM  -    40µM 0.166 0.057 0.001*** 0.009** 0.009** 0.001*** 
20µM  -    80µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.001*** 
20µM  -  160µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.001*** 
40µM  -    80µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.001*** 
40µM  -  160µM 0.001*** 0.001*** 0.001*** 0.009** 0.009** 0.001*** 
80µM  -  160µM 0.020* 0.001*** 0.001*** 0.465 0.009** 0.001*** 
 
   
Results also showed that there was significant difference in wound closure rate from 
time zero to 5hrs of the experiments. However after 5hrs in culture the rate of wound 
closure between the control cultures and the treatment cultures was quite different. 
Mean rate of wound closure in control cultures increased to 13.58m/hrs ± 0.32SD, but 
this was significantly increased in HCl treated cultures with higher concentration 
(P<0.001), with the rate of wound closure increased to 6.75m/hrs ± 0.16SD, 
6.39m/hrs ± 0.1SD, 12.46m/hrs ± 0.07SD and 25.87m/hrs ± 0.2SD in the 20µM, 
40µM, 80µM and 160µM HCl treatments groups, respectively (P<0.001). This indicates 
that the highest rate of wound closure was induced by 160µM HCl. From time 10hrs to 
15hrs of culture the rate of wound closure increased slightly further for all cases except 
160µM HCl (Rate of wound closure 10.76m/hrs ± 0.14SD). However, in the 20µM 
HCl treated cultures the rate of wound closure had increased only to 9.53m/hrs ± 
0.36SD. This was a represented a significantly smaller increase in wound closure rate 
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compared with the other treatment groups (P<0.001).  The rate of wound closure 
between time points 15hrs-20hrs was decreased for all cases except 20µM HCl 
(15.49m/hrs ± 0.09SD). At time points 20hrs-25hrs decrease rate of wound closure 
were observed for control treated cultures and all other HCl treated flasks except 80µM 
HCl with rate of 16.11m/hrs ± 0.11SD which was significantly greater that others 
(p=0.009). This rate was unchanged for control flasks (9.06m/hrs ± 0.04SD). This rate 
was 2.72m/hrs ± 0.02SD, 6.93m/hrs ± 0.23SD and 5.12m/hrs ± 0.15SD for 20µM, 
40µM and 160µM HCl concentrations, respectively, which is quite slow compared with 
the 80µM HCl (16.24m/hrs ± 0.11SD) (P<0.009). At time point between 25hrs-30hrs 
no rate of wound closure recorded as the wounds had healed completely for 80µM HCl, 
however, rate of wound closure for 40µM HCl was ~ 11.26m/hrs ± 0.22SD 
representing higher rate of wound closure and significantly different compare to others 
(p<0.001). 
 
5.8  DISCUSSION  
From observation and upon an initial scratch it was clearly seen that there were a 
number of rounded cells at the edges of the wound. It took a while for these rounded 
cells to become detached. After 15hrs and 20hrs of applying HCl it could be seen that, 
at certain points along the wound width, peaks started to form so that bridges were 
made across the width of the wound as cells extended to meet cells on the opposite side 
of the wound. This is a crucial part of the healing process when contact bridging has 
been accomplished (Hom, 2007). This closed the area of the wound further with the 
cells being able to make contact more easily in a smaller space. Cells such as 3T3 
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fibroblasts (Hollinger, 2004) migrate into a model wound site and are known to 
replicate exponentially (1 to 2, 2 to 4, 4 to 8, etc.) until contact inhibition takes place, 
which then slows the rate of replication (Heckman, 1994, Sefat, 2010b). Our results 
suggest that wound healing took place in all concentrations of HCl but at different rates. 
The 80µM concentration of HCl fully healed after 25hrs (p<0.001) whilst others 
remained open even after 30hrs. The 20µM and 40µM concentrations of HCl failed to 
close the wound after 30hrs with 24.56% ± 10.39SD and 16.03% ± 4.35SD of the 
wound remaining open respectively (p<0.001). The 80µM concentration of HCl was 
closely followed by the 160µM and with respect to the rate of wound closure up to the 
point of 20hrs this occurred with accelerated healing. This was slower for the 20µM and 
40µM of HCl (with a mean rate of wound closure ~ 6.75m/hrs ± 0.16SD and 
6.39m/hrs ± 0.1SD respectively). The 160µM concentration of HCl induced the 
quickest rate of repair but took 30hrs for the wound to become fully confluent with a 
large rate of closure between 5-10hrs (25.87m/hrs ± 0.20SD) indicating that this 
concentration increased wound closure rate as compared to the control. It is interesting 
to note that the greatest percentage of wound closure was between 5 and 15hrs for the 
80µM and 160µM concentrations of HCl. This indicates that the bone cells made a 
connection across the wound width by successful bridging with additions of HCl 
accelerating the process (Sefat, 2010b). It can be speculated that some of the hydrogen 
ions from the HCl bind to the serum proteins and cause a change in amino acid 
molecular structure and hence its function as a signalling molecule. Those hydrogen 
ions are known to bind to the negative sites on amino acids (Yeung, 1992) supports this 
view, and suggest that interaction could alter molecular structure and encourage changes 
in the folding of proteins. Protein structure influences function (Yeung, 1992) thus 
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hydrogen ion/plasma protein interactions or hydrogen ion/cell membrane protein 
interactions could activate signalling pathways altering gene expression and thus 
influence cell motility. There is evidence supporting this in the literature (Cheng, 2006). 
For example platelet activating factor (PAF) and interleukin 6 (IL-6) are both 
upregulated in oesophageal smooth muscle cells in response to treatment with HCl. 
There is also evidence in the literature the growth and development of different cells, 
including osteoblasts, is linked to the regulation of pH and the acidity of the 
extracellular microenvironment (Kohn, 2002). Skeletal tissue repair and mineralisation 
are influenced by the ionic and molecular composition of the extracellular fluids 
(Chakkalakal, 1994) and it is well established that Ca-P salts are precipitated in a pH 
dependent manner (Johnson, 1992, Chakkalakal, 1994, Posner, 1985). As a result, it has 
been suggested that bone repair and mineralisation are tissue pH dependent 
(Chakkalakal, 1994). On a cellular level even modest reductions in extracellular pH 
have an effect on osteoblast function in vitro (Kaysinger, 1998). It can be concluded that 
the cellular mechanisms involved in bone formation and resorption may therefore be 
responsive to the acid-base balance. It is necessary to know how pH affects bone 
metabolism, therefore some studies showed that during metabolic acidosis the activity 
of osteoblasts declines, whereas during metabolic alkalosis osteoblast activity increases 
(Kaysinger, 1998). Similarly, the pH in the immediate microenvironment of osteoblasts, 
in addition to the intracellular spaces of differentiating bone, varies with progressive 
stages of osteogenesis and may be linked to the regulation of gene expression (Ramp, 
1994). An experimental wound in vitro was examined to investigate the effects of pH 
for human fibroblast. The wounded monolayers were cultured at pH ranging from 7.2 to 
8.4. A significant decrease was recorded both in cell migration, and DNA synthesis in, 
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the experimental wounds as a result of pH increases (Lenghedeit, 1995). Finally Kohn 
et al. showed that small shifts in extracellular pH result in significant changes in bone 
marrow stromal cells (MSCs), which express markers of the osteoblast phenotype 
(Kohn, 2002). These pH effects potentially relate to the microenvironment that bone 
marrow stromal cells would likely be exposed to. This further confirms findings 
regarding the effect of HCl on MG63 bone cells. It was observed in our investigation 
that different concentrations of HCl did not affect the pH level of the media indicating 
that HCl was being sequestered away. However, this is inconclusive as the pH value 
was not properly evaluated through testing. Observation of the colour of the media 
indicated to the naked eye that the pH value was not affected.  
 
5.9  CONCLUSIONS  
Bone repair is a complex process with interconnecting phases through cell management 
with many factors affecting the promotion of a successful bone repair. Many areas are 
investigated to promote bone repair and increase the rate of closure. In vitro studies 
allow us to understand how cells behave and react to different parameters. This study 
examined the role of HCl in wound closure rates. It was found that higher 
concentrations of HCl, in particular 80µM and 160µM, promoted a faster rate of wound 
closure compared with the control. The 160µM concentration of HCl showed the fastest 
rate of closure between 5-10 hrs (with the mean rate of wound closure ~ 25.87m/hrs ± 
0.20SD). Once bridging had occurred the rate of wound repair decreased at ~15hrs up to 
confluency. A culture flask treated with 80µM HCl showed bridge formation at the 
wound site at 15hrs of healing and complete healing achieved at 25hrs. This meant early 
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bridging is an important factor and enhances the rate of wound closure. We assume that 
the serum proteins present in the media act as signalling molecules due to the surface 
charge changes from the release of hydrogen ions via the HCl. The availability of 
hydrogen ions is essential for these signalling pathways to accelerate wound repair 
through administration of HCl. 
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CHAPTER SIX 
6. THE EFFECT OF TGF- ISOMERS ON 
THE CELL MORPHOLOGY (SIZE AND 
NUMBER) OF HUMAN BONE CELLS 
 
6.1  INTRODUCTION 
Cell adhesion and protein adsorption are thought to be very important factors in cell 
culture and tissue engineering of any functional tissue (Fleming, 2000, Yang, 2010, 
Worz, 2012). It is well established that cells attach to the extracellular matrix (ECM) in 
vivo and that the presence of ECM is vital for any cell type within the body (Hollinger, 
2004, Yang, 2010). Much of the R&Ds in the 80’s and 90’s focused on the interaction 
of biomedical materials with proteins and cultured cells (Cooper, 1982, Ludwicka, 
1984, Flemming, 1999). In recent years, there has been an increased interest in how 
growth factors (Khan, 2000, Logeart-Avramoglou, 2005), mechanical stimulation 
(Hardiman, 2005, Kesavan, 2005), surface stiffness (Giesen, 2004, Maina, 2010, 
Foppiano, 2007b) and drugs (Barcew, 2008, Joshi, 2008) influence cell morphological 
changes. For instance, human bone cells were compared to marrow-derived human 
mesenchymal stem cells (HMSCs) for a duration of 12 weeks in order to investigate 
their capacity to proliferate and differentiate into osteoblasts under various culture 
conditions (Krattinger, 2011). Cell treated with FGF-2 and BMP2 were also compared. 
Cultures treated with FGF-2 increased cell proliferation of both cell types. BMP-2 
increased cell numbers and reduced osteoblastic differentiation in human bone cells 
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with the opposite effect seen in HMSCs (Krattinger, 2011). In 2009, Yang et al. 
analysed the influence of substrate topography on cell morphology of MG63 (Yang, 
2009). They found that cells spread faster on the nano-patterned surfaces than on the flat 
surface, suggesting that surface anisotropic features facilitate initial cell extension along 
its direction.  
 
Other groups investigated the role of extracellular Ca
2+
 and Mg
2+
 in osteoblast 
morphology and adhesion in the absence or presence of PDGF (Abed, 2009). They 
showed that the stimulation of osteoblast (MG63) proliferation and migration by PDGF 
was significantly reduced under culture conditions of low extracellular Mg
2+
 
concentrations (Abed, 2009). Therefore, the morphology of cells can be important in 
many contexts. In culture the morphology indicates the status of the cells, both in terms 
of the health of the cells and cell adhesion capacity (Yang, 2010, Worz, 2012). 
Variations in cell morphology can results from changes in underlying cytoskeletal 
organization and dynamics. For example, different protein coatings on a surface or 
chemical topography of the surface (e.g. micro-contact printing) can cause changes in 
morphology (Lo, 2004).  There is evidence that TGF-β isomers influence wound repair 
by modifying cell function and morphology in a number of tissues (Wu, 1997, 
Critchlow, 1995, Derynck, 2008, Janssen, 2005). Therefore, the aim of this study was to 
examine the effects of different TGF-β isomers on MG63 cell size, morphology and 
proliferation in vitro. 
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6.2  MATERIALS AND METHODS 
6.2.1  Cell culture  
MG63 cells were cultured as described previously in a low glucose (1g/L-D-Glucose) 
Dulbecco's Modified Eagle Medium (DMEM, Sigma Aldrich) supplemented with L-
glutamine (2.5 mM U/mL), Penicillin (100 U/mL), Streptomycin (0.1 mg/mL), 
Amphotericin B and fungizone (250µg/ml), HEPES (25mM) buffer (Sigma Aldrich-
UK) and 10% FCS v/v (fetal calf serum- PromoCell - UK). The bone cells were 
cultured inside culture flasks at a cell density of 50,000 cell/ml and bathed in the culture 
media. Culture flasks were incubated at 37
°
C for 48hrs. All supplements were purchased 
from Sigma Aldrich-UK except those mentioned. 
 
6.2.2  Cell size (length) 
TGF-β1, 2, and 3 were reconstituted as described in chapter 3. In order to investigate 
the effect of each TGF-β growth factor on cell length seven culture flasks were treated 
with the different TGF-β isomers including TGF-β1, TGF-β2, TGF-β3, TGF-β(1+2), 
TGF-β(1+2+3), TGF-β(1+3), TGF-β(2+3) and one culture flask remained un-treated as 
a control. Human bone cells were seeded at cell density of 50,000 cells/ml and 
photographs were taken every 6hrs for the first 24hrs and final imaging took place at 
36hrs. The cells were photographed using a light microscope and a digital camera. 
Pictures were captured and stored as TIF images using Scion Image Visi Capture from 
Scion Corporation. Image J software was used to measure the cell length. In order to 
measure cell length, 10 images were captured from randomly selected regions of each 
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culture flasks and the lengths of 100 cells were measured. Mean average cell length was 
calculated. There was some variability in initial cell length for each treatment. To 
normalise, the mean starting cell length was calculated per treatment and each starting 
cell length was expressed as a percentage of that mean. Cell length at each time point 
was therefore expressed as a percentage of the normalised mean cell length per 
treatment. 
 
6.2.3  Proliferation (cell number)  
The effect of different TGF-β isomers and their combinations including TGF-β(1+2), 
TGF-β(1+2+3), TGF-β(1+3), TGF-β(2+3) on proliferation rate of human bone cells was 
assessed. Seven culture flasks were seeded at cell densities of 50,000 cells/ml treated 
with different TGF-β isomers and one culture flask remained un-treated as a control. 
Photomicrographs were taken as described previously and cell numbers were 
determined from randomly selected regions of each culture flasks. The whole 
experiment was repeated three times and mean average cell number was calculated. 
There was some variability in initial cell number for each treatment. To normalise, the 
mean starting cell number was calculated per treatment and each starting cell number 
was expressed as a percentage of that mean. Cell number at each time point was 
therefore expressed as a percentage of the normalised mean cell number per treatment. 
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6.3  STATISTICAL ANALYSIS 
The mean % cell numbers and cell length were tested for normality using a Kolmogorov 
Smirnov test. Normally distributed (p > 0.05) were analysed using SPSS via a Oneway 
Analysis of Variance (ANOVA) followed by post Hoc Bonferroni tests. Kruskal-Wallis 
test and serial Mann Whitney tests were used for non-normally distributed results (p < 
0.05).  Statistical tests were performed such that a p value of < 0.05 was considered as 
indicating a significant difference.   
 
6.4  RESULTS 
Figures 6.1 – 6.8 show the images for the bone cells after seeding in Tissue Culture 
(TC) grade falcon cell culture flask after treatment with TGF-β1, TGF-β2, TGF-β3, 
TGF-β(1+2), TGF-β(1+2+3), TGF-β(1+3), TGF-β(2+3) and un-treated (control).  
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Figure 6.1 Images of human bone cells after seeding in TC grade falcon cell culture 
flask with no growth factor (Control) over a period of 36hrs (Scale bar=100m). 
 
 
Figure 6.2 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β1 over a period of 36hrs (Scale bar=100m). 
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Figure 6.3 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β2 over a period of 36hrs (Scale bar=100m). 
 
Figure 6.4 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β3 over a period of 36hrs (Scale bar=100m). 
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Figure 6.5 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β(1+2) over a period of 36hrs (Scale bar=100m). 
 
Figure 6.6 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β(1+2+3) over a period of 36hrs (Scale bar=100m). 
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Figure 6.7 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β(1+3) over a period of 36hrs (Scale bar=100m). 
 
Figure 6.8 Images of human bone cells after seeding in TC grade falcon cell culture 
flask treated with TGF-β(2+3) over a period of 36hrs (Scale bar=100m). 
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6.4.1  Cell length analysis 
The experiments examined the effect of different TGF-β isomers and their combinations 
on bone cell morphology including cell length and shape. Table 6.1 below shows the 
tabulated results for the human bone cell length against time for cells treated with TGF-
1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-(1+3), TGF-β(2+3) and un-
treated as control. Mean cell size at time zero was 18.32µm ± 2.54SD. From the results 
in Figure 6.9, it was found that cells treated with TGF-β(2+3) and TGF-(1+3) after 
36hrs (mean % cell lengths ~551.57% ± 9.14SD and 490.86% ± 9.62SD, respectively, p 
< 0.001) elongated more than all other treatments. Cells treated with TGF-β3, TGF-β2 
and control showed less elongation (mean % cell length ~ 469.91% ± 9.44SD, 470.87% 
± 12.90SD and 469.34 ± 8.41SD, respectively) compared to TGF-β(2+3) and TGF-
(1+3) after 36 hours in culture. There were no significant differences in mean % cell 
length between TGF-β2, TGF-3 and control after 36hrs of culture but there were 
significant differences at earlier time points (6hrs). It was found that TGF-β2 and TGF-
β3 cause a faster elongation 6hrs after seeding. This concurs with wound closure results 
in chapter 4. After 36hrs, TGF-β2 and TGF-3 did not have any effect on cell 
elongation when compared with the control. Cells in TGF-β1 treated culture flasks 
elongated less (with mean % cell length ~447.24% ± 24.30SD) compared with the 
cultures treated with TGF-β2, TGF-β3 and un-treated control cells but elongated more 
than cells treated with TGF-β(1+2) and TGF-β(1+2+3). The initial cell length for all 
culture flasks were similar and all treated culture flasks elongated after 36hrs except 
TGF-(1+2) and TGF-(1+2+3) with mean % cell length ~ 401.48% ± 13.01SD and 
311.34% ± 30.24SD, respectively, while cells treated with TGF-(1+3), TGF-β(2+3) 
showed greatest elongation. These results, therefore, suggest that TGF-β3 results in 
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more elongated cells when combined with either of the other two isomers to form TGF-
(1+3) and TGF-β(2+3) (See Tables 6.1-6.3). In comparison, cells treated with TGF-
(1+2), TGF-(1+2+3) showed less elongation. TGF-1 in contrast to TGF-2 and 
TGF-3 seemed to significantly (p < 0.05) (See Table 6.3) decrease cell elongation. 
Table 6.1 Descriptive statistics of mean % cell length against time for cells treated with 
TGF-1, TGF-2, TGF-3 and un-treated as control. 
 
Treatment 
 
Time (hrs) 
Mean % Cell length  
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
Control 
0hrs 99.98 ± 7.43 2.35 
6hrs 207.30 ± 11.17 3.53 
12hrs 331.57 ± 11.32 3.58 
18hrs 415.08 ± 10.18 3.22 
24hrs 438.84 ± 6.35 2.01 
36hrs 469.34 ± 8.41 2.66 
 
 
 
TGFβ1 
 
 
 
0hrs 99.98 ± 7.37 2.33 
6hrs 268.94 ± 8.71 2.75 
12hrs 330.06 ± 8.66 2.74 
18hrs 385.52 ± 14.38 4.55 
24hrs 429.00 ± 10.46 3.31 
36hrs 447.24 ± 24.30 7.68 
 
 
 
TGFβ2 
 
0hrs 99.98 ± 5.08 1.61 
6hrs 256.85 ± 9.53 3.01 
12hrs 335.86 ± 9.15 2.89 
18hrs 381.76 ± 15.85 5.01 
24hrs 414.64 ± 7.90 2.50 
36hrs 470.87 ± 12.90 4.08 
 
 
 
TGFβ3 
0hrs 99.99 ± 12.58 3.98 
6hrs 214.49 ± 5.49 1.74 
12hrs 328.99 ± 10.74 3.40 
18hrs 369.98 ± 11.89 3.76 
24hrs 403.25 ± 17.45 5.52 
36hrs 469.91 ± 9.44 2.99 
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Table 6.2 Descriptive statistics of mean % cell length against time  for cells treated with 
TGF-(1+2), TGF-(1+2+3), TGF-(1+3) and TGF-β(2+3). 
 
Treatment Time 
(hrs) 
Mean % Cell length 
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
TGFβ1+2 
 
0hrs 99.99 ± 15.76 4.98 
6hrs 211.11 ± 6.49 2.05 
12hrs 238.50 ± 12.15 3.84 
18hrs 252.16 ± 9.29 2.94 
24hrs 292.02 ± 8.60 2.72 
36hrs 401.48 ± 13.01 4.11 
 
 
 
 
TGFβ1+3 
 
0hrs 99.98 ± 8.86 2.80 
6hrs 232.42 ± 11.65 3.69 
12hrs 300.40 ± 8.18 2.59 
18hrs 337.11 ± 8.75 2.77 
24hrs 456.74 ± 10.55 3.34 
36hrs 490.86 ± 9.62 3.04 
 
 
 
TGFβ2+3 
 
0hrs 100.01 ± 7.15 2.26 
6hrs 273.70 ± 8.42 2.66 
12hrs 336.78 ± 9.34 2.95 
18hrs 385.51 ± 12.07 3.82 
24hrs 526.33 ± 12.94 4.09 
36hrs 551.57 ± 9.14 2.89 
 
 
 
TGFβ1+2+3 
 
0hrs 100.01 ± 11.35 3.59 
6hrs 139.56 ± 7.22 2.28 
12hrs 182.22 ± 13.03 4.12 
18hrs 221.65 ± 9.62 3.04 
24hrs 249.14 ± 15.69 4.96 
36hrs 311.34 ± 30.24 9.56 
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Table 6.3 P value derived from pair wise comparisons of mean % bone cell length vs. 
time treated with different TGF- isomers and their combinations. Pairs that are 
significantly different from one another showing marked by an asterisk (*) whereas * 
P<0.05, ** P<0.01 and *** P<0.001. 
Treatment Cell  
length 
0hrs 
Cell   
length 
6hrs 
Cell  
length 
12hrs 
Cell  
length 
18hrs 
Cell  
length 
24hrs 
Cell   
length 
36hrs 
Control – TGFβ1 1.000 0.001*** 1.000 0.001*** 0.580 0.023* 
Control – TGFβ2 1.000 0.001*** 0.983 0.001*** 0.001*** 0.880 
Control – TGFβ3 1.000 0.608 0.999 0.001*** 0.001*** 0.939 
Control – TGFβ1+2 1.000 0.978 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.024* 0.001*** 
Control – TGFβ2+3 1.000 0.001*** 0.952 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ2 1.000 0.058 0.917 0.996 0.134 0.013* 
TGFβ1 - TGFβ3 1.000 0.001*** 1.000 0.076 0.001*** 0.028* 
TGFβ1 - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ2+3 1.000 0.927 0.837 1.000 0.001*** 0.001*** 
TGFβ1 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ3 1.000 0.001*** 0.821 0.340 0.390 0.879 
TGFβ2 - TGFβ1+2 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.004** 
TGFβ2 - TGFβ2+3 1.000 0.001*** 1.000 0.996 0.001*** 0.001*** 
TGFβ2 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ1+2 1.000 0.989 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ2+3 1.000 0.001*** 0.709 0.076 0.001*** 0.001*** 
TGFβ3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ1+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+3 - TGFβ2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2+3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
 
Statistical analysis (See Table 6.3) showed that after 36hrs of culture there were 
significant differences in mean % cell length between cells treated with TGF-β(1+2), 
TGF-(1+2+3) and TGF-1 which represented less elongation (p<0.001). Cell treated 
with TGF-(1+2+3) showed least elongation compared to all other treatments. On the 
other hand, there were significant differences in mean % cell length between TGF-
β(2+3) and TGF-(1+3) after 36hrs of culture (p<0.001). Figure 6.9 show graph of 
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mean % cell length against time for cells treated with TGF-1, TGF-2, TGF-3, TGF-
(1+2), TGF-(1+2+3), TGF-(1+3), TGF-β(2+3) and un-treated as control. It is clear 
that there are significant differences (p<0.001) in mean % cell length between TGF-
(1+3) and TGF-β(2+3) with all other treatments after 36hrs of culture. Cells treated 
with TGF-β(2+3) showed most elongation compared to all other treatments. 
  
 
Figure 6.9 Graph of mean % cell length against time for cells treated with TGF-1, 
TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-(1+3), TGF-β(2+3) and un-
treated as control (Error bars represent standard deviation). 
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6.4.2  Analyses of Cell Proliferation (Cell number) 
Proliferation rate was also studied in order to investigate the effect of different TGF-β 
isomers on cell number of MG63 cells (See Figures 6.1 – 6.8). Tables 6.4 and 6.5 also 
give the statistical results for the human bone cell number against time for cells treated 
with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-(1+3), TGF-
β(2+3) and un-treated as control.  
 
Tables 6.4-6.6 and Figure 6.10 show the highest proliferation occurred in cultures 
treated with TGF-3 after 36hrs of culture (mean % cell number ~ 213.33% ± 7.41SD) 
followed by TGF-β(2+3) (mean % cell number ~ 181.40% ± 6.58SD). This suggests 
that there were more cell division (and cell attachment) in cell cultures treated with 
TGF-3 and TGF-β(2+3). In comparison, cells treated with TGF-1 and TGF-(1+2) 
show less proliferation after 36hrs of culture (mean % cell number ~ 138.30% ± 3.88SD 
and 134.78% ± 7.32SD, respectively). Results also showed that after 36hrs of culture 
there were significant differences in mean % cell number between cells treated with 
TGF-β3 and TGF-(2+3) (p=0.001) indicating that TGF-3 treated cells proliferated 
more than the other cells. On the other hand, there were no significant differences in 
mean % cell number between cells treated with TGF-β1 and TGF-β(1+2) (p=0.171) 
(See Table 6.6). Cells treated with TGF-β(1+3), TGF-β(1+2+3) and control showed 
similar results and there were no significant difference between them (mean % cell 
number ~ 162.79% ± 8.35SD, 163.04 ± 6.15SD and 160.00% ± 8.31SD, respectively). 
These results, therefore, suggest that any culture flask treated with TGF-β3 or any 
combination with TGF-β3 induced an increase in cell proliferation compared to all other 
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treated culture flasks. Control cultures and all cultures treated with TGF-β3 including 
their combinations also showed higher proliferation rates compared to the cultures 
treated with TGF-β1 and TGF-β2 (with mean % cell number ~ 138.30% ± 3.88SD for 
TGF-β1 and 147.14% ± 5.03SD for TGF-β2). This indicates that both TGF-β1 and 
TGF-β2 decreased cell proliferation compared to the control. There were significant 
differences in mean % cell number between cells treated with TGF-β1 and TGF-β2 
(p<0.001). Results also showed that at 36hrs of culture there were significant 
differences in mean % cell number between cells treated with TGF-β3 and all other 
treatments (p<0.001) indicating that cells treated with TGF-3 proliferated more than 
any of the other cells.  
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Table 6.4 Descriptive statistics of mean % bone cell number against time for cells 
treated with TGF-1, TGF-2, TGF-3 and un-treated as control (10000 Cells/Flask). 
 
 
Treatment 
 
Time (hrs) 
Mean % Cell Number 
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
Control 
0hrs 100.00 ± 8.11 2.27 
6hrs 113.33 ± 6.11 1.93 
12hrs 120.00 ± 4.57 1.44 
18hrs 135.56 ± 5.13 1.62 
24hrs 153.33 ± 8.57 2.71 
36hrs 160.00 ± 8.31 2.63 
 
 
 
TGFβ1 
 
 
 
0hrs 100.00 ± 5.76 1.82 
6hrs 108.51 ± 8.57 2.71 
12hrs 117.02 ± 12.88 4.07 
18hrs 121.27 ± 3.17 1.00 
24hrs 131.92 ± 7.30 2.31 
36hrs 138.30 ± 3.88 1.23 
 
 
 
TGFβ2 
 
0hrs 100.00 ± 3.77 1.19 
6hrs 107.55 ± 3.33 1.05 
12hrs 122.64 ± 3.88 1.23 
18hrs 139.63 ± 3.77 1.19 
24hrs 141.51 ± 5.18 1.64 
36hrs 147.17 ± 5.03 1.59 
 
 
 
TGFβ3 
0hrs 100.00 ± 3.63 1.15 
6hrs 137.78 ± 7.98 2.52 
12hrs 142.22 ± 4.91 1.55 
18hrs 151.11 ± 4.57 1.44 
24hrs 173.33 ± 2.34 0.74 
36hrs 213.33 ± 7.41 2.34 
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Table 6.5 Descriptive statistics of mean % bone cell number against time for cells 
treated with TGF-(1+2), TGF-(1+2+3), TGF-(1+3) and TGF-β(2+3) (10000 
Cells/Flask). 
 
Treatment Time 
(hrs) 
Mean % Cell Number 
± Std. Deviation (SD) 
Std. Error 
(SE) 
 
 
 
TGFβ1+2 
 
0hrs 100.00 ± 5.12 1.62 
6hrs 104.35 ± 5.61 1.77 
12hrs 108.70 ± 6.06 1.92 
18hrs 117.39 ± 6.23 1.97 
24hrs 123.91 ± 10.20 3.22 
36hrs 134.78 ± 7.32 2.31 
 
 
 
 
TGFβ1+3 
 
0hrs 100.00 ± 4.10 1.30 
6hrs 116.28 ± 6.20 1.96 
12hrs 132.56 ± 4.65 1.47 
18hrs 141.86 ± 7.44 2.35 
24hrs 151.16 ± 5.59 1.77 
36hrs 162.79 ± 8.35 2.64 
 
 
 
TGFβ2+3 
 
0hrs 100.00 ± 4.52 1.43 
6hrs 111.63 ± 6.85 2.17 
12hrs 127.91 ± 6.58 2.08 
18hrs 139.54 ± 8.13 2.57 
24hrs 162.79 ± 7.35 2.33 
36hrs 181.40 ± 6.58 2.08 
 
 
 
TGFβ1+2+3 
 
0hrs 100.00 ± 7.32 2.31 
6hrs 102.17 ± 5.32 1.68 
12hrs 115.22 ± 10.09 3.19 
18hrs 141.30 ± 6.40 2.02 
24hrs 154.35 ± 9.45 2.99 
36hrs 163.04 ± 6.15 1.94 
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Table 6.6 P value derived from pair wise comparisons of mean % bone cell number vs. 
time treated with TGF- isomers and their combinations. Pairs that are significantly 
different from one another are marked by an asterisk (*) whereas * P<0.05, ** P<0.01 
and *** P<0.001. 
 
Treatment Cell No. 
0hrs 
Cell No. 
6hrs 
Cell No. 
12hrs 
Cell No. 
18hrs 
Cell No. 
24hrs 
Cell No. 
36hrs 
Control – TGFβ1 0.545 0.702 0.984 0.001*** 0.001*** 0.001*** 
Control – TGFβ2 0.494 0.481 0.992 0.069 0.014* 0.002** 
Control – TGFβ3 0.540 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+2 0.493 0.05 0.020* 0.001*** 0.001*** 0.001*** 
Control – TGFβ1+3 0.543 0.969 0.006** 0.041* 0.998 0.325 
Control – TGFβ2+3 0.320 0.999 0.251 0.495 0.097 0.001*** 
Control – TGFβ1+2+3 0.544 0.005** 0.826 0.068 1.000 0.325 
TGFβ1 - TGFβ2 0.940 1.000 0.678 0.001*** 0.088 0.001*** 
TGFβ1 - TGFβ3 0.820 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ1+2 0.940 0.832 0.196 0.129 0.248 0.171 
TGFβ1 - TGFβ1+3 0.940 0.139 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ2+3 0.761 0.958 0.029* 0.001*** 0.001*** 0.001*** 
TGFβ1 - TGFβ1+2+3 1.000 0.362 0.999 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ3 0.939 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ2 - TGFβ1+2 0.819 0.952 0.002** 0.001*** 0.001*** 0.002** 
TGFβ2 - TGFβ1+3 0.939 0.062 0.064 0.363 0.084 0.001*** 
TGFβ2 - TGFβ2+3 0.702 0.845 0.745 0.705 0.001*** 0.001*** 
TGFβ2 - TGFβ1+2+3 0.879 0.576 0.327 0.196 0.005** 0.001*** 
TGFβ3 - TGFβ1+2 0.730 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ3 - TGFβ1+3 1.000 0.001*** 0.078 0.003** 0.001*** 0.001*** 
TGFβ3 - TGFβ2+3 0.465 0.001*** 0.001*** 0.005** 0.042* 0.001*** 
TGFβ3 - TGFβ1+2+3 0.761 0.001*** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ1+3 0.819 0.002** 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ2+3 0.672 0.199 0.001*** 0.001*** 0.001*** 0.001*** 
TGFβ1+2 - TGFβ1+2+3 0.939 0.995 0.496 0.001*** 0.001*** 0.001*** 
TGFβ1+3 - TGFβ2+3 0.847 0.738 0.845 0.493 0.017* 0.001*** 
TGFβ1+3 - TGFβ1+2+3 1.000 0.001*** 0.001*** 1.000 0.978 0.880 
TGFβ2+3 - TGFβ1+2+3 0.703 0.032 0.005** 0.447 0.191 0.001*** 
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Figure 6.10 Graph of mean % cell number against time for cells treated with TGF-1, 
TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-(1+3), TGF-β(2+3) and un-
treated as control (Error bars represent standard deviation). 
 
6.5  DISCUSSION 
The Transforming growth factor-β (TGF-β) is a powerful modulator of bone 
metabolism and both its anabolic and catabolic effects on bone have been investigated 
(Karsdal, 2001, Ehnert, 2010). TGF-β is a cytokine that profoundly alters osteoblast 
shape (Hurley, 1994). It is one of the most abundant growth factors in skeletal tissues 
(Bonewald, 1990, Sun, 2009) and, in mammals, comprises three isoforms; TGF-β1, 
TGF-β2, and TGF-β3, all of which are expressed by bone cells (Horner, 1998, Chin, 
2004) and interact with the known TGF-β receptors types I, II, and III (betaglycan) 
(Hartsough, 1997). All TGF-β isoforms display different biological activities 
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(Bonewald, 1996) although one isoform may be more potent than another in a given 
assay (Joyce, 1990, Chin, 2004). Since the role of TGF-β induced changes in osteoblast 
morphology is largely unknown various investigations suggest that TGF-β has multiple 
functions in bone metabolism (Karsdal, 2001). In vivo studies show that TGF-β can 
increase bone formation and promote fracture healing (Bonewald, 1996, Rosier, 1998). 
TGF-β1 knock-out mice display approximately a 30% decrease in tibial length and a 
reduction in bone mineral content (Geiser, 1998), consistent with the idea that TGF-β 
functions as a bone-forming agent. On the other hand, over expression of TGF-β2 
controlled by the osteoblast-specific osteocalcin promoter leads to bone loss 
(Erlebacher, 1996), and mice expressing a dominant-negative TGF-β type II receptor 
have no obvious skeletal defects apart from joint abnormalities that are probably due do 
chondrocytes malfunction (Serra, 1997, Khaghani, 2009a). These apparently conflicting 
results are also reflected in numerous studies in cell and tissue cultures where TGF-β 
seems to modulate various bone cell activities in opposite ways. For instance, both 
increases and decreases in osteoclast formation, bone resorption, osteoblast 
proliferation, and osteoblast differentiation have been reported (Bonewald, 1996, 
Centrella, 1994, Ehnert, 2010). TGF-β has various actions on bone cells while the 
intracellular signals triggered by the binding of TGF-β to its receptor are vast and 
complex. They include; phosphorylation and activation of Smad transcription factors; 
regulation of Ras, Rho, and other small G-proteins; activation of protein kinases such as 
TGF-β-activated kinase-1 (TAK1); mitogen-activated protein (MAP) kinases, and Src, 
recruitment of adaptor proteins and regulation of ion channels (Visser, 1998). In this 
chapter the hypothesis that different TGF-β isomers induced changes in osteoblast 
morphology and cell proliferation (cell number) was tested. Our results suggested that 
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cell morphology changes were observed more in cells treated with TGF-β(2+3) and 
TGF-β(1+3) followed by TGF-β3 and TGF-β2 and control treatments. A culture flask 
treated with TGF-β1 showed less elongation compared to cells treated with TGF-β3 and 
TGF-β2. In terms of proliferation cells treated with TGF-3 and TGF-β(2+3) showed a 
higher % cell number followed by TGF-β(1+2+3), TGF-β(1+3) and the control. TGF-
1 and TGF-2 did not induce proliferation. Regulation of cell shape is an important 
process that controls tissue morphogenesis, cell migration, differentiation, proliferation, 
and survival, presumably by regulating the expression of genes central to these 
processes (Boudreau, 1999, Lukashev, 1998, Nakamura, 2007). However, it is possible 
that TGF-β induced osteoblast elongation contributes to several aspects of TGF-β 
function in bone. Previous literature suggests that the increased bone resorption in 
response to TGF-β is due to the shape alterations of osteoblasts and is not mediated 
through the direct action of TGF-β on osteoclasts or by the production of osteoclast-
activating factors produced by MC cells in response to TGF-β (Hartsough, 1997, 
Nakamura, 2007). It has been demonstrated in epithelial cells that secretion of TGF-β 
can stimulate MAP kinase pathways and that they mediate some of the effects of TGF-β 
on gene expression (Hartsough, 1997). TGF-β induced osteoblast elongation was 
dependent on p38 MAP kinase activity, as assessed by using the p38 MAP kinase 
inhibitor. This is the first report functionally linking the p38 MAP kinase pathway to 
TGF-β in osteoblasts (Kozawa, 1999, Suzuki, 1999). Osteoblast shape changes induced 
by bFGF were only slightly inhibited, indicating that TGF-β and bFGF alter osteoblast 
morphology by using different intra-cellular signalling cascades. This finding is also 
consistent with the fact that the morphology of osteoblasts in response to TGF-β is 
obviously different from the morphology of osteoblasts treated with bFGF (Suzuki, 
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1999). At present it is not clear in which situations TGF-β could facilitate bone 
resorption/absorbtion in vivo by altering osteoblast shape (Karsdal, 2001, Serganova, 
2009). One possibility is that active TGF-β is produced during bone remodeling within 
the basic multi-cellular unit (BMU) of the osteon. Both osteoblasts and osteoclasts are 
able to synthesise TGF-β (Oursler, 1994, Oreffo, 1989, Bonewald, 1991, Selvamurugan, 
2004). Although osteoblasts are responsible for production of most of the TGF-β 
entrapped in bone matrix (Bonewald, 1994, Selvamurugan, 2004), the majority of active 
TGF-β appears to be generated by bone resorbing osteoclasts either through the release 
of TGF-β stored in bone matrix or by biosynthesis of new TGF-β  (Pfeilschifter, 1987). 
Active TGF-β may then be made accessible to osteoblasts through a process involving 
transcytosis (Mostov, 1997, Ruan, 2010). The selective activation of TGF-β by 
osteoclasts may fulfill a function by inducing the elongation of bone lining cells (Lucas, 
1989, Pfeilschifter, 1990, Ruan, 2010). It also well known that calcium ion present in 
bone matrix at the tendon-bone repair site is associated with new bone formation and 
improved collagen organisation at the healing tendon-bone interface (Kovacevic, 2011). 
The addition of TGF-β3 significantly improved the strength of the bone repair at 4 
weeks. There is an assumption that TGF-β3 is able to shift calcium ions into the wound 
area due to the need for this ion during osteoblast proliferation. The required calcium 
ion will be obtained from a source close to the wound. Bone itself is a rich and close 
source for calcium. On the other hand, decalcification causes bone to become less 
dense. These findings concur with our wound healing result in chapter 4 and current 
proliferation results in the current chapter. Our results showed an increase in wound 
healing, cell proliferation and cell length in present of TGF-β3. Thus, the precise role 
and mechanism of TGF-β with regard to osteoblast elongation remains to be 
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established. However, our results suggest that various TGF-β causes an increase or 
decrease in % cell number and cell length. The Focal adhesions activate signalling 
pathways, such as MAPK and JNK that regulate transcription factor activity and direct 
cell growth and differentiation (Giancotti, 1999). Many of these integrin-activated 
signalling cascades are required for osteoblast differentiation (Lai, 2001, Xiao, 2002). 
Alternatively as a future work it is useful to use other cell viability assays such as 
alamar blue, formazan based assay (MTT) and live/dead assay to quantitatively measure 
cell viability and proliferation using fluorescent or colorimetric detection strategies. In 
the next chapter we will look at the integrin expression and protein secretion of bone 
cells in the presence of TGF-β.  
 
6.6  CONCLUSIONS 
The results suggested that cell morphology changes were observed more in cells treated 
with TGF-β(2+3) and TGF-β(1+3) followed by TGF-β2 and TGF-3 and un-treated as 
the control. A culture flask treated with TGF-β1 showed less elongation compared to 
the control and other TGF-β isomers. In terms of proliferation cells treated with TGF-3 
and TGF-β(2+3) induced the greatest cell division followed by TGF-β(1+2+3), TGF-
β(1+3) and the control. TGF-3 and its combinations showed a higher proliferation 
compared to the control. TGF-1, TGF-2 and TGF-(1+2) showed less proliferation 
compared to the control. 
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CHAPTER SEVEN 
IMMUNOCYTOCHEMISTRY AND CELL 
IMAGING WITH THE WIDEFIELD SURFACE 
PLASMON RESONANCE (WSPR) 
MICROSCOPE 
 
7.1 INTRODUCTION  
In the previous chapters the effect of TGF-βs (either TGF- isomers in isolation or in 
combined form), HCl and BSA (as a TGF- solvent and carrier) were investigated in 
relation to wound healing, degree of cell detachment, cell size and cell number. TGF-β3 
and HCl enhanced the rate of cell detachment, proliferation and wound healing. The 
combination of TGF-3 with any other TGF- isomer seemed to cause better cell 
detachment and wound healing, while the absence of TGF-3 was associated with less 
cell detachment and wound healing. All previuos findings are directly related to the way 
cells interact with the surface. These findings suggest that TGF- isoforms modify cell 
surface interaction which could influence integrin expression. Cell-surface and cell-cell 
interactions are mediated by integrins and cell adhesion molecules (Akiyama, 1990, 
Yang, 2010, Eapen, 2012). Integrins are a group of membrane bound receptor protein 
which bind to components of the ECM (Hynes, 1992, Aoudjit, 2012) and they are 
capable of transducing signals from the  ECM to the cells which modulate cell 
behaviour such as migration, differentiation and the synthesis of specific proteins 
(Hynes, 1992, Keselowsky, 2004). When integrins are inserted into the front of the cell 
focal adhesions form, these focal adhesions prevent membrane retraction and provide 
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adhesive traction for cell movement (Bordeleau, 2008). Integrins are heterodimeric 
glycoproteins consisting of an α and β subunit in which the α chain conveys ligand 
specificity and the β chain provides linkage to the cytoskeleton via talin, vinculin, or α-
actinin (Saito, 2004, Clëzardin, 2009). The α and β chains have similar tertiary 
structures and are non-covalently linked via their extracellular globular domains. 
Integrins can be divided into two groups. The first group contains integrins that bind to 
matrix proteins found in basement membranes. In this group receptors bind to proteins 
such as collagen and laminin (Stephansson, 2002). The second group contains integrins 
that bind to extracellular matrix proteins such as fibronectin, vitronectin, osteopontin 
and fibrinogen, all of which are found during inflammation, wound healing or the 
development process (Saito, 2004). Integrins also play a part in the formation of 
hemidesmosomes. Hemidesmosomes are very small structures on the inner basal 
surface of keratinocytes and they link one cell to the extracellular matrix. Human bone 
cells are known to express high levels of α1β1, α3β1, α5β1 and αvβ5 integrins and 
lower levels of α2β1, α4β1, αvβ1 and αvβ3 integrins (Saito, 2004). All cell types in 
bone express β1 and α5 as integrins (Hughes, 1993, Saito, 2004, Clëzardin, 2009). The 
human osteosarcoma-derived cell line MG-63 has been shown (Hughes, 1993) to 
express α5β1 and α5β3 integrins and a variant of this line showing osteoblastic 
differentiation expresses increased levels of cell surface α5β1 integrin but not αVβ3. 
Furthermore, interleukin-Iβ induction of osteoblastic differentiation of MG-63 
osteosarcoma cells results in an induction of the expression of α5β1. Inhibition of the 
α5β1function with subunit-specific monoclonal antibodies inhibits this osteoblastic 
differentiation (Clëzardin, 2009). However, acquired expression of these receptors is a 
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common phenomenon in cultured cells and in vitro phenotypes may not reflect the 
pattern of expression in vivo.  
 
Stimulation of cell migration during wound repair depends on the presence of growth 
factors such as TGF-β (Sun, 2009, Chin, 2004). TGF-β is a cytokine that may play a 
role in the repair of tendon and bone (Kovacevic, 2011, Kandziora, 2002, Chin, 2004, 
Sefat, 2010d). TGF-β1 and, to a lesser extent, bone morphogenetic protein 2 (BMP-2) 
have been reported to regulate the gene expression of different osteoblast markers in 
vitro (Palcy, 1999, Bodoa, 2010, Ehnert, 2010). TGF-β functions to stimulate alterations 
in integrin expression as well as altering binding affinity (Chin, 2004). To investigate 
the expression of ECM proteins and integrins by bone cells treated with various TGF-β 
isomers in vitro, this work aims at undertaking an immunohistochemical study using 
monoclonal anti-collagen type I, monoclonal anti-Human fibronectin, monoclonal 
CD49c (Integrin α3) and monoclonal CD29 (Integrin β1) antibodies. 
 
In addition, one of the major problems associated with analysing cell guidance, 
alignment and cell behaviour is that of imaging the cell surface interface at Z sub-
micron resolutions sufficient to interrogate the nanometric scale spatiotemporal 
interfacial interactions in real time (Abdul Jamil, 2008a, Abdul Jamil, 2008b, Sefat, 
2010a). To date, these processes have been mostly examined using standard phase 
contrast light microscopy, confocal microscopy and immunofluorescence staining 
techniques. Unfortunately the Z resolution of phase contrast microscope systems is poor 
and, although the confocal system, by optically sectioning a sample, can allow imaging 
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at high Z resolutions, this requires the sample to be fixed and taken through 
immunostaining processes. This means that the imaging of interfacial interactions at 
high Z resolutions of live cells cannot be achieved. In order to overcome some of these 
deficiencies in interfacial imaging it is necessary to have a non-invasive mode of 
imaging at the interface. This may be achieved using surface plasmon (SP) microscopy. 
The pioneering work of Kretschmann and his colleagues in the 1960s indicated that 
attenuated total reflectance (ATR) prism based on SPs excitation could be induced in a 
configuration known as the Kretschmann configuration (Kretschmann, 1968). In this 
configuration (See Figure 7.1) p-polarised light striking the metallic coated surface from 
a region of high refractive index at a specific angle will resonantly excite the electrons 
in the metallic film (Kano, 1998). This resonance will propagate along the conductor, 
giving rise to a surface Plasmon wave, which decays resulting in the re-immission of 
light with no loss of energy. The SPR angle is changed when bio-molecular species bind 
to the coated metal layer and this changes the angle required to excite surface plasmons. 
This means that inefficient coupling between the incident light and the interface occurs 
and energy (light) is lost by diffraction. Thus, the binding of a molecular species to an 
interface in a surface plasmon microscope results in a change in the intensity of the 
reflected light. This feature gives rise to what has become the surface Plasmon 
microscope (Kano, 1998). The drawback with these systems are that surface plasmons 
can travel several microns before decaying and this limits the lateral resolution of 
surface plasmons to 10-20µm. The Widefield Surface Plasmon Resonance (WSPR) 
system was developed to circumvent these difficulties. In the WSPR, the surface 
Plasmon substrate consisting of a gold coated cover slip is illuminated with p-polarised 
light via a high NA objective lens at an angle sufficient to excite surface plasmons. 
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However, before reaching the objective lens the light passes through a rotatable diffuser. 
When stationary the transmission of the light through the diffuser illuminates the 
surface Plasmon substrate with a sub micron speckled pattern, but when rotated the 
speckled pattern of illumination is averaged giving rise to a wide field surface plasmon 
image with a lateral resolution that is no longer dependent on the propagation of surface 
plasmons, but that is dependent on the NA and wavelength of the illuminating P-
polarised light (Somekh, 2003, Abdul Jamil, 2008b). The aim of using this system in 
this thesis is to directly image cell surface interactions such as the formation of focal 
contacts or antibody/antigen interactions without the need for immunoflourescent 
techniques (Abdul Jamil, 2008a, Abdul Jamil, 2008b, Abdul Jamil, 2007a, Abdul Jamil, 
2007b, Sefat, 2010a).  
 
Figure 7.1 Schematic drawing of the typical Kretschmann configuration used to excite 
surface plasmons (Kano, 1998, Abdul Jamil, 2007b). 
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7.2  AIMS AND OBJECTIVES 
In previous chapters the effects of different TGF-β isomers and their combinations on 
cell behaviour in terms of cell morphology (size and shape), attachment and wound 
repair were investigated. These experiments indicated that TGF-β3 enhanced bone cell 
guidance to fibronectin, and therefore, immunostaining studies in this chapter will 
concentrate on determining which integrins are up regulated by TGF-β3. 
Immunostaining will also be used to determine if TGF-β3 modifies ECM secretion by 
the bone cells. In addition, imaging with WSPR will allow observation of the focal 
contacts without the need for immunostaining which that mediate the regulatory effects 
such as cell anchorage and direct numerous signaling proteins at sites of integrin 
binding and clustering. This could provide information on how TGF-s effect the 
formation of focal contact which could allow the acquisition of data that supports the 
findings of the trypsinisation study. The study using the WSPR is also hoped to shed 
light on how cells on guidance by micro patterened ECM proteins.    
 
7.3  MATERIALS AND METHODS  
7.3.1  Collagen Type I Immunostaining  
Coverslips were sterilised with 70% ethanol for at least 30 minutes and left in a laminar 
flow hood to dry. Human bone cells (MG63) and transforming growth factor beta 
(TGF-β) isomers were prepared. Three dry coverslips were placed into petridishes and 
5ml of cell suspension (10,000 cells/ml) was used along with 50µl of TGF-β1, 2 and 3 
to give final TGF-β1, 2 and 3 bathing concentrations of 5ng/ml, 10ng/ml and 50ng/ml, 
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respecticvley. The petridishes were sealed and incubated for 24-48hrs. After 48hrs the 
old media was aspirated and cells were washed three times with Hanks Balanced Salt 
Solution (HBSS). Fixation was carried out by bathing the slides in a 4% formaldehyde 
solution containing 1% BSA for 5-7 minutes at room temperature. Fixation was 
followed by three 5 minute washes in HBSS, the second of which contained 0.1M 
Glycine in order to prevent auto-fluorescence. Triton X-100 (0.1%) was used to 
permeabilize cells for 3-5 minutes. Coverslips were washed with HBSS three times. 
Cells were then treated with blocking solution (Goat serum or Image-iTTM FX signal 
enhancer) for 30 minutes and were again washed three times in HBSS. Cells were then 
incubated in 1:500 dilution of Monoclonal Anti-Collagen Type I primary antibody for 1 
hour in a humidity chamber at room temperature. Following incubation with the 
primary antibody, the coverslips were washed with HBSS three times at 15 minute 
intervals. Following washing, a secondary antibody (Alexa Fluor 488 Goat Anti-mouse 
IgG SFX kit, 5µg/ml, SIGMA) was applied for 1 hour in the dark at room temperature. 
The secondary antibody was washed off with HBSS three times at 15 minute intervals. 
Prior to imaging, cells were washed in Dapi (SIGMA) solution (10%) for 15 minutes 
and then imaged using a fluorescence microscope. Finally the total number of cells per 
micrograph was determined and number of cells stained with anti-collagen type I was 
counted per micrograph. Cell number was then expressed as the percentage number of 
stained cell per micrograph. Additional two samples were prepared without any TGF-β 
treatment as controls. One of them was stained for anti-collagen type I and the other was 
treated with the secondry antibody only without pre-incubation with the only collagen 
type I antibody.   
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7.3.2  Fibronectin Immunostaining 
Cells were cultured and treated with TGF-β 1, 2 and 3 as described in section 7.3.1. 
Cells were washed, fixed and permeabalised as previously described. The cells were 
then incubated in Monoclonal Anti-Human Fibronectin (working dilution of 1:5000) 
primary antibody for 1 hour in a humidity chamber at room temperature. Following this 
incubation the cells were washed with HBSS three times at 15 minute intervals. The 
cells were then incubated with a secondary antibody (Alexa Fluor 488 Goat Anti-mouse 
IgG SFX kit, 5µg/ml) for 1 hour in a dark area at room temperature. The cells were then 
washed with HBSS three times in 15 minute intervals and stored at 4°C for 3-4 days. 
Cells were finally washed in Dapi solution (10%) for 15 minutes and then imaged using 
a fluorescence microscope. Numbers of cells stained with anti-human fibronectin were 
measured. The % number of stained cells was then calculated as described in section 
7.3.1. Additional two samples were also prepared without any TGF-β treatment as 
controls. One of them was stained for anti-human fibronectin and the other one was 
treated with the secondry antibody only without pre-incubation with the only fibronectin 
antibody. 
 
7.3.3  Integrin Immunostaining 
Cells were cultured and treated with TGF-β 1, 2 and 3 and then were washed, fixed and 
permeabilized as described in section 7.3.1. Cells were incubated in CD49c (Integrin 
α3) and CD29 (Integrin β1) primary antibodies for 1 hour in humidity chamber at room 
temperature (with the dilution ratio of 1:500 and 1:1000, respectively). After this 
incubation, the coverslips were washed with HBSS three times in 15 minute intervals. 
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Secondary antibody (Alexa Fluor 488 Goat Anti-mouse IgG SFX kit, 5µg/ml) was 
applied for 1 hour in a dark area at room temperature. All incubations were performed 
in a humidity chamber to avoid the evaporation of reagents. The cells were then washed 
with HBSS three times in 15 minute intervals. Cells were then washed in Dapi solution 
(10%) for 15 minutes and finally imaged using a fluorescence microscope. The number 
of cells stained with α3 and β1 integrin was measured. Cell number was then expressed 
as percentage number of stained cells per micrograph.  
 
7.3.4  Control 
Cell cultures treated with no growth factor and no primary antibody (Ab) were used as 
negative controls while positive control represents absence of TGF-β only with addition 
of primary antibody. Additional samples were also prepared for each TGF-β treatment 
with and without applying the primary antibody. 
  
7.3.5 SPR substrate 
A prefabricated coverslip (0.18mm thick and 22mm diameter), coated with 50nm gold 
on top of 1nm chromium (for better adherence) (See Figure 7.2) were stamp patterned 
with fibronectin protein by using a 50m stamp. The substrate was then plated with 
MG63 bone cells (10,000 cells/coverslip). After fixing the cells, the substrates were 
dehydrated in serial alcohol and then imaged using a phase contrast light microscope. 
The substrates were then mounted in the sample holder of the WSPR microscope and 
imaged further. Additional gold substrates seeded with MG-63 bone cells were treated 
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with all TGF-β isomers and their combinations in order to be imaged using WSPR 
microscope.  
 
Figure 7.2 Illustration of the SPR substrate structures and sample orientation in the 
system during imaging with high NA objective lens. Diagram also indicates on which 
side the samples were placed (Sefat, 2010a, Sefat, 2010d). 
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7.4  STATISTICAL ANALYSIS 
The mean % number of stained cells per treatment group was tested for normality using 
a Kolmogorov Smirnov test. Normally distributed data (p > 0.05) was analysed using 
SPSS via a Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni 
test. Kruskal-Wallis test and serial Mann Whitney tests were used for non-normally 
distributed results (p < 0.05).  Statistical tests were performed such that a p value of < 
0.05 was considered as indicating a significant difference.   
 
7.5  RESULTS 
7.5.1   Immunostaining 
7.5.1.1 Collagen type I immunostaining 
The mean % number of stained cells per treatment group for immunocytochemistry 
with anti-collagen type I antibodies were normally distributed and thus analysed using 
SPSS via Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni 
test (See Tables 7.1 and 7.2). Immunofluorscence micrographs of human bone cells 
stained for anti collagen type I showed that the bone cells treated with TGF-β2 and 
TGF-β3 produced more collagen protein compared to the control (see Figure 7.3) (with 
mean % number of cells stained per micrograph ~ 100% ± 11.26SD after TGF-β2 
treatment, 93.10% ± 6.70SD for after TGF-β3 treatment and 37.93% ± 6.50SD for 
control cultures with no TGF-β treatment. Statistically, there are no significant 
differences in mean % number of cells stained per micrograph with collagen type I 
between TGF-β2 and TGF-β3 isomers (p=0.504). In these micrographs, cell surface 
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appears quite green with TGF-β3 treatment indicating release of high amount of 
collagen type I protein compared to the control with no TGF-β treatment (see Figure 
7.3). No specific staining was observed in the micrographs with no primary antibody 
confirming the specificity of the primary antibody and blue dapi staining represents live 
cells. Bone cells treated with TGF-β(1+2+3) also exhibited strong staining of cells with 
mean % number of cells stained per micrograph with anti-collagen type I ~ 79.31% ± 
2.27SD and this was similar to the staining observed after TGF-β2 and TGF-β3 
treatment. This suggests that both TGF-β2 and TGF-β3 may increase the secretion of 
collagen type I in MG63 bone cells. Cells treated with TGF-β1 (see Figure 7.3) shows 
only partial (weak) staining for collagen type I with mean % number of cells stained per 
micrograph with anti-collagen type I ~ 62.06% ± 6.50SD. This represents a significantly 
lower collagen type I expression in comparison to treatment with either TGF-β2 or 
TGF-β3 (p<0.001) (See Tables 7.1, 7.2 and Figure 7.4). Cells in control cultures with no 
TGF-β also show weak staining with mean % number of anti-collagen type I stained 
cells per micrograph ~ 37.93% ± 6.50SD when compared with cultures treated with 
TGF-β1 (mean % number of anti-collagen type I stained cells per micrograph ~ 62.06% 
± 6.50SD). The immunofluorscence micrographs (Figure 7.3) of human bone cells 
stained for anti collagen type I treated with TGF-β(2+3) and TGF-β(1+3) also show 
strong staining with mean % number of cells stained per micrograph with anti-collagen 
type I ~ 68.96% ± 8.60SD and 55.17% ± 5.62SD, respectively. However, there is a 
significant difference in the mean % number of cells stained per micrograph for 
collagen type I between these two cultures (p<0.01) and no significant difference was 
seen between TGF-β(2+3) and TGF-β(1+2+3) (p=0.074) treated cells (See Tables 7.1, 
7.2 and Figure 7.4). In the case of TGF-β(1+2) the mean % number of stained cells 
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(34.48% ± 8.45SD) was not significantly different from the control treated cells 
(p=0.975). Strong staining was seen in cultures treated with TGF-β2 and TGF-β3 
isomer combinations while culture flasks treated with TGF-β1 combinations 
demonstrated weak staining (See Figure 7.3). This suggests that the presence of TGF-β1 
in combination with other TGF-β isomers had an inhibitory effect on bone cell protein 
secretion (Sefat, 2009c). These results showed that there are significant differences in 
the mean % number of cells stained per micrograph for collagen type I between control 
and all TGF-β isomers (p<0.001) except for TGF-β(1+2) (p=0.975) (See Tables 7.1 and 
7.2). Overall, the staining results showed that TGF-β2 and TGF-β3 increased the mean 
% number of cells stained per micrograph with anti-collagen type I antibodies 
indicating that treatment with these cytokines enhanced collagen type I expression.  
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Figure 7.3 Immunofluorescence micrographs of human bone cell (MG63) treated with 
different TGF-β isomers and their combinations stained with dapi solution (blue) and 
anti-collagen type I (green). Negative control represents absence of both TGF-β and 
primary antibody (Ab) while positive control represents absence of TGF-β only with 
addition of primary antibody. Images in the right and left columns show dapi stained 
negative control bone cells following immunostaining in which the primary antibody 
was omitted (Scale bar = 100µm). 
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Table 7.1 Descriptive statistics for mean % numbers of bone cells stained with anti-
collagen type I  in culture treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-
(1+3), TGF-(2+3), TGF-(1+2+3) and control. 
 
 
 
 
Treatment 
Mean % numbers of bone cells stained 
with anti-collagen Type I 
±  
Std. Deviation 
(SD) 
Std. Error 
(SE) 
Control 37.93 ± 6.50 2.06 
TGFβ1 62.06 ± 6.50 2.06 
TGFβ2 100.00 ± 11.26 3.56 
TGFβ3 93.10 ± 6.70 2.11 
TGFβ1+2 34.48 ± 8.45 2.67 
TGFβ1+3 55.17 ± 5.62 1.78 
TGFβ2+3 68.96 ± 8.60 2.72 
TGFβ1+2+3 79.31 ± 2.27 2.29 
 
Table 7.2 P value derived from pair wise comparisons of mean % numbers of bone 
cells stained with anti-collagen type I in culture treated with TGF-1, TGF-2, TGF-3, 
TGF-(1+2), TGF-(1+3), TGF-(2+3), TGF-(1+2+3) and control. Pairs that are 
significantly different from one another are marked by an asterisk (*) whereas * P<0.05, 
** P<0.01 and *** P<0.001. 
 
Treatment P-value Sig diff Treatment P-value Sig diff 
Control – TGFβ1 0.001 *** TGFβ2 - TGFβ1+2 0.001 *** 
Control – TGFβ2 0.001 *** TGFβ2 - TGFβ1+3 0.001 *** 
Control – TGFβ3 0.001 *** TGFβ2 - TGFβ2+3 0.001 *** 
Control – TGFβ1+2 0.975  TGFβ2 - TGFβ1+2+3 0.001 *** 
Control – TGFβ1+3 0.001 *** TGFβ3 - TGFβ1+2 0.001 *** 
Control – TGFβ2+3 0.001 *** TGFβ3 - TGFβ1+3 0.001 *** 
Control – TGFβ1+2+3 0.001 *** TGFβ3 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ2 0.001 *** TGFβ3 - TGFβ1+2+3 0.004 ** 
TGFβ1 - TGFβ3 0.001 *** TGFβ1+2 - TGFβ1+3 0.001 *** 
TGFβ1 - TGFβ1+2 0.001 *** TGFβ1+2 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ1+3 0.504  TGFβ1+2 - TGFβ1+2+3 0.001 *** 
TGFβ1 - TGFβ2+3 0.504  TGFβ1+3 - TGFβ2+3 0.004 ** 
TGFβ1 - TGFβ1+2+3 0.001 *** TGFβ1+3 - TGFβ1+2+3 0.001 *** 
TGFβ2 - TGFβ3 0.504  TGFβ2+3 - TGFβ1+2+3 0.074  
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Figure 7.4 Bar chart showing mean % number of bone cells stained with anti-collagen 
type I for cells treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), 
TGF-(1+3), TGF-β(2+3) and un-treated as control (Error bars represent standard 
error). 
 
7.5.1.2 Fibronectin immunostaining 
The mean % number of stained cells per treatment group for immunocytochemistry 
with anti-human fibronectin antibodies did not show normal distribution and were 
analysed using SPSS via Kruskal-Wallis test and serial Mann Whitney tests (See Tables 
7.3 and 7.4). Figure 7.5 shows the immunofluorscence micrographs of human bone cells 
stained for anti-human fibronectin. It can be seen that bone cells treated with TGF-β3 
show good distribution of fibronectin around the periphery of the nucleus with a mean 
% number of cells stained per micrograph with anti-human fibronectin of 98.41% ± 
16.63SD. Staining was brighter compared to the control and although this could be an 
artefact, it could indicate a high secretion of fibronectin. Bone cells cultured and then 
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treated with TGF-β1 show evidence of less (weak) staining with a mean % number of 
cells stained per micrograph with anti-human fibronectin of 53.33% ± 7.69SD while 
TGF-β2 treated culture shows greater fibronectin production with more strong staining 
and a mean % number of cells stained per micrograph with anti-human fibronectin of 
93.33% ± 11.33SD (see Figures 7.5, 7.6, Tables 7.3 and 7.4). Statistically, there were no 
significant differences in the mean % number of cells stained per micrograph for anti-
human fibronectin between TGF-β2 and TGF-β3 treated cultures (p=0.266), while there 
are significant differences between cultures treated with TGF-β1 and other two isomers 
(p<0.001). Cells looked brighter and bigger in the case of TGF-β3, while fewer cells 
were stained in the case of TGF-β1. However, TGF-β1, TGF-β2 and TGF-β3 treated 
cells showed higher % number of cells stained as compared to control. Figure 7.5 
indicates that the presence of TGF-β3 in any combination was related to more stained 
cells with a mean % number of cells stained per micrograph with anti-human 
fibronectin of 72.66% ± 18.44SD for TGF-β(2+3) treated cells and 80.00% ± 11.33SD 
for TGF-β(1+2+3) treated cells (See Figures 7.5, 7.6, Tables 7.3 and 7.4). In all cultures 
treated with TGF-β3 combinations including TGF-β(2+3), TGF-β(1+3) and TGF-
β(1+2+3) there were some degree of strong staining with higher secretion of fibronectin 
protein as compared to TGF-β(1+2) in which less fibronectin secretion near the nucleus 
occurred. TGF-β(1+2) seemed to inhibit fibronectin significantly more than any other 
treatment, including those cells not exposed to any TGF-β (treatment controls).  
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Figure 7.5 Immunofluorescence micrographs of human bone cell (MG63) treated with 
different TGF-β isomers and their combinations stained with dapi solution (blue) and 
anti-human fibronectin (green). Negative control represents absence of both TGF-β and 
primary antibody while positive control represents absence of TGF-β only with addition 
of primary antibody. Images in the right and left columns show dapi stained negative 
control bone cells following immunostaining in which the primary antibody was omitted 
(Scale bar = 100µm). 
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Table 7.3 Descriptive statistics for mean % numbers of bone cells stained with anti-
human fibronectin in culture treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), 
TGF-(1+3), TGF-(2+3), TGF-(1+2+3) and control. 
 
 
 
Treatment 
Mean % numbers of bone cells 
stained with anti-human fibronectin 
± 
Std. Deviation 
(SD) 
Std. Error 
(SE) 
Control 33.33 ± 7.69 2.43 
TGFβ1 53.33 ± 7.69 2.43 
TGFβ2 93.33 ± 11.33 3.58 
TGFβ3 98.41 ± 16.63 5.26 
TGFβ1+2 20.00 ± 6.29 1.98 
TGFβ1+3 60.00 ± 17.21 5.44 
TGFβ2+3 72.66 ± 18.44 5.83 
TGFβ1+2+3 80.00 ± 11.33 3.58 
 
Table 7.4 P value derived from pair wise comparisons of mean % numbers of bone 
cells stained with anti-human fibronectin in culture treated with TGF-1, TGF-2, 
TGF-3, TGF-(1+2), TGF-(1+3), TGF-(2+3), TGF-(1+2+3) and control. Pairs that 
are significantly different from one another are marked by an asterisk (*) whereas * 
P<0.05, ** P<0.01 and *** P<0.001. 
 
Treatment P-value Sig diff Treatment P-value Sig diff 
Control – TGFβ1 0.001 *** TGFβ2 - TGFβ1+2 0.001 *** 
Control – TGFβ2 0.001 *** TGFβ2 - TGFβ1+3 0.001 *** 
Control – TGFβ3 0.001 *** TGFβ2 - TGFβ2+3 0.013 * 
Control – TGFβ1+2 0.002 ** TGFβ2 - TGFβ1+2+3 0.025 * 
Control – TGFβ1+3 0.001 *** TGFβ3 - TGFβ1+2 0.001 *** 
Control – TGFβ2+3 0.001 *** TGFβ3 - TGFβ1+3 0.001 *** 
Control – TGFβ1+2+3 0.001 *** TGFβ3 - TGFβ2+3 0.005 * 
TGFβ1 - TGFβ2 0.001 *** TGFβ3 - TGFβ1+2+3 0.001 *** 
TGFβ1 - TGFβ3 0.001 *** TGFβ1+2 - TGFβ1+3 0.001 *** 
TGFβ1 - TGFβ1+2 0.001 *** TGFβ1+2 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ1+3 0.539  TGFβ1+2 - TGFβ1+2+3 0.001 *** 
TGFβ1 - TGFβ2+3 0.012 * TGFβ1+3 - TGFβ2+3 0.148  
TGFβ1 - TGFβ1+2+3 0.001 *** TGFβ1+3 - TGFβ1+2+3 0.013 * 
TGFβ2 - TGFβ3 0.266  TGFβ2+3 - TGFβ1+2+3 0.338  
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There are significant differences in the mean % number of cells stained per micrograph 
between all TGF-β isomers and control (p<0.001). Also, no significant differences were 
obtained between TGF-β(1+3) and TGF-β(2+3) (p=0.148). Similar result were recorded 
between TGF-β(2+3) and TGF-β(1+2+3) (p=0.338). No specific staining was observed 
in the micrographs with absence of primary antibody confirming the specificity of the 
primary antibody. 
 
Figure 7.6 Bar chart showing mean % number of bone cells stained with anti-human 
fibronectin for cells treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-
(1+2+3), TGF-(1+3), TGF-β(2+3) and un-treated as control (Error bars represent 
standard error). 
 
 
 
7.5.1.3 Integrin immunostaining 
The mean % number of stained cells per treatment group after immunostaining with anti 
integrin-β1 antibodies were analyzed using SPSS via Kruskal–Wallis test as data was 
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not normally distributed (See Tables 7.5 and 7.6). Figure 7.7 shows the 
immunofluorescence micrographs of human bone cells stained for β1 integrin. It can be 
seen that bone cells treated with TGF-β3 show good protein secretion at the cell 
periphery giving the periphery of the cells bright and sharp edges. The mean % number 
of cells stained per micrograph with integrin β1 was 97.31% ± 12.65SD which indicate 
an increased occurrence of focal contact compared to the control treated cultures. 
Similar results were obtained for TGF-β2 with a mean % number of cells stained with 
integrin β1 of 89.47% ± 16.40SD, while bone cells treated with TGF-β1 show partial β1 
integrin staining concentrated near the nucleus with a mean % number of cells stained 
per micrograph of 57.89% ± 7.84SD (See Figures 7.7, 7.8, Tables 7.5 and 7.6). 
Treatment with all three TGF-β isomers seemed to induce higher integrin expression 
compared to the control in which the mean % number of cells stained per micrograph 
with integrin β1 was 42.11% ± 7.44SD. No specific staining was observed in the 
micrographs with absence of primary antibody, confirming the specificity of the 
primary antibody. There are significant differences recorded in the mean % number of 
cells stained with β1 integrin between cultures treated with TGF-β1 and the other two 
TGF-β isomers (p<0.001). Treatment with TGF-β3 combinations including TGF-
β(2+3), TGF-β(1+3) and TGF-β(1+2+3) showed some staining with a mean % number 
of cells stained per micrograph with integrin β1 of 68.42% ± 9.28SD, 57.89% ± 
12.65SD and 84.21% ± 11.34SD, respectively. Thus, treatment with TGF-β(2+3), TGF-
β(1+3) and TGF-β(1+2+3) induced an increased expression of β1 integrin when 
compared with the mean % (47.36% ± 9.28SD) of cells stained with anti β1 antibodies 
after TGF-β(1+2) treatment. However, this increase was only significant in the case of 
TGF-β(2+3) and TGF-β(1+2+3) (See Figures 7.7, 7.8, Tables 7.5 and 7.6).  
 198 
 
 
Figure 7.7 Immunofluorescence micrographs of human bone cell (MG63) treated with 
different TGF-β isomers and their combinations stained with dapi solution (blue) and 
Integrin-β1 (green). Negative control represents absence of both TGF-β and primary 
antibody while positive control represents absence of TGF-β only with addition of 
primary antibody. Images in the right and left columns show dapi stained negative 
control bone cells following immunostaining in which the primary antibody was omitted 
(Scale bar = 100µm). 
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Table 7.5 Descriptive statistics for mean % numbers of bone cells stained with1 
integrin in culture treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+3), 
TGF-(2+3), TGF-(1+2+3) and control. 
 
 
 
Treatment 
Mean % numbers of bone cells stained with  
β1 Integrin 
± Std. Deviation (SD) 
Std. Error 
(SE) 
Control 42.11 ± 7.44 2.35 
TGFβ1 57.89 ± 7.84 2.48 
TGFβ2 89.47 ± 16.40 5.18 
TGFβ3 97.31 ± 12.65 4.00 
TGFβ1+2 47.36 ± 9.28 2.93 
TGFβ1+3 57.89 ± 12.65 4.00 
TGFβ2+3 68.42 ± 9.28 2.93 
TGFβ1+2+3 84.21 ± 11.34 3.59 
 
Table 7.6 P value derived from pair wise comparisons of mean % numbers of bone 
cells stained with 1 integrin in culture treated with TGF-1, TGF-2, TGF-3, TGF-
(1+2), TGF-(1+3), TGF-(2+3), TGF-(1+2+3) and control. Pairs that are 
significantly different from one another are marked by an asterisk (*) whereas * P<0.05, 
** P<0.01 and *** P<0.001. 
 
Treatment P-value Sig diff Treatment P-value Sig diff 
Control – TGFβ1 0.001 *** TGFβ2 - TGFβ1+2 0.001 *** 
Control – TGFβ2 0.001 *** TGFβ2 - TGFβ1+3 0.001 *** 
Control – TGFβ3 0.001 *** TGFβ2 - TGFβ2+3 0.001 *** 
Control – TGFβ1+2 0.177  TGFβ2 - TGFβ1+2+3 0.23  
Control – TGFβ1+3 0.005 ** TGFβ3 - TGFβ1+2 0.001 *** 
Control – TGFβ2+3 0.001 *** TGFβ3 - TGFβ1+3 0.001 *** 
Control – TGFβ1+2+3 0.001 *** TGFβ3 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ2 0.001 *** TGFβ3 - TGFβ1+2+3 0.008 ** 
TGFβ1 - TGFβ3 0.001 *** TGFβ1+2 - TGFβ1+3 0.076  
TGFβ1 - TGFβ1+2 0.013 * TGFβ1+2 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ1+3 0.756  TGFβ1+2 - TGFβ1+2+3 0.001 *** 
TGFβ1 - TGFβ2+3 0.027 * TGFβ1+3 - TGFβ2+3 0.055  
TGFβ1 - TGFβ1+2+3 0.001 *** TGFβ1+3 - TGFβ1+2+3 0.001 *** 
TGFβ2 - TGFβ3 0.017 * TGFβ2+3 - TGFβ1+2+3 0.005 ** 
 
 200 
 
 
Figure 7.8 Bar chart showing mean % number of bone cells stained with β1 integrin for 
cells treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-
(1+3), TGF-β(2+3) and un-treated as control (Error bars represent standard error). 
 
The mean % number of stained cells per treatment group after immunostaining with anti 
integrin α3 antibodies showed normal distribution and were analysed using SPSS via 
Oneway Analysis of Variance (ANOVA) followed by a post Hoc Bonferroni test (See 
Tables 7.7 and 7.8). Figure 7.9 shows the immunofluorscence micrographs of human 
bone cells stained for α3 integrin. More integrin expression can be seen in the 
micrographs of cells treated with TGF-β3 and TGF-β(1+2+3) with mean % numbers of 
cells stained per micrograph with integrin α3 of 98.19% ± 16.14SD and 94.49% ± 
11.71SD, respectively. High integrin expression was seen and this was most intense 
near the periphery of the nucleus (See Figure 7.7). No significant difference in the mean 
% number of stained cells were recorded between TGF-β3 and TGF-β(1+2+3) 
(p=0.956). Results for TGF-β2 and TGF-β(2+3) showed some degree of 
 201 
 
immunostaining with a mean % number of cells stained per micrograph with integrin α3 
of 72.22% ± 8.28SD and 77.78% ± 11.11SD, respectively (See Figures 7.9, 7.10, Tables 
7.7 and 7.8). TGF-β treatment control cells and TGF-β(1+2) treated cells showed a 
similar results with mean % number of cells stained with integrin α3 of 27.77% ± 
6.41SD and 33.00% ± 12.83SD, respectively (p=0.956). There are no significant 
differences recorded between TGF-β2 treated cultures and cultures treated with TGF-
β(2+3) and TGF-β(1+3) (p=0.956). No specific staining was observed in the negative 
immunostaining controls confirming the specificity of the primary antibody and blue 
dapi staining represents live cells (See Figures 7.9, 7.10, Tables 7.7 and 7.8).  
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Figure 7.9 Immunofluorescence micrographs of human bone cell (MG63) treated with 
different TGF-β isomers and their combinations stained with dapi solution (blue) and 
Integrin-α3 (green). Negative control represents absence of both TGF-β and primary 
antibody while positive control represents absence of TGF-β only with addition of 
primary antibody. Images in the right and left columns show dapi stained negative 
control bone cells following immunostaining in which the primary antibody was omitted 
(Scale bar = 100µm). 
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Table 7.7 Descriptive statistics for mean % numbers of bone cells stained with α3 
integrin in culture treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+3), 
TGF-(2+3), TGF-(1+2+3) and control. 
 
 
 
 
Treatment 
Mean % numbers of bone cells stained 
with α3 integrin 
± 
Std. Deviation (SD) 
Std. Error 
(SE) 
Control 27.77 ± 6.41 2.03 
TGFβ1 55.55 ± 10.79 3.40 
TGFβ2 72.22 ± 8.28 2.61 
TGFβ3 98.19 ± 16.14 5.11 
TGFβ1+2 33.00 ± 12.83 4.06 
TGFβ1+3 66.66 ± 10.79 3.41 
TGFβ2+3 77.78 ± 11.11 3.51 
TGFβ1+2+3 94.49 ± 11.71 3.70 
 
Table 7.8 P value derived from pair wise comparisons of mean % numbers of bone 
cells stained with α3 integrin in culture treated with TGF-1, TGF-2, TGF-3, TGF-
(1+2), TGF-(1+3), TGF-(2+3), TGF-(1+2+3) and control. Pairs that are 
significantly different from one another are marked by an asterisk (*) whereas * P<0.05, 
** P<0.01 and *** P<0.001. 
 
Treatment P-value Sig diff Treatment P-value Sig diff 
Control – TGFβ1 0.001 *** TGFβ2 - TGFβ1+2 0.001 *** 
Control – TGFβ2 0.001 *** TGFβ2 - TGFβ1+3 0.956  
Control – TGFβ3 0.001 *** TGFβ2 - TGFβ2+3 0.956  
Control – TGFβ1+2 0.956  TGFβ2 - TGFβ1+2+3 0.001 *** 
Control – TGFβ1+3 0.001 *** TGFβ3 - TGFβ1+2 0.001 *** 
Control – TGFβ2+3 0.001 *** TGFβ3 - TGFβ1+3 0.001 *** 
Control – TGFβ1+2+3 0.001 *** TGFβ3 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ2 0.032 * TGFβ3 - TGFβ1+2+3 0.956  
TGFβ1 - TGFβ3 0.001 *** TGFβ1+2 - TGFβ1+3 0.001 *** 
TGFβ1 - TGFβ1+2 0.001 *** TGFβ1+2 - TGFβ2+3 0.001 *** 
TGFβ1 - TGFβ1+3 0.369  TGFβ1+2 - TGFβ1+2+3 0.001 *** 
TGFβ1 - TGFβ2+3 0.001 *** TGFβ1+3 - TGFβ2+3 0.369  
TGFβ1 - TGFβ1+2+3 0.001 *** TGFβ1+3 - TGFβ1+2+3 0.001 *** 
TGFβ2 - TGFβ3 0.001 *** TGFβ2+3 - TGFβ1+2+3 0.032 * 
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Figure 7.10 Bar chart showing mean % number of bone cells stained with β1 integrin 
for cells treated with TGF-1, TGF-2, TGF-3, TGF-(1+2), TGF-(1+2+3), TGF-
(1+3), TGF-β(2+3) and un-treated as control (Error bars represent standard error). 
 
7.5.2  WSPR 
7.5.2.1 Micro contact printed fibronectin 
The WSPR images, Figures 7.11a-b and 7.12, show cells on micro contact printed and 
un-treated surfaces. In the case of un-treated substrates, WSPR images revealed that 
high contrast features were arranged at the periphery of the cell and in concentric circles 
around the nucleus. Evidence from the previous work suggests that these bright contrast 
regions represent bands of focal contacts (Abdul Jamil, 2008a, Sefat, 2010a, Sefat, 
2010d). Cells on the patterned substrates had a very different morphology. They had 
high contrast features that mostly occurred around the periphery. No bands like 
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structures were seen around the nucleus. These features were brightest distal to the edge 
of the fibronectin guidance pattern.   
 
Figure 7.11 WSPR Images (a) un-guided MG63 bone cell outside the patterned area; 
(b) guided MG63 bone cell aligned almost 100% to the 50µm fibronectin stamp 
patterned (gold substrate) (scale bar 25µm) (Sefat, 2010d). 
 
 
Figure 7.12 WSPR Image of guided MG63 bone cell aligned almost 100% to the 50µm 
fibronectin stamp patterned on gold substrate; stamp pattern showed with yellow 
arrows (scale bar 25µm) (Sefat, 2010d). 
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7.5.2.2 TGF-β isomers 
Imaging with the WSPR system revealed that bone cells attached to the un-treated 
surface with high contrast concentrically arranged band like structures as shown in 
Figures 7.13. The highest contrast bands like components were localized at the cell 
periphery. Treatment with TGF-β1, TGF-β2 and TGF-β3 also modified the arrangement 
of the high contrast features within cells imaged with the WSPR. In the case of TGF-β1 
treated cells the bright high contrast regions were intense but only arranged around the 
periphery of the cell. In TGF-β2 and TGF-β3 cells the bright contrast regions were 
weaker but again mostly localised around the periphery. However in the TGF-β3 treated 
cells bright spec like features were visible scattered across the underside of the cell.  
 
 
Figure 7.13 WSPR images show focal contacts and concentric bank like structure of 
human bone cells on gold substrate (scale bar 25µm). 
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Figure 7.14 WSPR Images of human bone cell monolayer, a: control (un-treated); b: 
cell treated with TGF-1; c: cells treated with TGF-2;d: cells treated with TGF-3 
(scale bar 25 m). 
 
7.6  DISCUSSION  
TGF-β1, TGF-β2 and TGF-β3 increased the secretion of collagen type I in comparison 
to control treated cells, as did most combinations of TGF-β other than TGF-β(1+2). 
Between all TGF-β isomers, TGF-β2 and TGF-β3 increased collagen type I secretion 
significantly more than other treatments. TGF-β2 and TGF-β3 also significantly 
increased fibronectin secretion over all other treatments. There were significant 
differences between fibronectin secretion between TGF-β1 and TGF-β2 treatments. All 
TGF-β treatments increased the expression of the β1 integrin subunit, although 
expression was significantly greater in cells treated with TGF-β3. A large increase in β1 
expression was also seen in TGF-β2 and TGF-β(1+2+3) treated cells. The α3 integrin 
expression was also significantly increased by all TGF-β isoforms, but the expression 
was greatest in those cells treated with TGF-β3 and TGF-β(1+2+3).  In relation to 
wound repair, it has been found that TGF-β stimulates cell proliferation and bone 
formation in rat cells (Huang, 2007, Antosz, 1989). TGF-β is detected in cartilage 
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(Pelton, 1991) and bone (Hering, 2001) and up-regulation of TGF-β occurs during 
embryonic bone formation (Pelton, 1991) and in adult fracture healing (Wang, 1990). 
Little is known about the effect of different TGF-β isomers on integrin expression in 
bone. All three TGF-β isoforms are detected in bone, but TGF-β1 is thought  to be the 
most abundant (Hering, 2001, Linkhartc, 1996). There is also evidence that the 
expression of all three TGF-β isomers is up-regulated during fracture healing suggesting 
that their roles are not limited to embryonic bone development, but extend to adult bone 
remodelling (Cho, 2002). Many contradictory reports have been published on the 
function of TGF-β-1 in bone and it is necessary to reconcile experimental discrepancies 
that have been reported for this cytokine (Janssen, 2005, Ehnert, 2010). Several 
investigations reported the biphasic effects of TGF-β-1 in bone (Shinar, 1990, 
Yamaguchi, 1995). Recently, however, one group (Kale, 2004a, Kale, 2004b) provided 
a possible explanation for this in which various concentrations of TGF-β-1 and 
treatment time result in biphasic effects. Our results in chapter 4 (Sefat, 2009c) showed 
that TGF-β1 induced a decreased % wound closure compared with the other two 
isomers. Results in the current chapter also support this finding as culture flasks treated 
with TGF-β1 showed a smaller mean % number of cells stained for anti-collagen type I, 
anti-human fibronectin, α3 and β1 integrins when compared to the other two TGF-β 
isomers. This means that the binding of integrin adhesion receptors to ECM 
components, such as fibronectin and type I collagen, activates signalling pathways. 
Integrin-mediated interactions with ECM proteins are central to osteoblastic functions 
(Garcia, 2005). For instance, Damsky et. al., showed that integrin interactions, in 
particular α3β1, with fibronectin are essential for osteoblast survival, proliferation, 
osteoblast-specific gene expression, and matrix mineralisation (Moursi, 1996, Globus, 
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1998). Integrin interactions with type I collagen are also important.  Blocking adhesion 
with type I collagen-specific peptides or antibodies directed against the collagen-
binding integrin α2β1 interferes with the expression of osteoblast specific genes, and 
matrix mineralisation (Xiao, 1998, Mizuno, 2000). Also, Lemieux and his colleagues 
implicated the involvement of fibronectin binding integrins including α3β1 and α5β1 as 
well as glycoprotein in osteoblast proliferation (Lemieux, 2010). This concurs with our 
finding that antibodies raised against collagen, anti-human fibronectin, α3 and β1 
integrins. This suggests that, in combination with growth-factor receptors, focal 
adhesions activate signalling pathways, such as MAPK and JNK that regulate 
transcription factor activity and direct cell growth and differentiation (Giancotti, 1999). 
Many of these integrin-activated signalling cascades are required for osteoblast 
differentiation (Lai, 2001, Xiao, 2002). To our knowledge, no detailed information on 
the integrin expression of TGF-β-2 and TGF-β-3 in MG63 bone cell is currently 
available. However, results from the present study showed that TGF-β-2, TGF-β-3, 
TGF-β(2+3) and TGF-β(1+2+3) significantly increased the expression of α3 and β1 
integrin subunits when compared to the controls. The α3 and β1 integrins were also 
significantly increased following TGF-β treatments, suggesting that α3β1 is involved in 
collagen and fibronectin secretion while TGF-β1 showed less protein secretion 
compared to cultures treated with TGF-β-2, TGF-β-3, TGF-β(2+3) and TGF-β(1+2+3). 
Additionally it is beneficial to use other technique such as RT-PCR to measure collagen 
type I.  
 
In this chapter we have also looked at the cell surface interface at submicron lateral 
resolutions using the WSPR system. This system was used previously to image the 
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interface between HaCaT cells and the gold layer (Abdul Jamil, 2008a). Imaging in air 
enabled the visualisation of high resolution and high-contrast submicron features 
identiﬁed by vinculin immunostaining as a component of focal contacts and focal 
adhesions and, imaging in ﬂuid enabled cell surface interfacial interactions to be tracked 
by time-lapse video WSPR microscopy. These findings indicated that the cell surface 
interface, and thus indirectly the cell signalling mechanisms, may be readily 
interrogated in live cells without the use of labelling techniques (Abdul Jamil, 2008a, 
Abdul Jamil, 2008b, Abdul Jamil, 2007a, Abdul Jamil, 2007b, Sefat, 2010a). WSPR 
images revealed that high contrast features associated with the formation of focal 
contacts with a high prevalence on the edge of the cells distal to the edge of fibronectin 
patterns. This combined with evidence from the guidance experiments (Sefat, 2010a) 
indicated that the greatest degree of alignment occurred along the edge of the larger 
fibronectin protein patterns, which suggests that the cells were in fact aligning to small 
features, specifically the interface between the fibronectin coated and fibronectin free 
areas of the culture substrate. WSPR imaging also revealed that MG63 bone cells 
organised the majority of their focal contacts along the periphery of the cell distal to the 
edge of the fibronectin pattern and this was quite surprising. It is believed (Britland, 
1996, Britland, 1992b) that cells generally cluster their focal contacts along a guidance 
cue. This change in cell morphology and the distribution of focal contacts associated 
with the edge of the fibronectin patterns indicates that the interaction between cells and 
the edge of the pattern induces a reorganisation of focal contacts such that the region of 
the cell guided by the edge of the fibronectin pattern is relatively loosely coupled to the 
cell culture substrate, but the region of the cell positioned away from that edge is quite 
tightly coupled to the fibronectin coated region of the culture substrate. This in turn 
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suggests that guidance is not necessarily associated with enhanced cell substrate 
coupling along the guidance cue, but may be more associated with a decreased coupling 
at the guidance cue. Such an arrangement may influence cytoplasmic streaming and as 
such modulate cell extension. Verification of this finding is required. The results 
showed that the edge of the guidance cue (fibronectin pattern) reduced contact between 
the cell and the underlying substances but cells were guided and oriented in the same 
direction as the pattern despite the edge related decrease in cell surface attachment 
(Sefat, 2010a). Bone cell alignment to the edge of the fibronectin pattern is very much 
in line with the bone cell behaviour in vivo in that bone cells are guided by ECM fibres 
that have dimensions comparable to the edges of our stamp patterns (Hu, 2005). Thus, 
cells align to the edges of the fibronectin pattern and fibronectin free regions in our 
cultured substrates indicating that cell guidance in vivo may not necessarily be 
associated with increased attachment to the edge of the fibronectin fibers, but 
potentially associated with edge-related decreases in cell fibre attachment and increased 
membrane fluidity. The WSPR images of cells on the patterned surfaces certainly 
support this view. This could also partially explain the poor guidance to smaller repeat 
patterns in that cells can span these patterns and are thus subject to multiple guidance 
cues, which in turn could reduce the guidance effect. On the other hand, TGF-β treated 
bone cells had a very different peripheral structure only visible via the WSPR images 
(See figure 7.14a-d). The TGF-β treated cells acquired a high-contrast band like 
structure at the boarder of the elongated cell along with less concentrically formed band 
like features across the cell body. This caused the cells to extend more indicating that 
the interaction between cells and all the different isomers of TGF-β with different rates 
induces significant changes in cell activity such as cell signalling resulting in up-
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regulation of the proteins associated with the cells acquiring a more migratory 
phenotype.  
 
7.7  CONCLUSIONS 
Human bone cells (MG63) were immunostained for collagen type I, fibronectin, β1 and 
α3 integrin expressions treated with different TGF-β isomers and their combinations. 
The immunostaining results showed that treatment with TGF-β3 significantly increased 
collagen type I secretion and β1 and α3 integrin expression as compared to TGF-β1. It 
was also found that TGF-β1 seemed to decrease collagen type 1, anti-human fibronectin 
secretion and α3 and β1 integrin expression in comparison to TGF-β2 and TGF-β3. 
TGF-β2 also showed similar results to that of TGF-β3. All TGF-β isomers showed an 
increase in collagen type I, anti-human fibronectin secretion and α3 and β1 integrin 
expression compared to the control. Imaging with WSPR allowed observation of the 
focal contacts without the need for immunostaining. WSPR images revealed guided 
cells with high contrast band-like structures at the border of cells distal to the edge of 
the guided cue to which they aligned and with less concentrically formed band-like 
features across the cell body for un-guided cells. It is believed that the high contrast 
features are associated with the formation of focal contacts on the edge of the cells 
distal to the edge of fibronectin patterns, which suggests that cell guidance is aided by a 
decrease in cell attachment along a guidance feature. 
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CHAPTER EIGHT 
8. OVERALL DISCUSSION, CONCLUSIONS 
AND FURTHER FUTURE WORK 
 
The Aim of this thesis was to determine how the different TGF- isoforms, and 
extracellular matrix proteins influenced the behaviour of MG63 bone cells in terms of 
responses to cell guidance on extracellular matrix molecules (Sefat, 2008, Sefat, 2010a), 
cell surface attachment (Sefat, 2009a, Sefat, 2010c), model wound repair (Sefat, 2009b, 
Sefat, 2009c, Sefat, 2009d, Sefat, 2010d) and integrin expression. Experiments were 
also performed to determine if HCl effects on wound closure were dose dependent 
(Sefat, 2010b). The effect of different TGF-β isomers and their combinations on 
proliferation rate and cell length of human bone cells were also assessed. Imaging with 
WSPR allowed observation of the cell surface interactions without the need for 
immunostaining (Sefat, 2010a, Abdul Jamil, 2008b) and was thus used to assess the 
effect of TGF-β isomers on cell attachment and guidance. 
 
The results indicated that cells aligned well on the 50m and 100µm wide fibronectin 
patterned coverslips compared to those with smaller width. In comparison, cells aligned 
less readily to collagen and laminin. The results for the trypsinisation assay indicated 
that treatment with the HCl (TGF-β isomer solvent), TGF-1, TGF-2 and TGF-3 all 
decreased cell attachment, but this effect was significantly greater in the case of HCl 
and TGF-3 (p<0.001). In terms of wound healing, all TGF-β treatments caused 
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different rate of wound closure in vitro. TGF-β3 caused the fastest wound closure over 
30hrs followed by TGF-β2 and TGF-β1. Complete wound closure was also achieved 
after 30hrs in the presence of 50ng/ml HCl and 50ng/ml BSA/HCl, whereas wounds 
remained open in control cultures over the same time period. Cells treated with 
combinations of TGF-β isomers behaved similarly in vitro but with different rate of 
wound closure. All TGF-β combinations induced faster wound healing rates than 
controls. Previous studies indicated that combinations of cytokines such as platelet-
derived growth factor (PDGF) and insulin-like growth factor (IGF-1) enhanced bone 
repair (Stefani, 2000), but our results explain that combination of TGF-β isomers did 
not necessarily further enhance wound closure. Wound closure was dependent on HCl 
dose with the 80µM and 160µM concentrations inducing increases in wound closure 
rates that were both significantly greater than those induced by 20µM, 40µM and 
control treatments (p<0.001). Cell morphology changes occurred more significantly in 
cells treated with TGF-β3. In terms of proliferation rate, TGF-3 and TGF-β2 alone 
increased cell numbers compared to TGF-β1 and combinations of TGF-β. 
Immunostaining indicated that treatment with TGF-β3 significantly promoted the 
secretion of collagen type I and fibronectin and increased integrin α3 and β1 expression. 
WSPR images allowed the cell attachment to be examined. The results indicated that 
the distribution of focal contacts changed depending on treatment. For instance WSPR 
images revealed that high contrast features associated with the formation of focal 
contacts occurred with high prevalence on the edge of the cells distal to the edge of 
fibronectin patterns. In the case of TGF-β1 treated cells the bright high contrast regions 
were intense but only arranged around the periphery of the cell. In TGF-β2 and TGF-β3 
cells the bright contrast regions were weaker but again mostly localised around the 
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periphery. It follows therefore that TGF-β changed the distribution of focal contact, and 
hence, without TGF-β treatment focal contact seemed to be in concentric arrays at 
periphery. Specifically, TGF-β3 focal contact seemed to be scattered across cell surface 
interface. Thus, TGF-βs reduce cell surface attachment which supports findings in 
trypsinisation.   
 
The results of the experiment examining guidance of MG63 cells on micro contact 
printed substrates (Chapter 2) showed that cells aligned most readily to fibronectin 
patterned coverslips, especially to the 50m width with mean angle of 7.87˚  3.07˚ SD, 
and 100m patterns with a mean angle of 6.46˚  5.01˚ SD. In comparison, cells 
aligned less well to the collagen and laminin patterns, with the best mean angle of 
alignment of 9.67˚  4.19˚ SD occurring in the 50m collagen wide pattern and the best 
alignment on the laminin patterns with a mean angle of 14.36˚  1.57˚ SD occurring on 
the 50m stamp patterned substrates. This suggests that fibronectin is an importent 
protein in the repair of bone. It has also been shown in the literature that fibronectin is 
an important protein which was upregulated in damaged bone (Tang, 2004). The impact 
of the ECM proteins on cell morphology and function is also quite well documented. 
For example, epithelial, osteoblast and chondrogenic cells as well as fibroblasts have 
been used to examine cell responses to substrate chemistry (Lim, 2007, Khaghani, 
2008). To understand how substrates influence morphology it is important to be able to 
examine cell surface interface. Cells interact with surfaces via lamellipodia and 
filopodia (Adams, 2002, DeMali, 2003). It has been reported (Dalby, 2007) that cells  
extend their cell protrusions in all directions on a flat un-patterned surface, but extended 
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cell protrusions followed guidance features on a micro pattern surface. Consequently, 
cells elongated and aligned along the pattern direction. The angles of the cell 
protrusions against the pattern direction were almost three times lower on the MCP 
plates than those on the un-patterned substrates. We observed clearly via WSPR images 
(Chapter 7) that the leading edges of the cell protrusions extended/elongated along the 
patterned substrates micro contact printed with fibronectin (Sefat, 2010a). However, the 
WSPR images also allowed the imaging of the focal contact associated with this 
guidance. In all cases focal contact accumulated on the edge of the cell parallel to the 
edge of the pattern indicating that the edge of the cell encountering the pattern was more 
loosely attached to the substrates than the edge parallel and distal to the edge of the 
pattern. This suggests that MG63 cells aligned to a substrate via mechanism involving a 
loose/weak attachment to the edge of a guidance cue and an exploration of that edge via 
lamellipodia and filopodia. The results from the guidance experiments (Chapter 2) 
indicated that cell alignment is extracellular matrix dependent with guidance greater on 
fibronectin compared to collagen and laminin (Sefat, 2010a). This indicates that the 
alignment is in turn dependent on the expression of different integrins and those 
integrins associated with coupling to fibronectin being most important. Similar findings 
have been made by others, for example, it has been shown that FGF2 in human 
osteoblast induces the expression of integrins that couple to fibronectin (Jang, 2002). 
 
The trypsinisation results (Chapter 3) suggested that TGF-β2 and TGF-β3 do not 
stimulate bone-ECM adhesion (Sefat, 2009a, Sefat, 2010c). Bone cells cultured in 
medium with TGF-β2 and TGF-β3 supplementation separately displayed a faster rate of 
cell/surface detachment. There is evidence in the literature that many cell types take on 
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a migratory phenotype during wound repair and this migratory phenotype can be 
associated with a change in the degree of cell surface attachment (Foppiano, 2007a). 
Thus, it is possible that TGF-β2 and TGF-β3 could aid this process in bone. In contrast, 
the degree of cell surface attachment was increased in bone cells cultured with TGF-β1. 
This finding indicates potentially that inhibition or activation of TGF-β1 may induce 
bone cell migration and potentially bone repair. This view is supported in the litrature 
(Davidson, 2005) showing the effects of TGF-β isoforms in damaged cartilage. In this 
study TGF-β appears to play an important role in repair of cartilage and that lack of 
TGF-β responsiveness in old mice might be at the root of osteoarthritis (OA) 
development. There is also evidence in the literature that pH can influence wound repair 
(Lenghedeit, 1995). This poses a problem in studies examining the effect of TGF-β 
isoforms. In that TGF-β2 and TGF-β3 are solubilized in HCl solution. Thus, 
experiments examining the influence of TGF-β isoforms on cell behaviour may have 
actually identified cell responses that are pH dependent. To examine this possibility cell 
attachment was examined via trypsinisation studies in which cells incubated in media 
containing HCl at the concentration that wound be present if the cells were treated with 
the TGF-β isoforms. The results showed that HCl, BSA and HCl/BSA enhanced the rate 
of cell detachment in relation to the negative controls, indicating perhaps that TGF-β3 
does not act alone in influencing the degree of cell attachment, but instead may function 
synergistically with signalling pathways that are dependent on the availability of 
hydrogen ions. Such a mechanism could depend on signalling molecules undergoing a 
conformational change on binding hydrogen ions. This view is supported by 
information in the literature that TGF-β in bone is activated by changes in pH/hydrogen 
ion concentration (Wrana, 1994). 
 218 
 
The effect of TGF-β isomers in wound healing of bone cell monolayer was the next 
target of this research programme (Chapter 4) (Sefat, 2010d, Sefat, 2009b, Sefat, 
2009c, Sefat, 2009d). Our studies showed that the bone monolayers treated with TGF-
β3 and TGF-β2 demonstrated rapid decreases in wound width during 25hrs of wound 
healing. This may be related to TGF-β increasing the secretion of ECM molecules at the 
wound edge, which functions by capturing cells via the integrin ECM interactions at the 
wound edge, thus helping migration into the wound site (Celeste, 2002). In comparison 
TGF-β3 and TGF-β2 caused cells to detach faster from surface and thus, helping 
migration into the wound site. Such a mechanism may be useful in therapeutic 
procedures by filling a wound site with large number of bone cells which would 
presumably enable the deposition of ECM across the wound surface enabling cell 
migration and proliferation into the wound. TGF-β1 had slower healing effect in vitro 
compared to TGF-β3 and TGF-β2 suggesting that TGF-β1 decreases cell migration. 
TGF-β isomers also influence cell morphology which is well known, for example TGF-
β1 in chondrocytes plays a very important role in rapid formation of fibroblast like 
chondrocyte cells in vitro (Chi, 2004). This could be linked to an up-regulation in the 
production of extracellular matrix and extended collagen type-I fibres causing the cells 
to flatten and occupy a larger area which prohibits cells migration and consequently 
reduces cell proliferation (Nakamura, 2007) or by differential upregulation of specific 
integrins (Hardiman, 2005). HCl and BSA/HCl treated cells also showed very good 
wound healing response as compared to the control. However, no clinical research has 
yet been undertaken on TGF-β3 or HCl, thus this work provided an initial step in 
evaluating the effects of TGF-β3, HCl and HCl/BSA in vitro in relation to bone wound 
closure and the healing process in vitro. Growth factors can also be combined in order 
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to induce cell responses in vivo and it is probable that growth factors seldom act alone 
(Chapter 4). The results of this work showed that in the case of combined TGF-β 
isomer treated cells, the rate of wound closure was significantly higher (P < 0.001) 
compared to un-treated controls. However, treatment with TGF-β1, 2 and 3 alone 
induced significantly faster wound closure rates than did treatment with combination of 
TGF-βs. 
 
A number of chemical, physical and biological mechanisms have also been indicated in 
the activation of TGF-β (Lawrence, 1985, Brown, 1990, Zamora, 2007). Exposure to 
extremes of pH or urea, as well as heat treatment activates TGF-β in vitro (Zamora, 
2007, Brown, 1990). Further investigations were carried out (Chapter 5) to evaluate the 
effect of various HCl concentrations in wound healing of bone cell monolayers (Sefat, 
2010b). The results showed that HCl accelerated the bridging process, thus, enhanced 
the rate of wound closure. This response was dose dependent with fastest healing 
occurring in response to treatment with higher concentrations of HCl (80µM and 
160µM) as compared to the control. It could be speculated that some of the hydrogen 
ions from the HCl bind to the serum proteins and cause a change in surface charge and 
hence change protein folding and function (Kohn, 2002). In this system, changes in 
hydrogen ion availability could activate signalling proteins in the serum, which then 
induce changes in cell behaviour associated with encouraging cell differentiation and 
proliferation during bone healing. In this work it was also found that different 
concentrations of HCl did not seem to affect the pH level of the media as monitored by 
observations of media colour, indicating that HCl was being sequestered away. 
Unfortunately this finding is inconclusive and requires verification via definitive 
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measurements of media pH via a highly sensitive pH meter. Therefore, an increase in 
HCl concentration could influence cell behaviour and this could indicate that bone cells 
are highly sensitive to tiny fluctuations in hydrogen ion concentration.   
 
In this thesis cell morphology (Cell length) and proliferation rate were also examined in 
response to different TGF-β isomers (Chapter 6). The role of TGF-β induced changes 
in osteoblast morphology is largely unknown. Our results suggested that cells treated 
with TGF-3 and TGF-β(2+3) showed high % cell proliferation followed by TGF-
β(1+2+3), TGF-β(1+3) and control. TGF-1 and TGF-2 did not seem to enhance cell 
proliferation. These results also suggested that changes in cell length were more 
pronounced in cells treated with TGF-β(2+3) and TGF-β(1+3) followed by TGF-β3, 
TGF-β2 and TGF-β1. As mentioned earlier, regulation of cell shape is an important 
process that controls tissue morphogenesis, cell migration, differentiation, proliferation, 
and survival, presumably by regulating expression of genes central to these processes 
(Boudreau, 1999, Lukashev, 1998, Nakamura, 2007). However, it is possible that TGF-
β induced osteoblast elongation contributes to several aspects of TGF-β function in 
bone (Hartsough, 1997, Nakamura, 2007). At present, it is not clear in which situations 
TGF-β could facilitate bone resorption in vivo by altering osteoblast shape (Karsdal, 
2001, Serganova, 2009). One possibility is that active TGF-β is produced during bone 
remodeling within the basic multicellular unit (BMU) of the osteon. Both osteoblasts 
and osteoclasts are able to synthesize TGF-β (Oursler, 1994, Oreffo, 1989, Bonewald, 
1991, Selvamurugan, 2004). Although osteoblasts are responsible for production of 
most of the TGF-β entrapped in bone matrix (Bonewald, 1994, Selvamurugan, 2004), 
the majority of active TGF-β appears to be generated by bone resorbing osteoclasts 
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either through release of TGF-β stored in bone matrix or by biosynthesis of new TGF-β  
(Pfeilschifter, 1987). Active TGF-β may then be made accessible to osteoblasts through 
a process involving transcytosis (Mostov, 1997, Ruan, 2010). The selective activation of 
TGF-β by osteoclasts may fulfill a function by inducing elongation of bone lining cells 
(Lucas, 1989, Pfeilschifter, 1990, Ruan, 2010). Thus, the precise role and mechanism of 
TGF-β with regard to osteoblast elongation remains to be established. 
The question now arising is how TGF-β related wound repair may associate with 
changes in the expression of integrins? To examine this MG63 cells were 
immunostained for collagen type I, fibronectin, β1 and α3 integrin following treatment 
with different TGF-β isomers and their combinations (Chapter 7). Previous 
experiments in this thesis identified differences in the way TGF-β isoforms influence 
cellular behaviour including collective cell migration during model wound repair, 
degree of cell detachment during trypsinisation assay, cell morphological changes and 
cell proliferation. However, little is known about the effect of different TGF-β isomers 
on integrin expression in bone. There is evidence that the expression of all three TGF-β 
isomers is up regulated during fracture healing (Cho, 2002). This means binding of 
integrin adhesion receptors to ECM components, such as fibronectin and type I 
collagen, activates signalling pathways. Many studies have implicated the involvement 
of integrin/ECM protein interactions with cell proliferation. For example, 
osteoblast/fibronectin binding via integrins including α3β1 and α5β1 are thought to 
influence osteoblast proliferation (Lemieux, 2010, Clëzardin, 2009, Hughes, 1993). This 
supports the finding of the thesis that suggests TGF-β1, 2 and 3 increases the secretion 
of collagen and fibronectin and the expression of α3 and β1 integrins. 
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FURTHER FUTURE WORK 
It was quantitavely and qualitatively observed in this work that for fibronectin rich 
patterns cell function greatly improved for osteoblast-like (human bone cell) 
monolayers, especially with presence of cytokines (TGF-β3) speeding the rate of wound 
repair in vitro. These results along with the findings of other researchers, (Couchman, 
1990) imply that TGF-β3 may enhance wound repair in vivo. This could be further 
investigated by examining the effects of wound closure in a 3D model. 
 
Results in this thesis examined cell responses in a 2D environment. For instance, 
different TGF- isoforms, and extracellular matrix proteins influenced the behaviour of 
MG63 bone cells in terms of responses to cell guidance on extracellular matrix 
molecules, cell surface attachment, model wound repair and integrin expression in a 2D 
environment. The effect of different TGF-β isomers and their combinations on 
proliferation rate and cell length of human bone cells were also assessed in a 2D 
environment. However, evidence from the literature indicates that bone cells behave 
differently in a 3D environment and that the 3D culture systems in vitro mimic the in 
vivo situation more closely than the two-dimensional (2D) cultures (Trojania, 2005, 
Kale, 2000, Ferrera, 2002). Normal human osteoblasts or human osteosarcoma cell lines 
were mixed and cultured into hydrogel (Trojania, 2005). It was demonstrated that this 
matrice represents a new system of 3D culture in which the differentiation of human 
osteogenic cells is promoted. The osteosarcoma cells were grown as viable clonogenic 
spheroids and acquired a more mature phenotype compared to the same cells grown in a 
monolayer culture on tissue culture grade plastic (Trojania, 2005). Results of this thesis 
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clearly contributed to a better understanding of osteoblast-like cell behaviour or cell 
biology from MG63 osteosarcoma cell line (or type). Future/further work would 
therefore benefit the experiments undertaken in this thesis being repeated in 3D cell 
cultures on various scaffolds, or on various orthopaedic implants using our model for 
monolayer cell interactions.  
 
The overall aim should be to develop a 3D scaffold incorporating the ECM molecules 
required to enhance bone repair and to determine how cell behaviour in a 3D scaffold is 
modified by TGF-β 1, 2 and 3. 
This future work would involve:  
1) Development of a 3D culture system in which bone cells may be grown and in 
which a model wound could be generated.  
2) The identification of which combination of cytokines enhance wound repair in a 
3D culture system. The aim here would be to find out if the results acquired in 
the 2D system are mirrored by similar outcomes in a 3D model wound. 
 
We have also investigated the effect of TGF-β1, -β2 and -β3 against control and 
different concentrations of HCl to determine which treatments promote model wound 
repair. Further research should be carried out to concentrate on the specific range of 
80µM and 160µM concentrations of HCl which seem to enhance wound closure, more 
effectively. Also, supplementary experiments should be carried out to investigate and 
compare the wound closure properties of bone cell monolayers treated with different 
TGF-β isomers using the same concentration. Observation also concluded that the pH of 
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the media was not changed significantly due to any colour change of the media. 
However, very small pH differences have detrimental effects on cell behaviour and 
measurement of the pH values may be required in order to verify that the application of 
HCl in this study had no impact on the pH of the culture media. If this were the case it 
would support our suggestion that HCl is being sequestered away by the media and 
serum proteins. A micro pH meter (e.g. Micro 500 pH meter –Palintest instruments) 
could be used to enable this.  
 
The MG63 osteoblast-like cell lines used in this work were derived from osteosarcomas, 
which share certain important features of the osteoblast phenotype. However, it is not 
clear if all the characteristics of MG63 cells are identical to those of bone forming 
osteoblasts in the body. It is possible that MG63 cells have acquired gene mutations that 
make their responses dissimilar to bone cells in vivo (Okabe, 2010). Thus repeat 
experiments with primary bone cells could be required to confirm the findings of this 
thesis.  
 
The method of the initial scratching of the monolayer was non-uniform which could 
affect the healing growth rate of the MG63 bone cells. Uneven scratching due to human 
error could contribute to a variation in scratch width. Thus the MG63 bone cells were 
able to bridge more quickly and become confluent and that larger initial scratches took 
longer to heal. A method of uniform scratching in a 3D system need to be developed to 
allow for more accurate results. 
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ABSTRACT: This work examines the role of the extracellular matrix (ECM) proteins, collagen and 
fibronectin along with transforming growth factor β-3 (TGF β-3) in skin cell engineering and wound 
repair. The regulation of growth factors in wound repair is known to determine the rate and type of the 
healing as well as cell infiltration. This gives the rationale to further investigate growth factors in skin 
substitutes. Our studies investigated the role of TGF β-3 on cell behaviour in combination with culture on 
extracellular matrix patterns of collagen and fibronectin. Differences in the cell behaviour in vitro, e.g. 
adhesion, can be attributed to the interaction of different protein-specific integrins during cell–cell and 
cell–matrix adhesion. Experiments investigating cell guidance found that cells aligned better to collagen 
stamped patterns than fibronectin patterned surfaces, although fibronectin was more consistent over a 
range of stamp sizes. This highlights the important role of fibronectin in wound repair, facilitating cell 
adhesion and migration. It also indicates the potential benefits of fibronectin and ECM proteins in skin 
replacements, as they provide a platform for cell migration and adhesion. Detachment studies of protein-
treated surfaces seeded with keratinocyte cells illustrated that TGF β-3 treated cells detached more readily 
than cells without TGF β-3. The expressions of these proteins and growth factors are important signalling 
molecules allowing timely healing and graft integration. The current literature reveals that the use of skin 
substitutes is still not widespread due to various shortcomings such as high costs; susceptibility to 
infection and long lead times, which together show the ineffectiveness of skin replacements. It is 
therefore our conclusion that cell guidance, cell migration and growth factors have a direct impact upon 
the healing cascade and scarring profiles in skin tissue. A deeper understanding of cellular 
communication, wound repair, and current skin equivalents may lead to development of better skin 
substitutes to mimic native tissue and optimize conditions for favourable wound closure.  
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ABSTRACT: Tissue engineering may help in the restoration of tissue function. Cells in the body 
attach to the normal scaffold known as extracellular matrix. The in-vitro environment allows the 
examination of the way in which cells behave in relation to the ECM. Micro-contact printing (MCP) 
allows the deposition of molecule at precise and predetermined geometry on a surface and is thus ideal for 
examining directed cellular adhesion, migration, differentiation and network formation in vitro. The aim 
of this study was to identify the role of collagen, fibronectin and laminin, in the adhesion and alignment 
of the human bone cell line (MG63) to different microcontact printed ECM patterns. Collagen, 
fibronectin and laminin were stamp patterned onto glass slides using templates consisting of 5-, 10-, 25-, 
50- and 100-μm-wide repeal grating. MG63 cells were seeded at 15 000 cells per patterned coverslip. The 
effects of initial cell attachment on different substrates were investigated by recording cell images at 
different time points after cell seeding (2, 5 and 18 h). IMAGE J software was used to find the angle 
between the long axis of cells and different patterns and mean length. Cells on the fibronectin pattern 
attached and elongated at early stages after seeding. In the case of collagen and laminin, cells did not 
adhere readily and appeared more rounded until 18hrs after seeding. The cells aligned very well on 
fibronectin patterned coverslips, especially to the 50 μm, with mean angle of 7.87 ± 3.07 and 100-μm 
patterns with a mean angle of 6.46 ± 5.01. In comparison the alignment of the cells to the collagen and 
laminin patterns was poor, with the best mean angle of alignment (mean angle of 9.67 ± 4.19) occurring 
in the 50-μm collagen wide pattern and the best alignment on the laminin patterns (mean angle of 14.36 ± 
1.57) occurring in the 50-μm stamp patterned. Differences in cell length mirrored those of alignment, 
with cells acquiring the greatest length when showing the greatest degree of alignment. The results 
indicate that MG63 cells respond most to 50- and 100-μmwide fibronectin patterns, which suggests that 
the cells attach mostly via fibronectin-specific integrins.  
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ABSTRACT: The use of tissue engineering in the treatment of cartilage injuries is in its 
infancy. To understand how chondrocyte cells behave in the wound environment requires in 
vitro experiments designed to characterize chondrocyte responses to model guidance cues. This 
study examined the alignment and spreading of chondrocyte cells derived from 1–5-day-old 
Sprague-Dawley rats on 5-, 10-, 25-, 50- and 100-μm-wide repeal grating of micro contact 
printed fibronectin, laminin and collagen type-1. Cells were plated on the patterned substrate of 
concentration of 5000 cells cm−2. At 48 h after seeding, the effect on cell alignment of these 
patterned proteins was examined. Using IMAGE-J software it was found that chondrocytes 
aligned to the 50-μm laminin (mean angle = 23.4 and SD 7.02) and showed no alignment to the 
fibronectin pattern. The highest degree of alignment was observed with chondrocytes grown on 
the 100-μm-wide collagen type-I pattern (mean angle of alignment 18.9 ± 6.797). In all cases 
the chondrocyte cells were small (laminin mean size 36.2 μm ± 14.4 SD, collagen mean size 
34.03 μm ± 7.2 SD and fibronectin mean size 33.87 μm ± 11.9 SD) and rounded. Of the cells 
plated on all the substrates, only 50–60% were firmly attached. There was no significant change 
of proliferation rate in relation to different proteins.  
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ABSTRACT:  Following injury to the skin, keratinocytes within the epidermis migrate and 
proliferate to fill the wound bed, a process known as re-epithelialization. The understanding of 
keratinocyte- extracellular matrix interactions during wound repair and how these events 
influence the scarring process remains to be fully elucidated. Studying cellular responses to 
different ECM proteins will play a central role in the identification of Integrins regulated as part 
of the response to growth factors such as TGF-β. Microcontact printing has been commonly 
used for the assembly of protein monolayers onto surfaces. The specific patterning of protein on 
substrate allows cellular adhesion, migration and proliferation to be studied. In this study, a 
human keratinocyte cell line (HaCat cells) was used to study the response to different ECM 
proteins central to wound repair. Fibronectin, laminin and collagen type I were patterned onto 
glass substrates to analyse cell alignment. A variety of stamps were produced with grating 
repeats 1.8, 5, 10, 25, 50 and 100 lm in width. Following stamp patterning, substrates were 
incubated with HaCat cells for 24 h at 37 _C. Cells were imaged using a phase contrast 
microscope and VISICAPTURE software. Cell length, width and angle of alignment to patterns 
were analysed using IMAGE J software. We demonstrate that HaCaT cell adhesion and 
alignment can be influenced by the patterning of proteins on glass substrate. For each of the 
three proteins, fibronectin, laminin and collagen type I the smallest average angle of alignment 
was seen with the 50 lm pattern (7.52_± 1.73, 6.52_± 1.33 and 17.97_± 3.42, respectively). 
Fibronectin and laminin achieved the best cell alignment indicating that HaCat cells adhere via 
integrins that favour these proteins. The aim of future work will be to identify potential 
Integrins involved in keratinocyte-ECM interactions and to understand how these integrins are 
regulated by chemical mediators such as TGF-β. 
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ABSTRACT:  Harvesting of pure cells from primary tissue is difficult as isolated tissue 
contains various cell types. Articular cartilage is highly specialized tissue that functions by 
forming a smooth surface enabling joint movement. Cartilage is mostly made up of chonrocytes. 
However, when harvesting cartilage, other tissues arise from the synovial membranes, tendons 
and even nerves. This makes acquisition of a pure chondrocyte culture challenging. Harvesting 
chondrocytes from neonatal rat joints is even more difficult because the larger joints such as the 
knee joint are roughly about 2 mm in diameter. Thus despite careful isolation from neonatal rat 
joints, cartilage will be accompanied by a mixture of bone cells and non-cartilaginous 
connective tissue. Cells derived from this tissue will therefore need to be purified. In this study 
the different adhesion affinity of dissimilar cells on solid surface was used to separate 
chondrocytes from other cell types. This was achieved by plating primary cell suspensions in 
tissue culture grade (TC) cell culture flasks and removing those unattached cells after 20 min. 
The unattached cells were then re-plated in a new TC grade cell culture flask. This process was 
repeated a further six times, after which the final cell suspension was allowed to attach to the 
surface for 100 min. This resulted in the generation of eight cell cultures, plus one control in 
which the serial attachment process was not used. All nine cultures were incubated at 37 _C for 
4 days and then immunostained with monoclonal Anti S-100 (b-subunit – SIGMA) antibody 
and monoclonal anti collagen type-I antibody (SIGMA). Immunocytochemical staining showed 
that control cultures consisted of a mixture of chondrocytes and other cell types. However, of 
those cultures derived from the serial attachment process, chondrocytes only became evident 
after 100 min of cell attachment. By the eighth plating the cultures contained almost 100% 
chondrocytes. These results suggest that chondrocytes can be readily isolated and purified by a 
prolonged differential adhesion technique with a primary incubation extending for 140 min.  
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Abstract- Imaging interfacial environment has proved challenging using standard imaging 
systems. This is a problem that may be circumvented using the widefield surface plasmon 
microscope (WSPR). Surface plasmon microscopy relies on the excitation of electron 
oscillations at a conductor/dielectric interface by P polarised light striking that interface at a 
specific surface plasmon resonance (SPR) angle. The SPR angle can be changed by application 
of a molecular species to the conductor, which modifies the mean refractive index at that 
interface and thus alters the coupling efficiency between the conductor and the P-polarised light. 
Commercial SPR microscopes unfortunately have poor lateral resolutions, but the WSPR uses a 
high numerical aperture lens to excite surface plasmons, and thus not only enables nanometric Z 
axes imaging of interfacial molecular interactions but also enables SPR imaging at micron to 
submicron lateral resolutions. Initial work has shown that this system can be used to image 
cell/surface interactions. This paper focuses on looking at the use of the WSPR microscope in 
the imaging of a human keratinocyte cell line (HaCat cells), bone cells, neonatal rat intestinal 
smooth muscle cells and neonatal rat knee joint derived chondrocytes. Of these cell types the 
HaCat cells couple tightly to the cell culture surface, and this is reflected by clear band like 
arrangements of focal contacts, in comparison chondrocytes, smooth muscle cells and bone cells 
couple less strongly to the surface and this is reflected by less clearly defined arrangements of 
focal contacts. In all cases WSPR microscopy also enabled identification of internal cellular 
features, specifically the nucleus and in the case of smooth muscle cells contractile filament like 
structures.  
 
Keywords– Surface plasmon, cell imaging, interfaces. 
INTRODUCTION 
Cells respond to a wide range of guidance cues, include, including surface chemistry, 
topography, chemical gradients, electric fields and magnetic fields [1-5]. However, all 
of these guidance cues illicit a cellular response via altered gene upregulation and by 
promoting  modifications in the cytoskeleton. Many of these gene upregulations also 
result in modifications in cell surface receptors, which in turn enable cells to respond 
differently to the cellular environment. In wound repair for example the TGF beta 
family of cytokines not only promote migration of macrophages and neutrophils into a  
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Abstract: A newly developed Widefield Surface Plasmon Resonance (WSPR) Microscope was used to investigate the morphology 
of MG63 bone cells and their interfacial interactions with ECM proteins. This allowed detailed imaging of cell surface coupling at 
lateral resolution down to ~500nm. In this work, bone repair was investigated and modulated by different stimulus including growth 
factors. TGF-β3 is a cytokine known to be associated with the scarless healing of skin and it is highly probable that it may play a 
role in the repair of other tissues. Thus the aim of this study was to investigate the effect of TGF-β3 on closure of a model wound in 
cultured monolayers of the MG63 human bone cells. This in vitro work examined and compared the wound closure properties of 
TGF-β3, and its dosage carriers HCl and BSA/HCl. The wound healing response was investigated in TC grade culture flasks by 
creating a wound (with average scratch width of 300μm10-30μm SD, 1.7-5μm SEM) on confluent monolayers of MG63 human 
bone cells. After wounding, cultures were then treated with 50ng/ml TGF-3 at concentration of 4mM HCl and 1mg/ml BSA and 
distilled water. Also, the same method was applied for cell cultured monolayers with no growth factor as control and with HCl/BSA 
and HCl only solutions. After wounding, wound width was measured every 5 hours over a 30-hour period. The results showed that 
TGF-β3 enhanced the rate of wound repair in a monolayer of MG63 bone cells. It was found that after 20 hours all the culture flasks 
treated with TGF-β3 (with 15.5% of wound remained open), HCl (with 16% of wound remained open) and finally BSA/HCl (with  
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Abstract:  Widefield Surface Plasmon Resonance (WSPR) microscope was used to investigate 
cell surface interactions under two different culture conditions: bone cells cultured on SPR substrate with 
transforming growth factor β3 (TGF-β3) and without as control. Trypsinisation was carried out in order to investigate 
its effect on cell detachment, in the presence of TGF-3, HCl or BSA/HCl solutions. Trypsin was therefore added to 
four groups of bone cells with addition of TGF-3, HCl, HCl/BSA solutions and one additional flask as control. 
These results further confirmed that application of TGF-3, HCl and HCl/BSA decreased the degree of cell 
attachment on surface of culture flasks. HCl and BSA/HCl were tested as they are the carriers and solvents for TGF-
β3. Cell detachment in control was about 43% after 6 minutes, which is slow. Bone cells in the presence of BSA/HCl 
started detaching from the surface about 4-5 minutes and cell detachment was about 63% after 6 minutes which was 
faster as compared to the control. Bone cells in the presence of HCl alone started detaching from the surface about 2 
minutes (after applying trypsin) and cell detachment was about 69% after 6 minutes which was faster compared to the 
BSA/HCl and control. Trypsinisation experiments for bone cells cultured with TGF-3 (50ng/ml) showed that cells 
started to detach from the surface about 1 minute after application of trypsin and cell detachment was about 85% after 
4 minutes which was faster as compared to the control, HCl and BSA/HCl.  
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